Verapamil

Explore a selection of our essential drug information below, or:

Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.

SUBSCRIBERECOMMENDED FOR PHARMA

Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Summary

Verapamil is a non-dihydropyridine calcium channel blocker used in the treatment of angina, arrhythmia, and hypertension.

Brand Names

Calan, Isoptin, Tarka, Verelan

Generic Name

Verapamil

DrugBank Accession Number

DB00661

Background

Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina,¹⁹ and was the first calcium channel antagonist to be introduced into therapy in the early 1960s.¹³ It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like diltiazem and flunarizine, but is chemically unrelated to other cardioactive medications.¹⁹ Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate.⁵

Type

Small Molecule

Groups

Approved

Structure

Similar Structures

Weight: Average: 454.6016
Monoisotopic: 454.283157714
Chemical Formula: C₂₇H₃₈N₂O₄

Synonyms

Iproveratril
Verapamil
Vérapamil
Verapamilo
Verapamilum

External IDs

CP-16,533-1
D-365

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Verapamil is indicated in the treatment of vasopastic (i.e. Prinzmetal's) angina, unstable angina, and chronic stable angina. It is also indicated to treat hypertension, for the prophylaxis of repetitive paroxysmal supraventricular tachycardia, and in combination with digoxin to control ventricular rate in patients with atrial fibrillation or atrial flutter.¹⁹ Given intravenously, it is indicated for the treatment of various supraventricular tachyarrhythmias, including rapid conversion to sinus rhythm in patients with supraventricular tachycardia and for temporary control of ventricular rate in patients with atrial fibrillation or atrial flutter.¹⁸

Verapamil is commonly used off-label for prophylaxis of cluster headaches.⁴

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Dose Form
Treatment of	Chronic stable angina pectoris		••••••••••••	••••••
Prophylaxis of	Cluster headache		••• •••••
Used in combination to manage	Heart rate	Regimen in combination with: Digoxin (DB00390), Digitoxin (DB01396)	••••••••••••	••••••
Treatment of	High blood pressure (hypertension)		••••••••••••	•••••••• •••••••• •••••••• ••••••• ••••••• •••••••• •••••••
Used in combination to manage	Hypertension	Combination Product in combination with: Trandolapril (DB00519)	••••••••••••	••••••• •••••••• •••••••
Prophylaxis of	Paroxysmal supraventricular tachycardia		••••••••••••	••••••
Treatment of	Supraventricular tachyarrhythmia		••••••••••••	•••••••••• ••••••••
Treatment of	Unstable angina pectoris		••••••••••••	••••••
Treatment of	Vasospastic angina		••••••••••••	••••••

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Verapamil is an L-type calcium channel blocker with antiarrhythmic, antianginal, and antihypertensive activity.¹⁹ Immediate-release verapamil has a relatively short duration of action, requiring dosing 3 to 4 times daily,¹⁹ but extended-release formulations are available that allow for once-daily dosing.^17,22 As verapamil is a negative inotropic medication (i.e. it decreases the strength of myocardial contraction), it should not be used in patients with severe left ventricular dysfunction or hypertrophic cardiomyopathy as the decrease in contractility caused by verapamil may increase the risk of exacerbating these pre-existing conditions.¹⁷

Mechanism of action

Verapamil inhibits L-type calcium channels by binding to a specific area of their alpha-1 subunit,¹⁷Cav1.2, which is highly expressed on L-type calcium channels in vascular smooth muscle and myocardial tissue where these channels are responsible for the control of peripheral vascular resistance and heart contractility.¹⁰ Calcium influx through these channels allows for the propagation of action potentials necessary for the contraction of muscle tissue and the heart's electrical pacemaker activity. Verapamil binds to these channels in a voltage- and frequency-dependent manner, meaning affinity is increased 1) as vascular smooth muscle membrane potential is reduced, and 2) with excessive depolarizing stimulus.¹⁷

Verapamil's mechanism of action in the treatment of angina and hypertension is likely due to the mechanism described above. Inhibition of calcium influx prevents the contraction of vascular smooth muscle, causing relaxation/dilation of blood vessels throughout the peripheral circulation - this lowers systemic vascular resistance (i.e. afterload) and thus blood pressure. This reduction in vascular resistance also reduces the force against which the heart must push, decreasing myocardial energy consumption and oxygen requirements and thus alleviating angina.¹⁹

Electrical activity through the AV node is responsible for determining heart rate, and this activity is dependent upon calcium influx through L-type calcium channels. By inhibiting these channels and decreasing the influx of calcium, verapamil prolongs the refractory period of the AV node and slows conduction, thereby slowing and controlling the heart rate in patients with arrhythmia.¹⁹

Verapamil's mechanism of action in the treatment of cluster headaches is unclear, but is thought to result from an effect on other calcium channels (e.g. N-, P-, Q-, or T-type).⁴

Verapamil is known to interact with other targets, including other calcium channels,^14,15,7,8 potassium channels,^6,16,4 and adrenergic receptors.^11,12

Target	Actions	Organism
AVoltage-dependent L-type calcium channel subunit alpha-1C	inhibitor	Humans
UVoltage-dependent N-type calcium channel subunit alpha-1B	inhibitor	Humans
UVoltage-dependent P/Q-type calcium channel subunit alpha-1A	inhibitor	Humans
UATP-sensitive inward rectifier potassium channel 11	inhibitor	Humans
UVoltage-dependent T-type calcium channel subunit alpha-1G	inhibitor	Humans
UVoltage-dependent T-type calcium channel subunit alpha-1H	inhibitor	Humans
UPotassium voltage-gated channel subfamily H member 2	inhibitor	Humans
USodium-dependent serotonin transporter	unknown	Humans
UAlpha-1A adrenergic receptor	antagonist	Humans
UAlpha-1B adrenergic receptor	antagonist	Humans
UAlpha-1D adrenergic receptor	antagonist	Humans
UVoltage-dependent calcium channel	inhibitor	Humans
UP-glycoprotein 1	inhibitor blocker	Humans

Absorption

More than 90% of orally administered verapamil is absorbed - despite this, bioavailability ranges only from 20% to 30% due to rapid biotransformation following first-pass metabolism in the portal circulation.¹⁹ Absorption kinetic parameters are largely dependent on the specific formulation of verapamil involved. Immediate-release verapamil reaches peak plasma concentrations (i.e. T_max) between 1-2 hours following administration,¹⁹ whereas sustained-release formulations tend to have a T_max between 6 - 11 hours.^17,22

AUC and C_max values are similarly dependent upon formulation. Chronic administration of immediate-release verapamil every 6 hours resulted in plasma concentrations between 125 and 400 ng/mL.¹⁹ Steady-state AUC_0-24h and C_max values for a sustained-release formulation were 1037 ng∙h/ml and 77.8 ng/mL for the R-isomer and 195 ng∙h/ml and 16.8 ng/mL for the S-isomer, respectively.¹⁷

Interestingly, the absorption kinetics of verapamil are highly stereospecific - following oral administration of immediate-release verapamil every 8 hours, the relative systemic availability of the S-enantiomer compared to the R-enantiomer was 13% after a single dose and 18% at steady-state.¹⁷

Volume of distribution

Verapamil has a steady-state volume of distribution of approximately 300L for its R-enantiomer and 500L for its S-enantiomer.⁴

Protein binding

Verapamil is extensively protein-bound in plasma. R-verapamil is 94% bound to serum albumin while S-verapamil is 88% bound. Additionally, R-verapamil is 92% bound to alpha-1 acid glycoprotein and S-verapamil is 86% bound.¹⁹

Metabolism

Verapamil is extensively metabolized by the liver, with up to 80% of an administered dose subject to elimination via pre-systemic metabolism - interestingly, this first-pass metabolism appears to clear the S-enantiomer of verapamil much faster than the R-enantiomer.^17,9 The remaining parent drug undergoes O-demethylation, N-dealkylation, and N-demethylation to a number of different metabolites via the cytochrome P450 enzyme system.⁹ Norverapamil, one of the major circulating metabolites, is the result of verapamil's N-demethylation via CYP2C8, CYP3A4, and CYP3A5,⁹ and carries approximately 20% of the cardiovascular activity of its parent drug.¹⁷ The other major pathway involved in verapamil metabolism is N-dealkylation via CYP2C8, CYP3A4, and CYP1A2 to the D-617 metabolite. Both norverapamil and D-617 are further metabolized by other CYP isoenzymes to various secondary metabolites. CYP2D6 and CYP2E1 have also been implicated in the metabolic pathway of verapamil, albeit to a minor extent.⁹ Minor pathways of verapamil metabolism involve its O-demethylation to D-703 via CYP2C8, CYP2C9, and CYP2C18, and to D-702 via CYP2C9 and CYP2C18.⁹

Several steps in verapamil's metabolic pathway show stereoselective preference for the S-enantiomer of the given substrate, including the generation of the D-620 metabolite by CYP3A4/5 and the D-617 metabolite by CYP2C8.⁹

Hover over products below to view reaction partners

Verapamil

Route of elimination

Approximately 70% of an administered dose is excreted as metabolites in the urine and ≥16% in the feces within 5 days. Approximately 3% - 4% is excreted in the urine as unchanged drug.¹⁹

Half-life

Single-dose studies of immediate-release verapamil have demonstrated an elimination half-life of 2.8 to 7.4 hours, which increases to 4.5 to 12.0 hours following repetitive dosing.¹⁹ The elimination half-life is also prolonged in patients with hepatic insufficiency (14 to 16 hours) and in the elderly (approximately 20 hours).¹⁷ Intravenously administered verapamil has rapid distribution phase half-life of approximately 4 minutes, followed by a terminal elimination phase half-life of 2 to 5 hours.¹⁸

Clearance

Systemic clearance following 3 weeks of continuous treatment was approximately 340 mL/min for R-verapamil and 664 mL/min for S-verapamil.⁵ Of note, apparent oral clearance appears to vary significantly between single dose and multiple-dose conditions. The apparent oral clearance following single doses of verapamil was approximately 1007 mL/min for R-verapamil and 5481 mL/min for S-verapamil, whereas 3 weeks of continuous treatment resulted in apparent oral clearance values of approximately 651 mL/min for R-verapamil and 2855 mL/min for S-verapamil.⁵

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Verapamil's reported oral TDLo is 14.4 mg/kg in women and 3.429 mg/kg in men.²¹ The oral LD₅₀ is 150 mg/kg in rats and 163 mg/kg in mice.²¹

As there is no antidote for verapamil overdosage, treatment is largely supportive. Symptoms of overdose are generally consistent with verapamil's adverse effect profile (i.e. hypotension, bradycardia, arrhythmia) but instances of non-cardiogenic pulmonary edema have been observed following ingestion of large overdoses (up to 9 grams).¹⁷ In acute overdosage, consider the use of gastrointestinal decontamination with cathartics and/or bowel irrigation. Patients presenting with significant myocardial depression may require intravenous calcium, atropine, vasopressors, or other inotropes. Consider the formulation responsible for the overdose prior to treatment - sustained-release formulations may result in delayed pharmacodynamic effects, and these patients should be monitored closely for at least 48 hours following ingestion.¹⁷

Pathways

Pathway	Category
Verapamil Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
Beta-1 adrenergic receptor	---	(G;G) / (C;G)	G > C	Effect Directly Studied	Patients with this genotype require a lower dosage of verapamil to achieve a favourable rate-control response when treating atrial fibrillation.	Details

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
1,2-Benzodiazepine	The metabolism of 1,2-Benzodiazepine can be decreased when combined with Verapamil.
Abacavir	Verapamil may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abaloparatide	The risk or severity of adverse effects can be increased when Verapamil is combined with Abaloparatide.
Abametapir	The serum concentration of Verapamil can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Verapamil can be increased when combined with Abatacept.
Abemaciclib	The serum concentration of Abemaciclib can be increased when it is combined with Verapamil.
Abiraterone	The serum concentration of Verapamil can be increased when it is combined with Abiraterone.
Abrocitinib	The serum concentration of Verapamil can be increased when it is combined with Abrocitinib.
Acalabrutinib	The metabolism of Acalabrutinib can be decreased when combined with Verapamil.
Acarbose	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Acarbose.
Acebutolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Acebutolol.
Aceclofenac	Aceclofenac may decrease the excretion rate of Verapamil which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Acenocoumarol	The serum concentration of Acenocoumarol can be increased when it is combined with Verapamil.
Acetaminophen	The metabolism of Acetaminophen can be decreased when combined with Verapamil.
Acetazolamide	Acetazolamide may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
Acetohexamide	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Acetohexamide.
Acetylcholine	The risk or severity of adverse effects can be increased when Verapamil is combined with Acetylcholine.
Acetyldigitoxin	Acetyldigitoxin may increase the arrhythmogenic activities of Verapamil.
Acetylsalicylic acid	The risk or severity of bleeding can be increased when Verapamil is combined with Acetylsalicylic acid.
Aclidinium	Verapamil may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine	Verapamil may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir	The metabolism of Acyclovir can be decreased when combined with Verapamil.
Adagrasib	The metabolism of Adagrasib can be decreased when combined with Verapamil.
Adalimumab	The metabolism of Verapamil can be increased when combined with Adalimumab.
Adefovir dipivoxil	Adefovir dipivoxil may decrease the excretion rate of Verapamil which could result in a higher serum level.
Adenosine	Adenosine may increase the arrhythmogenic activities of Verapamil.
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Verapamil.
Agomelatine	The metabolism of Agomelatine can be decreased when combined with Verapamil.
Ajmaline	Verapamil may increase the arrhythmogenic activities of Ajmaline.
Albendazole	The metabolism of Verapamil can be increased when combined with Albendazole.
Albiglutide	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Albiglutide.
Albuterol	Verapamil may decrease the excretion rate of Salbutamol which could result in a higher serum level.
Albutrepenonacog alfa	Verapamil may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alclofenac	Alclofenac may decrease the excretion rate of Verapamil which could result in a higher serum level.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Verapamil.
Alectinib	The metabolism of Alectinib can be decreased when combined with Verapamil.
Alfentanil	The metabolism of Alfentanil can be decreased when combined with Verapamil.
Alfuzosin	Verapamil may increase the hypotensive activities of Alfuzosin.
Aliskiren	The metabolism of Aliskiren can be decreased when combined with Verapamil.
Alloin	The therapeutic efficacy of Alloin can be decreased when used in combination with Verapamil.
Allopurinol	Allopurinol may decrease the excretion rate of Verapamil which could result in a higher serum level.
Almasilate	Verapamil may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almotriptan	The metabolism of Almotriptan can be decreased when combined with Verapamil.
Alogliptin	The metabolism of Alogliptin can be decreased when combined with Verapamil.
Alosetron	The metabolism of Alosetron can be decreased when combined with Verapamil.
Alpelisib	The metabolism of Alpelisib can be decreased when combined with Verapamil.
Alprazolam	The metabolism of Alprazolam can be decreased when combined with Verapamil.
Amantadine	The risk or severity of adverse effects can be increased when Verapamil is combined with Amantadine.
Ambrisentan	The metabolism of Ambrisentan can be decreased when combined with Verapamil.
Ambroxol	The metabolism of Ambroxol can be decreased when combined with Verapamil.
Amifostine	The risk or severity of adverse effects can be increased when Verapamil is combined with Amifostine.
Amikacin	Verapamil may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Verapamil.
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Verapamil.
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Verapamil.
Aminosalicylic acid	The risk or severity of bleeding can be increased when Verapamil is combined with Aminosalicylic acid.
Amiodarone	The risk or severity of adverse effects can be increased when Amiodarone is combined with Verapamil.
Amitriptyline	The metabolism of Amitriptyline can be decreased when combined with Verapamil.
Amlodipine	Amlodipine may increase the arrhythmogenic activities of Verapamil.
Ammonium chloride	Verapamil may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
Amobarbital	Amobarbital may increase the hypotensive activities of Verapamil.
Amoxapine	The metabolism of Amoxapine can be decreased when combined with Verapamil.
Amoxicillin	Verapamil may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Amphetamine	The therapeutic efficacy of Verapamil can be decreased when used in combination with Amphetamine.
Amphotericin B	Verapamil may decrease the nephrotoxic activities of Amphotericin B.
Ampicillin	Ampicillin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Amprenavir	The metabolism of Verapamil can be decreased when combined with Amprenavir.
Amrinone	Verapamil may decrease the excretion rate of Amrinone which could result in a higher serum level.
Amyl Nitrite	Verapamil may increase the vasodilatory activities of Amyl Nitrite.
Anagrelide	The metabolism of Verapamil can be decreased when combined with Anagrelide.
Anakinra	The metabolism of Verapamil can be increased when combined with Anakinra.
Ancestim	Verapamil may decrease the excretion rate of Ancestim which could result in a higher serum level.
Antihemophilic factor (recombinant), PEGylated	Verapamil may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Verapamil.
Antithrombin III human	Verapamil may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Antrafenine	Antrafenine may decrease the excretion rate of Verapamil which could result in a higher serum level.
Apalutamide	The serum concentration of Verapamil can be decreased when it is combined with Apalutamide.
Apixaban	The metabolism of Apixaban can be decreased when combined with Verapamil.
Apomorphine	The metabolism of Apomorphine can be decreased when combined with Verapamil.
Apremilast	The metabolism of Verapamil can be increased when combined with Apremilast.
Aprepitant	The metabolism of Aprepitant can be decreased when combined with Verapamil.
Aprocitentan	Verapamil may increase the hypotensive activities of Aprocitentan.
Arbutamine	The therapeutic efficacy of Arbutamine can be decreased when used in combination with Verapamil.
Arformoterol	Verapamil may decrease the excretion rate of Arformoterol which could result in a higher serum level.
Aripiprazole	The metabolism of Aripiprazole can be decreased when combined with Verapamil.
Aripiprazole lauroxil	The metabolism of Aripiprazole lauroxil can be decreased when combined with Verapamil.
Armodafinil	The metabolism of Verapamil can be increased when combined with Armodafinil.
Arsenic trioxide	The serum concentration of Verapamil can be increased when it is combined with Arsenic trioxide.
Artemether	The metabolism of Artemether can be decreased when combined with Verapamil.
Asciminib	The serum concentration of Verapamil can be increased when it is combined with Asciminib.
Asenapine	The metabolism of Asenapine can be decreased when combined with Verapamil.
Astemizole	The metabolism of Astemizole can be decreased when combined with Verapamil.
Asunaprevir	The metabolism of Asunaprevir can be decreased when combined with Verapamil.
Atazanavir	The metabolism of Verapamil can be decreased when combined with Atazanavir.
Atenolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Atenolol.
Atogepant	The metabolism of Atogepant can be decreased when combined with Verapamil.
Atomoxetine	The metabolism of Atomoxetine can be decreased when combined with Verapamil.
Atorvastatin	The serum concentration of Verapamil can be increased when it is combined with Atorvastatin.
Atovaquone	The metabolism of Atovaquone can be decreased when combined with Verapamil.
Atracurium	Verapamil may increase the neuromuscular blocking activities of Atracurium.
Atracurium besylate	Verapamil may increase the neuromuscular blocking activities of Atracurium besylate.
Atropine	Atropine may increase the arrhythmogenic activities of Verapamil.
Auranofin	Verapamil may decrease the excretion rate of Auranofin which could result in a higher serum level.
Aurothioglucose	Verapamil may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Avacopan	The metabolism of Avacopan can be decreased when combined with Verapamil.
Avanafil	The metabolism of Avanafil can be decreased when combined with Verapamil.
Avapritinib	The metabolism of Avapritinib can be decreased when combined with Verapamil.
Avatrombopag	The metabolism of Avatrombopag can be decreased when combined with Verapamil.
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Verapamil.
Azacitidine	Verapamil may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Azathioprine	The metabolism of Azathioprine can be decreased when combined with Verapamil.
Azelaic acid	Azelaic acid may decrease the excretion rate of Verapamil which could result in a higher serum level.
Azelastine	The metabolism of Azelastine can be decreased when combined with Verapamil.
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Verapamil is combined with Azilsartan medoxomil.
Azithromycin	The metabolism of Azithromycin can be decreased when combined with Verapamil.
Aztreonam	Aztreonam may decrease the excretion rate of Verapamil which could result in a higher serum level.
Bacitracin	Bacitracin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Baclofen	Baclofen may decrease the excretion rate of Verapamil which could result in a higher serum level.
Balsalazide	The risk or severity of bleeding can be increased when Verapamil is combined with Balsalazide.
Baricitinib	The metabolism of Baricitinib can be decreased when combined with Verapamil.
Beclomethasone dipropionate	The metabolism of Beclomethasone dipropionate can be decreased when combined with Verapamil.
Bedaquiline	The metabolism of Bedaquiline can be decreased when combined with Verapamil.
Belantamab mafodotin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Verapamil.
Belinostat	The serum concentration of Belinostat can be increased when it is combined with Verapamil.
Belumosudil	The metabolism of Belumosudil can be decreased when combined with Verapamil.
Benazepril	The risk or severity of adverse effects can be increased when Benazepril is combined with Verapamil.
Bendamustine	The serum concentration of Bendamustine can be increased when it is combined with Verapamil.
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Verapamil.
Benorilate	Benorilate may decrease the excretion rate of Verapamil which could result in a higher serum level.
Benoxaprofen	Benoxaprofen may decrease the excretion rate of Verapamil which could result in a higher serum level.
Benserazide	Verapamil may decrease the excretion rate of Benserazide which could result in a higher serum level.
Benzatropine	Benzatropine may decrease the excretion rate of Verapamil which could result in a higher serum level.
Benznidazole	Verapamil may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Benzocaine	The metabolism of Benzocaine can be decreased when combined with Verapamil.
Benzphetamine	The therapeutic efficacy of Verapamil can be decreased when used in combination with Benzphetamine.
Benzthiazide	Benzthiazide may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
Benzydamine	Benzydamine may decrease the excretion rate of Verapamil which could result in a higher serum level.
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Verapamil.
Bepotastine	Verapamil may decrease the excretion rate of Bepotastine which could result in a higher serum level.
Bepridil	Verapamil may increase the arrhythmogenic activities of Bepridil.
Beractant	Verapamil may increase the bradycardic activities of Beractant.
Berotralstat	The serum concentration of Berotralstat can be increased when it is combined with Verapamil.
Betamethasone	The metabolism of Betamethasone can be decreased when combined with Verapamil.
Betamethasone phosphate	The metabolism of Betamethasone phosphate can be decreased when combined with Verapamil.
Betaxolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Betaxolol.
Bethanidine	The therapeutic efficacy of Bethanidine can be decreased when used in combination with Verapamil.
Betrixaban	The serum concentration of Betrixaban can be increased when it is combined with Verapamil.
Bexagliflozin	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Bexagliflozin.
Bexarotene	The metabolism of Bexarotene can be decreased when combined with Verapamil.
Bezafibrate	The metabolism of Bezafibrate can be decreased when combined with Verapamil.
Bicalutamide	The metabolism of Bicalutamide can be decreased when combined with Verapamil.
Bicisate	Verapamil may decrease the excretion rate of Bicisate which could result in a higher serum level.
Bictegravir	The metabolism of Bictegravir can be decreased when combined with Verapamil.
Bifonazole	The therapeutic efficacy of Bifonazole can be increased when used in combination with Verapamil.
Bimekizumab	The metabolism of Verapamil can be increased when combined with Bimekizumab.
Binimetinib	The serum concentration of Binimetinib can be increased when it is combined with Verapamil.
Bioallethrin	Verapamil may increase the arrhythmogenic activities of Bioallethrin.
Bisacodyl	The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Verapamil.
Bismuth subgallate	Verapamil may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bismuth subsalicylate	The risk or severity of bleeding can be increased when Verapamil is combined with Bismuth subsalicylate.
Bisoprolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Bisoprolol.
Bisoxatin	The therapeutic efficacy of Bisoxatin can be decreased when used in combination with Verapamil.
Bleomycin	Bleomycin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Boceprevir	The serum concentration of Verapamil can be increased when it is combined with Boceprevir.
Bortezomib	The serum concentration of Bortezomib can be increased when it is combined with Verapamil.
Bosentan	The metabolism of Bosentan can be decreased when combined with Verapamil.
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Verapamil.
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Verapamil.
Bretylium	Verapamil may increase the arrhythmogenic activities of Bretylium.
Brexpiprazole	The metabolism of Brexpiprazole can be decreased when combined with Verapamil.
Brigatinib	The metabolism of Brigatinib can be decreased when combined with Verapamil.
Brivaracetam	The metabolism of Brivaracetam can be decreased when combined with Verapamil.
Bromazepam	The metabolism of Bromazepam can be decreased when combined with Verapamil.
Bromocriptine	The metabolism of Bromocriptine can be decreased when combined with Verapamil.
Bromotheophylline	The metabolism of Bromotheophylline can be decreased when combined with Verapamil.
Budesonide	The metabolism of Budesonide can be decreased when combined with Verapamil.
Bumadizone	Bumadizone may decrease the excretion rate of Verapamil which could result in a higher serum level.
Bumetanide	The risk or severity of adverse effects can be increased when Verapamil is combined with Bumetanide.
Bupivacaine	The metabolism of Bupivacaine can be decreased when combined with Verapamil.
Buprenorphine	The metabolism of Buprenorphine can be decreased when combined with Verapamil.
Bupropion	Verapamil may decrease the excretion rate of Bupropion which could result in a higher serum level.
Buspirone	The serum concentration of Buspirone can be increased when it is combined with Verapamil.
Busulfan	The metabolism of Busulfan can be decreased when combined with Verapamil.
Butabarbital	Butabarbital may increase the hypotensive activities of Verapamil.
Butalbital	Butalbital may increase the hypotensive activities of Verapamil.
Cabazitaxel	The metabolism of Cabazitaxel can be decreased when combined with Verapamil.
Cabergoline	The serum concentration of Cabergoline can be increased when it is combined with Verapamil.
Cabozantinib	The metabolism of Cabozantinib can be decreased when combined with Verapamil.
Caffeine	The metabolism of Verapamil can be decreased when combined with Caffeine.
Calcitriol	The metabolism of Calcitriol can be decreased when combined with Verapamil.
Calcium acetate	The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium acetate.
Calcium chloride	The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium chloride.
Calcium glubionate anhydrous	The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium glubionate anhydrous.
Calcium glucoheptonate	The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium glucoheptonate.
Calcium gluconate	The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium gluconate.
Calcium levulinate	The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium levulinate.
Calcium polycarbophil	The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Verapamil.
Calfactant	Verapamil may increase the bradycardic activities of Calfactant.
Canagliflozin	The metabolism of Canagliflozin can be decreased when combined with Verapamil.
Canakinumab	The metabolism of Verapamil can be increased when combined with Canakinumab.
Candesartan cilexetil	The risk or severity of adverse effects can be increased when Verapamil is combined with Candesartan cilexetil.
Cannabidiol	The metabolism of Cannabidiol can be decreased when combined with Verapamil.
Canrenoic acid	Canrenoic acid may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
Capecitabine	Verapamil may decrease the excretion rate of Capecitabine which could result in a higher serum level.
Capivasertib	The serum concentration of Capivasertib can be increased when it is combined with Verapamil.
Capmatinib	The serum concentration of Capmatinib can be increased when it is combined with Verapamil.
Capreomycin	Verapamil may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Capsaicin	The metabolism of Verapamil can be increased when combined with Capsaicin.
Captopril	The risk or severity of adverse effects can be increased when Verapamil is combined with Captopril.
Carbamazepine	The serum concentration of Carbamazepine can be increased when it is combined with Verapamil.
Carbetocin	The risk or severity of adverse effects can be increased when Verapamil is combined with Carbetocin.
Carbidopa	Carbidopa may decrease the excretion rate of Verapamil which could result in a higher serum level.
Carboplatin	Carboplatin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Carboxymethylcellulose	The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Verapamil.
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Verapamil.
Cariprazine	The metabolism of Cariprazine can be decreased when combined with Verapamil.
Carmustine	The metabolism of Verapamil can be decreased when combined with Carmustine.
Carprofen	Carprofen may decrease the excretion rate of Verapamil which could result in a higher serum level.
Carteolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Carteolol.
Carvedilol	The risk or severity of adverse effects can be increased when Verapamil is combined with Carvedilol.
Castor oil	The therapeutic efficacy of Castor oil can be decreased when used in combination with Verapamil.
Cefaclor	Cefaclor may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefadroxil	Cefadroxil may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefalotin	Cefalotin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefamandole	Cefamandole may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefapirin	Cefapirin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefazolin	Cefazolin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefdinir	Cefdinir may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefditoren	Cefditoren may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefepime	Cefepime may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefmenoxime	Cefmenoxime may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefmetazole	Cefmetazole may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefonicid	Cefonicid may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefoperazone	Cefoperazone may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ceforanide	Ceforanide may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefotaxime	Cefotaxime may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefotetan	Cefotetan may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefotiam	Cefotiam may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefoxitin	Cefoxitin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefpiramide	Cefpiramide may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefpirome	Cefpirome may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefpodoxime	Cefpodoxime may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefprozil	Cefprozil may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefradine	Cefradine may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ceftaroline fosamil	Ceftaroline fosamil may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ceftazidime	Ceftazidime may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ceftibuten	Ceftibuten may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ceftizoxime	Ceftizoxime may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ceftobiprole	Ceftobiprole may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ceftolozane	Verapamil may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftriaxone	Ceftriaxone may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cefuroxime	Cefuroxime may decrease the excretion rate of Verapamil which could result in a higher serum level.
Celecoxib	The metabolism of Celecoxib can be decreased when combined with Verapamil.
Celiprolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Celiprolol.
Cenobamate	The serum concentration of Verapamil can be decreased when it is combined with Cenobamate.
Cephalexin	The metabolism of Cephalexin can be decreased when combined with Verapamil.
Cephaloglycin	Cephaloglycin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ceritinib	Verapamil may increase the bradycardic activities of Ceritinib.
Cerivastatin	The metabolism of Cerivastatin can be decreased when combined with Verapamil.
Certolizumab pegol	The metabolism of Verapamil can be increased when combined with Certolizumab pegol.
Cetirizine	Cetirizine may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cevimeline	The metabolism of Cevimeline can be decreased when combined with Verapamil.
Chenodeoxycholic acid	The metabolism of Chenodeoxycholic acid can be decreased when combined with Verapamil.
Chloral hydrate	Verapamil may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
Chloramphenicol	The metabolism of Verapamil can be decreased when combined with Chloramphenicol.
Chloroquine	The metabolism of Chloroquine can be decreased when combined with Verapamil.
Chlorothiazide	The risk or severity of adverse effects can be increased when Verapamil is combined with Chlorothiazide.
Chlorpheniramine	The metabolism of Chlorpheniramine can be decreased when combined with Verapamil.
Chlorpromazine	The metabolism of Chlorpromazine can be decreased when combined with Verapamil.
Chlorpropamide	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Chlorpropamide.
Chlorthalidone	The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Verapamil.
Chlorzoxazone	The metabolism of Chlorzoxazone can be decreased when combined with Verapamil.
Cholecalciferol	The metabolism of Cholecalciferol can be decreased when combined with Verapamil.
Choline	The risk or severity of adverse effects can be increased when Choline is combined with Verapamil.
Choline C 11	Verapamil may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
Choline magnesium trisalicylate	Choline magnesium trisalicylate may decrease the excretion rate of Verapamil which could result in a higher serum level.
Choline salicylate	The risk or severity of bleeding can be increased when Verapamil is combined with Choline salicylate.
Chondroitin sulfate	Verapamil may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chromic chloride	Verapamil may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromic nitrate	Verapamil may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
Chromium	Verapamil may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium gluconate	Verapamil may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
Chromium nicotinate	Verapamil may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromous sulfate	Verapamil may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
Ciclesonide	The metabolism of Ciclesonide can be decreased when combined with Verapamil.
Cidofovir	Cidofovir may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cilazapril	The risk or severity of adverse effects can be increased when Verapamil is combined with Cilazapril.
Cilostazol	The metabolism of Cilostazol can be decreased when combined with Verapamil.
Cimetidine	The serum concentration of Verapamil can be increased when it is combined with Cimetidine.
Cinacalcet	The metabolism of Cinacalcet can be decreased when combined with Verapamil.
Cinnarizine	Cinnarizine may increase the arrhythmogenic activities of Verapamil.
Cinoxacin	The metabolism of Verapamil can be decreased when combined with Cinoxacin.
Ciprofloxacin	The metabolism of Verapamil can be decreased when combined with Ciprofloxacin.
Cisapride	The metabolism of Cisapride can be decreased when combined with Verapamil.
Cisatracurium	Verapamil may increase the neuromuscular blocking activities of Cisatracurium.
Cisplatin	Verapamil may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Citalopram	The metabolism of Citalopram can be decreased when combined with Verapamil.
Clarithromycin	The risk or severity of adverse effects can be increased when Clarithromycin is combined with Verapamil.
Clenbuterol	The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Verapamil.
Clevidipine	Verapamil may increase the arrhythmogenic activities of Clevidipine.
Clindamycin	The metabolism of Clindamycin can be decreased when combined with Verapamil.
Clobazam	The metabolism of Clobazam can be decreased when combined with Verapamil.
Clobetasol propionate	The metabolism of Clobetasol propionate can be decreased when combined with Verapamil.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Verapamil.
Clofazimine	The serum concentration of Verapamil can be increased when it is combined with Clofazimine.
Clofibrate	The metabolism of Clofibrate can be decreased when combined with Verapamil.
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Verapamil.
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Verapamil.
Clonazepam	The metabolism of Clonazepam can be decreased when combined with Verapamil.
Clonidine	Verapamil may increase the atrioventricular blocking (AV block) activities of Clonidine.
Clopidogrel	The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Verapamil.
Clorazepic acid	The metabolism of Clorazepic acid can be decreased when combined with Verapamil.
Clotiazepam	The metabolism of Clotiazepam can be decreased when combined with Verapamil.
Clove oil	Verapamil may decrease the excretion rate of Clove oil which could result in a higher serum level.
Clozapine	The serum concentration of Clozapine can be increased when it is combined with Verapamil.
Cobicistat	The metabolism of Verapamil can be decreased when combined with Cobicistat.
Cobimetinib	The metabolism of Cobimetinib can be decreased when combined with Verapamil.
Codeine	The metabolism of Codeine can be decreased when combined with Verapamil.
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Verapamil.
Colistimethate	Colistimethate may decrease the excretion rate of Verapamil which could result in a higher serum level.
Colistin	Verapamil may decrease the excretion rate of Colistin which could result in a higher serum level.
Conivaptan	The metabolism of Verapamil can be decreased when combined with Conivaptan.
Conjugated estrogens	The metabolism of Conjugated estrogens can be decreased when combined with Verapamil.
Copanlisib	The metabolism of Copanlisib can be decreased when combined with Verapamil.
Corifollitropin alfa	Verapamil may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
Corticotropin	The metabolism of Corticotropin can be decreased when combined with Verapamil.
Cortisone acetate	The metabolism of Cortisone acetate can be decreased when combined with Verapamil.
Crizotinib	Crizotinib may increase the bradycardic activities of Verapamil.
Cryptenamine	Verapamil may increase the hypotensive activities of Cryptenamine.
Curcumin	The metabolism of Verapamil can be decreased when combined with Curcumin.
Cyanocobalamin	Cyanocobalamin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Cyclandelate	Verapamil may increase the arrhythmogenic activities of Cyclandelate.
Cyclobenzaprine	The metabolism of Cyclobenzaprine can be decreased when combined with Verapamil.
Cyclopenthiazide	Cyclopenthiazide may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
Cyclophosphamide	The metabolism of Cyclophosphamide can be decreased when combined with Verapamil.
Cyclosporine	The serum concentration of Cyclosporine can be increased when it is combined with Verapamil.
Cyclothiazide	Cyclothiazide may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
Cyproterone acetate	The metabolism of Verapamil can be increased when combined with Cyproterone acetate.
Cytarabine	The risk or severity of adverse effects can be increased when Verapamil is combined with Cytarabine.
Dabigatran etexilate	The serum concentration of Dabigatran etexilate can be increased when it is combined with Verapamil.
Dabrafenib	The serum concentration of Verapamil can be decreased when it is combined with Dabrafenib.
Dacarbazine	The metabolism of Dacarbazine can be decreased when combined with Verapamil.
Daclatasvir	The metabolism of Daclatasvir can be decreased when combined with Verapamil.
Dacomitinib	The serum concentration of Dacomitinib can be increased when it is combined with Verapamil.
Dactinomycin	The serum concentration of Dactinomycin can be increased when it is combined with Verapamil.
Dalfampridine	Verapamil may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Danazol	The metabolism of Verapamil can be decreased when combined with Danazol.
Danicopan	The serum concentration of Verapamil can be increased when it is combined with Danicopan.
Dantrolene	The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Verapamil.
Dantron	The therapeutic efficacy of Dantron can be decreased when used in combination with Verapamil.
Dapagliflozin	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Dapagliflozin.
Dapsone	The metabolism of Dapsone can be decreased when combined with Verapamil.
Daptomycin	The serum concentration of Daptomycin can be increased when it is combined with Verapamil.
Daridorexant	The metabolism of Daridorexant can be decreased when combined with Verapamil.
Darifenacin	The metabolism of Darifenacin can be decreased when combined with Verapamil.
Darolutamide	The metabolism of Darolutamide can be decreased when combined with Verapamil.
Darunavir	The serum concentration of Verapamil can be increased when it is combined with Darunavir.
Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Verapamil.
Dasatinib	The serum concentration of Dasatinib can be increased when it is combined with Verapamil.
Dasiglucagon	Verapamil may increase the hypotensive activities of Dasiglucagon.
Daunorubicin	The metabolism of Verapamil can be increased when combined with Daunorubicin.
Debrisoquine	The metabolism of Debrisoquine can be decreased when combined with Verapamil.
Deferasirox	The serum concentration of Verapamil can be increased when it is combined with Deferasirox.
Deferiprone	Verapamil may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Deflazacort	The serum concentration of Deflazacort can be increased when it is combined with Verapamil.
Dehydrocholic acid	The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Verapamil.
Delafloxacin	Verapamil may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Delamanid	The metabolism of Delamanid can be decreased when combined with Verapamil.
Delavirdine	The metabolism of Verapamil can be decreased when combined with Delavirdine.
Deserpidine	Verapamil may increase the hypotensive activities of Deserpidine.
Desflurane	The risk or severity of myocardial depression can be increased when Verapamil is combined with Desflurane.
Desipramine	The metabolism of Desipramine can be decreased when combined with Verapamil.
Deslanoside	Verapamil may increase the arrhythmogenic activities of Deslanoside.
Desmopressin	Desmopressin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Desogestrel	The metabolism of Desogestrel can be decreased when combined with Verapamil.
Desoxycorticosterone acetate	The metabolism of Desoxycorticosterone acetate can be decreased when combined with Verapamil.
Desvenlafaxine	The metabolism of Desvenlafaxine can be decreased when combined with Verapamil.
Deutetrabenazine	The metabolism of Deutetrabenazine can be decreased when combined with Verapamil.
Dexamethasone	The metabolism of Verapamil can be increased when combined with Dexamethasone.
Dexamethasone acetate	The metabolism of Dexamethasone acetate can be decreased when combined with Verapamil.
Dexchlorpheniramine maleate	The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Verapamil.
Dexfenfluramine	The metabolism of Dexfenfluramine can be decreased when combined with Verapamil.
Dexibuprofen	Dexibuprofen may decrease the excretion rate of Verapamil which could result in a higher serum level.
Dexketoprofen	Dexketoprofen may decrease the excretion rate of Verapamil which could result in a higher serum level.
Dexlansoprazole	The metabolism of Dexlansoprazole can be decreased when combined with Verapamil.
Dexmedetomidine	The metabolism of Verapamil can be decreased when combined with Dexmedetomidine.
Dexpanthenol	Verapamil may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dexrazoxane	Dexrazoxane may decrease the excretion rate of Verapamil which could result in a higher serum level.
Dextran	Verapamil may decrease the excretion rate of Dextran which could result in a higher serum level.
Dextroamphetamine	The therapeutic efficacy of Verapamil can be decreased when used in combination with Dextroamphetamine.
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Verapamil.
Dextropropoxyphene	The metabolism of Dextropropoxyphene can be decreased when combined with Verapamil.
Diacerein	The metabolism of Verapamil can be decreased when combined with Diacerein.
Diatrizoate	Diatrizoate may decrease the excretion rate of Verapamil which could result in a higher serum level.
Diazepam	The metabolism of Diazepam can be decreased when combined with Verapamil.
Diazoxide	The risk or severity of adverse effects can be increased when Verapamil is combined with Diazoxide.
Dichlorobenzyl alcohol	Verapamil may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Diclofenac	The metabolism of Diclofenac can be decreased when combined with Verapamil.
Diclofenamide	The risk or severity of adverse effects can be increased when Verapamil is combined with Diclofenamide.
Dicyclomine	Verapamil may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Didanosine	Verapamil may decrease the excretion rate of Didanosine which could result in a higher serum level.
Dienogest	The metabolism of Dienogest can be decreased when combined with Verapamil.
Diethylpropion	The therapeutic efficacy of Verapamil can be decreased when used in combination with Diethylpropion.
Diethylstilbestrol	The metabolism of Diethylstilbestrol can be decreased when combined with Verapamil.
Diflunisal	The risk or severity of bleeding can be increased when Verapamil is combined with Diflunisal.
Difluocortolone	The metabolism of Difluocortolone can be decreased when combined with Verapamil.
Digitoxin	Verapamil may increase the arrhythmogenic activities of Digitoxin.
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Verapamil.
Dihydralazine	The metabolism of Verapamil can be decreased when combined with Dihydralazine.
Dihydro-alpha-ergocryptine	The metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Verapamil.
Dihydrocodeine	The metabolism of Dihydrocodeine can be decreased when combined with Verapamil.
Dihydroergocornine	The metabolism of Dihydroergocornine can be decreased when combined with Verapamil.
Dihydroergocristine	The metabolism of Dihydroergocristine can be decreased when combined with Verapamil.
Dihydroergotamine	The metabolism of Dihydroergotamine can be decreased when combined with Verapamil.
Dihydrostreptomycin	Dihydrostreptomycin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Diltiazem	Diltiazem may increase the arrhythmogenic activities of Verapamil.
Dimercaprol	Verapamil may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
Dimethyl sulfoxide	Verapamil may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
Dinutuximab	The risk or severity of adverse effects can be increased when Verapamil is combined with Dinutuximab.
Diosmin	The serum concentration of Verapamil can be increased when it is combined with Diosmin.
Diphenhydramine	The metabolism of Diphenhydramine can be decreased when combined with Verapamil.
Dipotassium phosphate	The therapeutic efficacy of Dipotassium phosphate can be decreased when used in combination with Verapamil.
Dipyridamole	The risk or severity of adverse effects can be increased when Verapamil is combined with Dipyridamole.
Disopyramide	The risk or severity of sinus node depression can be increased when Verapamil is combined with Disopyramide.
Disulfiram	The metabolism of Disulfiram can be decreased when combined with Verapamil.
DL-Methylephedrine	Verapamil may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Dobutamine	Verapamil may decrease the excretion rate of Dobutamine which could result in a higher serum level.
Docetaxel	The metabolism of Docetaxel can be decreased when combined with Verapamil.
Docusate	The therapeutic efficacy of Docusate can be decreased when used in combination with Verapamil.
Dofetilide	The serum concentration of Dofetilide can be increased when it is combined with Verapamil.
Dolasetron	The metabolism of Dolasetron can be decreased when combined with Verapamil.
Dolutegravir	The serum concentration of Dolutegravir can be increased when it is combined with Verapamil.
Domperidone	The metabolism of Domperidone can be decreased when combined with Verapamil.
Donepezil	The metabolism of Donepezil can be decreased when combined with Verapamil.
Dopamine	The risk or severity of adverse effects can be increased when Verapamil is combined with Dopamine.
Dopexamine	The therapeutic efficacy of Dopexamine can be decreased when used in combination with Verapamil.
Doravirine	The metabolism of Doravirine can be decreased when combined with Verapamil.
Doripenem	Verapamil may decrease the excretion rate of Doripenem which could result in a higher serum level.
Dosulepin	The metabolism of Verapamil can be decreased when combined with Dosulepin.
Doxacurium	Verapamil may increase the neuromuscular blocking activities of Doxacurium.
Doxazosin	The metabolism of Doxazosin can be decreased when combined with Verapamil.
Doxepin	The metabolism of Doxepin can be decreased when combined with Verapamil.
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Verapamil.
Doxycycline	Doxycycline may decrease the excretion rate of Verapamil which could result in a higher serum level.
Dronabinol	The serum concentration of Dronabinol can be increased when it is combined with Verapamil.
Dronedarone	The serum concentration of Verapamil can be increased when it is combined with Dronedarone.
Droperidol	The risk or severity of hypotension can be increased when Droperidol is combined with Verapamil.
Drospirenone	The metabolism of Drospirenone can be decreased when combined with Verapamil.
Droxidopa	Verapamil may decrease the hypertensive activities of Droxidopa.
Dulaglutide	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Dulaglutide.
Duloxetine	The risk or severity of orthostatic hypotension and syncope can be increased when Verapamil is combined with Duloxetine.
Dutasteride	The metabolism of Dutasteride can be decreased when combined with Verapamil.
Duvelisib	The metabolism of Duvelisib can be decreased when combined with Verapamil.
Dydrogesterone	The metabolism of Dydrogesterone can be decreased when combined with Verapamil.
Dyphylline	Dyphylline may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ebastine	The metabolism of Ebastine can be decreased when combined with Verapamil.
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Verapamil.
Edrophonium	Verapamil may decrease the excretion rate of Edrophonium which could result in a higher serum level.
Efavirenz	The serum concentration of Verapamil can be decreased when it is combined with Efavirenz.
Elacestrant	The serum concentration of Elacestrant can be increased when it is combined with Verapamil.
Elagolix	The serum concentration of Elagolix can be increased when it is combined with Verapamil.
Elbasvir	The metabolism of Elbasvir can be decreased when combined with Verapamil.
Eletriptan	The metabolism of Eletriptan can be decreased when combined with Verapamil.
Elexacaftor	The serum concentration of Elexacaftor can be increased when it is combined with Verapamil.
Eliglustat	The metabolism of Eliglustat can be decreased when combined with Verapamil.
Eltrombopag	The metabolism of Eltrombopag can be decreased when combined with Verapamil.
Elvitegravir	The metabolism of Verapamil can be decreased when combined with Elvitegravir.
Emapalumab	The metabolism of Verapamil can be increased when combined with Emapalumab.
Empagliflozin	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Empagliflozin.
Enalapril	The risk or severity of adverse effects can be increased when Enalapril is combined with Verapamil.
Enalaprilat	The risk or severity of adverse effects can be increased when Verapamil is combined with Enalaprilat.
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Verapamil.
Encainide	Verapamil may increase the arrhythmogenic activities of Encainide.
Encorafenib	The serum concentration of Encorafenib can be increased when it is combined with Verapamil.
Enflurane	The risk or severity of myocardial depression can be increased when Verapamil is combined with Enflurane.
Enfortumab vedotin	The metabolism of Enfortumab vedotin can be decreased when combined with Verapamil.
Enoxacin	The metabolism of Verapamil can be decreased when combined with Enoxacin.
Entecavir	The metabolism of Verapamil can be decreased when combined with Entecavir.
Entrectinib	The metabolism of Entrectinib can be decreased when combined with Verapamil.
Enzalutamide	The serum concentration of Verapamil can be decreased when it is combined with Enzalutamide.
Epcoritamab	The serum concentration of Verapamil can be increased when it is combined with Epcoritamab.
Ephedrine	Verapamil may decrease the hypertensive activities of Ephedrine.
Epinastine	The metabolism of Epinastine can be decreased when combined with Verapamil.
Epinephrine	The risk or severity of adverse effects can be increased when Verapamil is combined with Epinephrine.
Eplerenone	The metabolism of Eplerenone can be decreased when combined with Verapamil.
Epoprostenol	The risk or severity of adverse effects can be increased when Verapamil is combined with Epoprostenol.
Eprosartan	The risk or severity of adverse effects can be increased when Verapamil is combined with Eprosartan.
Eravacycline	The metabolism of Eravacycline can be decreased when combined with Verapamil.
Erdafitinib	The serum concentration of Verapamil can be increased when it is combined with Erdafitinib.
Ergoloid mesylate	The metabolism of Ergoloid mesylate can be decreased when combined with Verapamil.
Ergometrine	The metabolism of Ergometrine can be decreased when combined with Verapamil.
Ergotamine	The metabolism of Verapamil can be decreased when combined with Ergotamine.
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Verapamil.
Ertapenem	Ertapenem may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ertugliflozin	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Ertugliflozin.
Erythrityl tetranitrate	Verapamil may increase the vasodilatory activities of Erythrityl tetranitrate.
Erythromycin	The risk or severity of adverse effects can be increased when Erythromycin is combined with Verapamil.
Escitalopram	The metabolism of Escitalopram can be decreased when combined with Verapamil.
Esketamine	The metabolism of Esketamine can be decreased when combined with Verapamil.
Esmolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Esmolol.
Esomeprazole	The metabolism of Esomeprazole can be decreased when combined with Verapamil.
Estazolam	The metabolism of Estazolam can be decreased when combined with Verapamil.
Esterified estrogens	The metabolism of Esterified estrogens can be decreased when combined with Verapamil.
Estetrol	The metabolism of Estetrol can be decreased when combined with Verapamil.
Estradiol	The metabolism of Estradiol can be decreased when combined with Verapamil.
Estradiol acetate	The metabolism of Estradiol acetate can be decreased when combined with Verapamil.
Estradiol benzoate	The metabolism of Estradiol benzoate can be decreased when combined with Verapamil.
Estradiol cypionate	The metabolism of Estradiol cypionate can be decreased when combined with Verapamil.
Estradiol dienanthate	The metabolism of Estradiol dienanthate can be decreased when combined with Verapamil.
Estradiol valerate	The metabolism of Estradiol valerate can be decreased when combined with Verapamil.
Estramustine	The metabolism of Estramustine can be decreased when combined with Verapamil.
Estrone sulfate	The metabolism of Estrone sulfate can be decreased when combined with Verapamil.
Eszopiclone	The metabolism of Eszopiclone can be decreased when combined with Verapamil.
Etacrynic acid	The risk or severity of adverse effects can be increased when Verapamil is combined with Etacrynic acid.
Etafedrine	Verapamil may decrease the excretion rate of Etafedrine which could result in a higher serum level.
Etanercept	The metabolism of Verapamil can be increased when combined with Etanercept.
Ethambutol	Ethambutol may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ethanol	The serum concentration of Ethanol can be increased when it is combined with Verapamil.
Ethinylestradiol	The metabolism of Ethinylestradiol can be decreased when combined with Verapamil.
Ethosuximide	Ethosuximide may increase the arrhythmogenic activities of Verapamil.
Ethynodiol diacetate	The metabolism of Ethynodiol diacetate can be decreased when combined with Verapamil.
Etilefrine	The therapeutic efficacy of Etilefrine can be decreased when used in combination with Verapamil.
Etodolac	Etodolac may decrease the excretion rate of Verapamil which could result in a higher serum level.
Etomidate	Etomidate may decrease the excretion rate of Verapamil which could result in a higher serum level.
Etonogestrel	The metabolism of Etonogestrel can be decreased when combined with Verapamil.
Etoposide	The serum concentration of Etoposide can be increased when it is combined with Verapamil.
Etoricoxib	The metabolism of Etoricoxib can be decreased when combined with Verapamil.
Etrasimod	The risk or severity of QTc prolongation and torsade de pointes can be increased when Etrasimod is combined with Verapamil.
Etravirine	The metabolism of Etravirine can be decreased when combined with Verapamil.
Eucalyptus oil	Verapamil may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Verapamil.
Exemestane	The metabolism of Exemestane can be decreased when combined with Verapamil.
Exenatide	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Exenatide.
Ezogabine	Verapamil may decrease the excretion rate of Ezogabine which could result in a higher serum level.
Famotidine	The metabolism of Verapamil can be decreased when combined with Famotidine.
Favipiravir	The serum concentration of Verapamil can be increased when it is combined with Favipiravir.
Fedratinib	The serum concentration of Verapamil can be increased when it is combined with Fedratinib.
Felbamate	The metabolism of Felbamate can be decreased when combined with Verapamil.
Felodipine	Verapamil may increase the arrhythmogenic activities of Felodipine.
Fenbufen	Fenbufen may decrease the excretion rate of Verapamil which could result in a higher serum level.
Fenfluramine	The metabolism of Verapamil can be decreased when combined with Fenfluramine.
Fenofibrate	The metabolism of Fenofibrate can be decreased when combined with Verapamil.
Fenofibric acid	Verapamil may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Fenoldopam	The risk or severity of adverse effects can be increased when Verapamil is combined with Fenoldopam.
Fenoprofen	Fenoprofen may decrease the excretion rate of Verapamil which could result in a higher serum level.
Fenoterol	The therapeutic efficacy of Fenoterol can be decreased when used in combination with Verapamil.
Fentanyl	The metabolism of Fentanyl can be decreased when combined with Verapamil.
Fesoterodine	The metabolism of Fesoterodine can be decreased when combined with Verapamil.
Fexinidazole	The risk or severity of adverse effects can be increased when Verapamil is combined with Fexinidazole.
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Verapamil.
Fezolinetant	The metabolism of Fezolinetant can be decreased when combined with Verapamil.
Finasteride	The metabolism of Finasteride can be decreased when combined with Verapamil.
Finerenone	The serum concentration of Finerenone can be increased when it is combined with Verapamil.
Fingolimod	The risk or severity of bradycardia can be increased when Verapamil is combined with Fingolimod.
Fish oil	Verapamil may increase the arrhythmogenic activities of Fish oil.
Flavoxate	Verapamil may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Flecainide	The risk or severity of adverse effects can be increased when Verapamil is combined with Flecainide.
Flibanserin	The metabolism of Flibanserin can be decreased when combined with Verapamil.
Floctafenine	Floctafenine may decrease the excretion rate of Verapamil which could result in a higher serum level.
Florbetaben F-18	Verapamil may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir (18F)	Verapamil may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Floxuridine	Floxuridine may decrease the excretion rate of Verapamil which could result in a higher serum level.
Fluconazole	The metabolism of Verapamil can be decreased when combined with Fluconazole.
Flucytosine	Verapamil may decrease the excretion rate of Flucytosine which could result in a higher serum level.
Fludeoxyglucose (18F)	Verapamil may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Fludrocortisone	The metabolism of Fludrocortisone can be decreased when combined with Verapamil.
Flumazenil	Verapamil may decrease the excretion rate of Flumazenil which could result in a higher serum level.
Flumethasone	The metabolism of Flumethasone can be decreased when combined with Verapamil.
Flunarizine	Verapamil may increase the arrhythmogenic activities of Flunarizine.
Flunitrazepam	The metabolism of Flunitrazepam can be decreased when combined with Verapamil.
Fluocinolone acetonide	The metabolism of Fluocinolone acetonide can be decreased when combined with Verapamil.
Fluocinonide	The metabolism of Fluocinonide can be decreased when combined with Verapamil.
Fluocortolone	The metabolism of Fluocortolone can be decreased when combined with Verapamil.
Fluorouracil	The metabolism of Verapamil can be decreased when combined with Fluorouracil.
Fluoxetine	The metabolism of Verapamil can be decreased when combined with Fluoxetine.
Flupentixol	The risk or severity of hypotension can be increased when Flupentixol is combined with Verapamil.
Fluprednisolone	The metabolism of Fluprednisolone can be decreased when combined with Verapamil.
Flurazepam	The metabolism of Flurazepam can be decreased when combined with Verapamil.
Flurbiprofen	Flurbiprofen may decrease the excretion rate of Verapamil which could result in a higher serum level.
Fluspirilene	Verapamil may increase the arrhythmogenic activities of Fluspirilene.
Flutamide	The metabolism of Flutamide can be decreased when combined with Verapamil.
Fluticasone	The metabolism of Fluticasone can be decreased when combined with Verapamil.
Fluticasone furoate	The serum concentration of Fluticasone furoate can be increased when it is combined with Verapamil.
Fluticasone propionate	The metabolism of Fluticasone propionate can be decreased when combined with Verapamil.
Fluvastatin	The metabolism of Fluvastatin can be decreased when combined with Verapamil.
Fluvoxamine	The metabolism of Verapamil can be decreased when combined with Fluvoxamine.
Folic acid	Folic acid may decrease the excretion rate of Verapamil which could result in a higher serum level.
Fomepizole	Verapamil may decrease the excretion rate of Fomepizole which could result in a higher serum level.
Fondaparinux	Fondaparinux may decrease the excretion rate of Verapamil which could result in a higher serum level.
Formestane	Verapamil may decrease the excretion rate of Formestane which could result in a higher serum level.
Formoterol	The risk or severity of adverse effects can be increased when Verapamil is combined with Formoterol.
Fosamprenavir	The metabolism of Fosamprenavir can be decreased when combined with Verapamil.
Fosaprepitant	The metabolism of Fosaprepitant can be decreased when combined with Verapamil.
Foscarnet	Foscarnet may decrease the excretion rate of Verapamil which could result in a higher serum level.
Fosfomycin	Verapamil may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Fosinopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Verapamil.
Fosnetupitant	The metabolism of Fosnetupitant can be decreased when combined with Verapamil.
Fosphenytoin	The serum concentration of Verapamil can be decreased when it is combined with Fosphenytoin.
Fostamatinib	The metabolism of Fostamatinib can be decreased when combined with Verapamil.
Fostemsavir	The metabolism of Fostemsavir can be decreased when combined with Verapamil.
Framycetin	Framycetin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Frangula purshiana bark	The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Verapamil.
Frovatriptan	The metabolism of Frovatriptan can be decreased when combined with Verapamil.
Fruquintinib	The metabolism of Fruquintinib can be decreased when combined with Verapamil.
Furosemide	The risk or severity of adverse effects can be increased when Verapamil is combined with Furosemide.
Fusidic acid	The metabolism of Fusidic acid can be decreased when combined with Verapamil.
Futibatinib	The serum concentration of Futibatinib can be increased when it is combined with Verapamil.
Gabapentin enacarbil	Verapamil may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Gadobenic acid	Verapamil may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
Gadodiamide	Gadodiamide may decrease the excretion rate of Verapamil which could result in a higher serum level.
Gadofosveset trisodium	Verapamil may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Gadopentetic acid	Verapamil may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
Gadoteric acid	Verapamil may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol	Gadoteridol may decrease the excretion rate of Verapamil which could result in a higher serum level.
Galantamine	The metabolism of Galantamine can be decreased when combined with Verapamil.
Gallamine triethiodide	Verapamil may increase the neuromuscular blocking activities of Gallamine triethiodide.
Ganciclovir	The risk or severity of adverse effects can be increased when Verapamil is combined with Ganciclovir.
Gatifloxacin	The metabolism of Verapamil can be decreased when combined with Gatifloxacin.
Gefitinib	The metabolism of Gefitinib can be decreased when combined with Verapamil.
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Verapamil.
Gemfibrozil	The metabolism of Gemfibrozil can be decreased when combined with Verapamil.
Gemifloxacin	The metabolism of Verapamil can be decreased when combined with Gemifloxacin.
Gentamicin	Verapamil may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gepirone	The serum concentration of Gepirone can be increased when it is combined with Verapamil.
Gestrinone	The metabolism of Gestrinone can be decreased when combined with Verapamil.
Gilteritinib	The metabolism of Gilteritinib can be decreased when combined with Verapamil.
Gimeracil	Verapamil may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Givosiran	The serum concentration of Verapamil can be increased when it is combined with Givosiran.
Glasdegib	The metabolism of Glasdegib can be decreased when combined with Verapamil.
Glecaprevir	The serum concentration of Glecaprevir can be increased when it is combined with Verapamil.
Gliclazide	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Gliclazide.
Glimepiride	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Glimepiride.
Glipizide	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Glipizide.
Gliquidone	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Gliquidone.
Glofitamab	The serum concentration of Verapamil can be increased when it is combined with Glofitamab.
Gluconic Acid	The therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Verapamil.
Glyburide	The metabolism of Glyburide can be decreased when combined with Verapamil.
Glycerin	The therapeutic efficacy of Glycerin can be decreased when used in combination with Verapamil.
Glycerol phenylbutyrate	Verapamil may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
Glymidine	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Glymidine.
Golimumab	The metabolism of Verapamil can be increased when combined with Golimumab.
Golodirsen	Verapamil may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Goserelin	Goserelin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Granisetron	The metabolism of Granisetron can be decreased when combined with Verapamil.
Grazoprevir	The metabolism of Grazoprevir can be decreased when combined with Verapamil.
Grepafloxacin	The metabolism of Grepafloxacin can be decreased when combined with Verapamil.
Guanabenz	The metabolism of Verapamil can be decreased when combined with Guanabenz.
Guanadrel	Verapamil may increase the hypotensive activities of Guanadrel.
Guanethidine	Verapamil may decrease the excretion rate of Guanethidine which could result in a higher serum level.
Guanfacine	The metabolism of Guanfacine can be decreased when combined with Verapamil.
Guanoxan	Verapamil may increase the hypotensive activities of Guanoxan.
Halofantrine	The metabolism of Halofantrine can be decreased when combined with Verapamil.
Haloperidol	The serum concentration of Haloperidol can be increased when it is combined with Verapamil.
Halothane	The risk or severity of myocardial depression can be increased when Verapamil is combined with Halothane.
Histamine	The risk or severity of adverse effects can be increased when Verapamil is combined with Histamine.
Hydralazine	The risk or severity of adverse effects can be increased when Verapamil is combined with Hydralazine.
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Verapamil is combined with Hydrochlorothiazide.
Hydrocodone	The metabolism of Hydrocodone can be decreased when combined with Verapamil.
Hydrocortisone	The metabolism of Hydrocortisone can be decreased when combined with Verapamil.
Hydrocortisone acetate	The metabolism of Hydrocortisone acetate can be decreased when combined with Verapamil.
Hydrocortisone butyrate	The metabolism of Hydrocortisone butyrate can be decreased when combined with Verapamil.
Hydrocortisone cypionate	The metabolism of Hydrocortisone cypionate can be decreased when combined with Verapamil.
Hydrocortisone phosphate	The metabolism of Hydrocortisone phosphate can be decreased when combined with Verapamil.
Hydrocortisone succinate	The metabolism of Hydrocortisone succinate can be decreased when combined with Verapamil.
Hydroflumethiazide	The risk or severity of adverse effects can be increased when Verapamil is combined with Hydroflumethiazide.
Hydromorphone	Hydromorphone may decrease the excretion rate of Verapamil which could result in a higher serum level.
Hydrotalcite	The risk or severity of hypotension can be increased when Hydrotalcite is combined with Verapamil.
Hydroxocobalamin	Hydroxocobalamin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Hydroxychloroquine	The metabolism of Hydroxychloroquine can be decreased when combined with Verapamil.
Hydroxyethyl Starch	Verapamil may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Hydroxyprogesterone caproate	The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Verapamil.
Hydroxyzine	The metabolism of Hydroxyzine can be decreased when combined with Verapamil.
Hyoscyamine	Hyoscyamine may increase the arrhythmogenic activities of Verapamil.
Ibrexafungerp	The metabolism of Ibrexafungerp can be decreased when combined with Verapamil.
Ibrutinib	The metabolism of Ibrutinib can be decreased when combined with Verapamil.
Ibuprofen	The metabolism of Ibuprofen can be decreased when combined with Verapamil.
Ibutilide	Ibutilide may increase the arrhythmogenic activities of Verapamil.
Icatibant	Verapamil may decrease the excretion rate of Icatibant which could result in a higher serum level.
Icosapent	Icosapent may decrease the excretion rate of Verapamil which could result in a higher serum level.
Idarubicin	The metabolism of Idarubicin can be decreased when combined with Verapamil.
Idarucizumab	Verapamil may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Idebenone	Verapamil may decrease the excretion rate of Idebenone which could result in a higher serum level.
Idelalisib	The metabolism of Idelalisib can be decreased when combined with Verapamil.
Ifosfamide	The metabolism of Ifosfamide can be decreased when combined with Verapamil.
Iloperidone	The risk or severity of hypotension can be increased when Verapamil is combined with Iloperidone.
Iloprost	Iloprost may increase the hypotensive activities of Verapamil.
Imatinib	The metabolism of Imatinib can be decreased when combined with Verapamil.
Imipramine	The serum concentration of Imipramine can be increased when it is combined with Verapamil.
Indacaterol	The metabolism of Indacaterol can be decreased when combined with Verapamil.
Indapamide	The metabolism of Indapamide can be decreased when combined with Verapamil.
Indigotindisulfonic acid	Verapamil may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Indinavir	The metabolism of Verapamil can be decreased when combined with Indinavir.
Indomethacin	Indomethacin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Indoramin	The risk or severity of hypotension can be increased when Indoramin is combined with Verapamil.
Infigratinib	The metabolism of Infigratinib can be decreased when combined with Verapamil.
Infliximab	The metabolism of Verapamil can be increased when combined with Infliximab.
Inosine pranobex	Verapamil may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Inositol	Verapamil may decrease the excretion rate of Inositol which could result in a higher serum level.
Inotersen	Inotersen may decrease the excretion rate of Verapamil which could result in a higher serum level.
Insulin aspart	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Insulin aspart.
Insulin beef	The metabolism of Verapamil can be increased when combined with Insulin beef.
Insulin degludec	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Insulin degludec.
Insulin detemir	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Insulin detemir.
Insulin glargine	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Insulin glargine.
Insulin glulisine	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Insulin glulisine.
Insulin human	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Insulin human.
Insulin lispro	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Insulin lispro.
Insulin pork	The metabolism of Verapamil can be increased when combined with Insulin pork.
Interferon alfa-2a	The metabolism of Verapamil can be decreased when combined with Interferon alfa-2a.
Interferon alfa-2b	The metabolism of Verapamil can be decreased when combined with Interferon alfa-2b.
Interferon alfa-n1	The metabolism of Verapamil can be decreased when combined with Interferon alfa-n1.
Interferon alfa-n3	The metabolism of Verapamil can be decreased when combined with Interferon alfa-n3.
Interferon alfacon-1	The metabolism of Verapamil can be decreased when combined with Interferon alfacon-1.
Interferon beta-1a	The metabolism of Verapamil can be decreased when combined with Interferon beta-1a.
Interferon beta-1b	The metabolism of Verapamil can be decreased when combined with Interferon beta-1b.
Interferon gamma-1b	The metabolism of Verapamil can be decreased when combined with Interferon gamma-1b.
Iobenguane sulfate I-123	Verapamil may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Iodixanol	Verapamil may decrease the excretion rate of Iodixanol which could result in a higher serum level.
Iofetamine I-123	The therapeutic efficacy of Verapamil can be decreased when used in combination with Iofetamine I-123.
Ioflupane I-123	Verapamil may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
Iopromide	Verapamil may decrease the excretion rate of Iopromide which could result in a higher serum level.
Iothalamic acid	Verapamil may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol	Verapamil may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ioxilan	Verapamil may decrease the excretion rate of Ioxilan which could result in a higher serum level.
Ipecac	The metabolism of Ipecac can be decreased when combined with Verapamil.
Ipilimumab	Verapamil may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Iptacopan	The metabolism of Iptacopan can be decreased when combined with Verapamil.
Irbesartan	The risk or severity of adverse effects can be increased when Verapamil is combined with Irbesartan.
Irinotecan	The metabolism of Irinotecan can be decreased when combined with Verapamil.
Isavuconazole	The serum concentration of Verapamil can be increased when it is combined with Isavuconazole.
Isavuconazonium	The serum concentration of Verapamil can be increased when it is combined with Isavuconazonium.
Isocarboxazid	Isocarboxazid may increase the orthostatic hypotensive activities of Verapamil.
Isoetharine	The therapeutic efficacy of Isoetharine can be decreased when used in combination with Verapamil.
Isoflurane	The risk or severity of myocardial depression can be increased when Verapamil is combined with Isoflurane.
Isometheptene	The therapeutic efficacy of Isometheptene can be decreased when used in combination with Verapamil.
Isoniazid	The metabolism of Verapamil can be decreased when combined with Isoniazid.
Isoprenaline	The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Verapamil.
Isosorbide	Verapamil may increase the vasodilatory activities of Isosorbide.
Isosorbide dinitrate	Verapamil may increase the vasodilatory activities of Isosorbide dinitrate.
Isosorbide mononitrate	Verapamil may increase the vasodilatory activities of Isosorbide mononitrate.
Isosulfan blue	Verapamil may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Isotretinoin	The metabolism of Isotretinoin can be decreased when combined with Verapamil.
Isoxicam	Isoxicam may decrease the excretion rate of Verapamil which could result in a higher serum level.
Isoxsuprine	The risk or severity of adverse effects can be increased when Verapamil is combined with Isoxsuprine.
Isradipine	Isradipine may increase the arrhythmogenic activities of Verapamil.
Istradefylline	The metabolism of Istradefylline can be decreased when combined with Verapamil.
Itraconazole	The metabolism of Verapamil can be decreased when combined with Itraconazole.
Ivabradine	The metabolism of Ivabradine can be decreased when combined with Verapamil.
Ivacaftor	The metabolism of Ivacaftor can be decreased when combined with Verapamil.
Ivermectin	The metabolism of Ivermectin can be decreased when combined with Verapamil.
Ivosidenib	The metabolism of Ivosidenib can be decreased when combined with Verapamil.
Ixabepilone	The metabolism of Ixabepilone can be decreased when combined with Verapamil.
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Verapamil.
Kanamycin	Verapamil may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Ketamine	The metabolism of Ketamine can be decreased when combined with Verapamil.
Ketazolam	The metabolism of Ketazolam can be decreased when combined with Verapamil.
Ketoconazole	The metabolism of Verapamil can be decreased when combined with Ketoconazole.
Ketoprofen	Ketoprofen may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ketorolac	Ketorolac may decrease the excretion rate of Verapamil which could result in a higher serum level.
Labetalol	The risk or severity of adverse effects can be increased when Verapamil is combined with Labetalol.
Lacidipine	Verapamil may increase the hypotensive activities of Lacidipine.
Lacosamide	The risk or severity of ventricular arrhythmias, bradycardia, and heart block can be increased when Verapamil is combined with Lacosamide.
Lactitol	The therapeutic efficacy of Lactitol can be decreased when used in combination with Verapamil.
Lactulose	The therapeutic efficacy of Lactulose can be decreased when used in combination with Verapamil.
Lamivudine	The risk or severity of adverse effects can be increased when Verapamil is combined with Lamivudine.
Lamotrigine	Lamotrigine may increase the arrhythmogenic activities of Verapamil.
Lanreotide	Verapamil may increase the bradycardic activities of Lanreotide.
Lansoprazole	The metabolism of Lansoprazole can be decreased when combined with Verapamil.
Lapatinib	The metabolism of Lapatinib can be decreased when combined with Verapamil.
Larotrectinib	The metabolism of Larotrectinib can be decreased when combined with Verapamil.
Lasmiditan	The serum concentration of Verapamil can be increased when it is combined with Lasmiditan.
Latamoxef	Latamoxef may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Verapamil.
Lefamulin	Verapamil may decrease the excretion rate of Lefamulin which could result in a higher serum level.
Leflunomide	The serum concentration of Verapamil can be decreased when it is combined with Leflunomide.
Lemborexant	The serum concentration of Lemborexant can be increased when it is combined with Verapamil.
Lenacapavir	The metabolism of Lenacapavir can be decreased when combined with Verapamil.
Lenalidomide	Lenalidomide may decrease the excretion rate of Verapamil which could result in a higher serum level.
Leniolisib	The metabolism of Verapamil can be decreased when combined with Leniolisib.
Lenvatinib	The serum concentration of Lenvatinib can be increased when it is combined with Verapamil.
Lercanidipine	Lercanidipine may increase the arrhythmogenic activities of Verapamil.
Lesinurad	Verapamil may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Letermovir	The metabolism of Verapamil can be decreased when combined with Letermovir.
Letrozole	The metabolism of Letrozole can be decreased when combined with Verapamil.
Leuprolide	Leuprolide may decrease the excretion rate of Verapamil which could result in a higher serum level.
Levacetylmethadol	The metabolism of Levacetylmethadol can be decreased when combined with Verapamil.
Levamlodipine	The serum concentration of Levamlodipine can be increased when it is combined with Verapamil.
Levobetaxolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Levobetaxolol.
Levobunolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Levobunolol.
Levobupivacaine	The metabolism of Levobupivacaine can be decreased when combined with Verapamil.
Levocarnitine	Levocarnitine may decrease the excretion rate of Verapamil which could result in a higher serum level.
Levocetirizine	The metabolism of Levocetirizine can be decreased when combined with Verapamil.
Levodopa	The risk or severity of hypotension and orthostatic hypotension can be increased when Verapamil is combined with Levodopa.
Levofloxacin	Verapamil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.
Levoketoconazole	The metabolism of Verapamil can be decreased when combined with Levoketoconazole.
Levomenthol	Verapamil may increase the arrhythmogenic activities of Levomenthol.
Levomilnacipran	The metabolism of Levomilnacipran can be decreased when combined with Verapamil.
Levonordefrin	Verapamil may decrease the hypertensive activities of Levonordefrin.
Levonorgestrel	The metabolism of Levonorgestrel can be decreased when combined with Verapamil.
Levosalbutamol	Verapamil may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Levosimendan	Verapamil may increase the arrhythmogenic activities of Levosimendan.
Lidocaine	Lidocaine may increase the arrhythmogenic activities of Verapamil.
Lidoflazine	Verapamil may increase the arrhythmogenic activities of Lidoflazine.
Linaclotide	The therapeutic efficacy of Linaclotide can be decreased when used in combination with Verapamil.
Linagliptin	The metabolism of Linagliptin can be decreased when combined with Verapamil.
Linezolid	Linezolid may increase the orthostatic hypotensive activities of Verapamil.
Liothyronine	Liothyronine may decrease the excretion rate of Verapamil which could result in a higher serum level.
Liotrix	The metabolism of Liotrix can be decreased when combined with Verapamil.
Liraglutide	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Liraglutide.
Lisdexamfetamine	The serum concentration of dextroamphetamine, an active metabolite of Lisdexamfetamine, can be increased when used in combination with Verapamil.
Lisinopril	The risk or severity of adverse effects can be increased when Verapamil is combined with Lisinopril.
Lisuride	The metabolism of Lisuride can be decreased when combined with Verapamil.
Lithium carbonate	The risk or severity of adverse effects can be increased when Verapamil is combined with Lithium carbonate.
Lithium citrate	The risk or severity of adverse effects can be increased when Verapamil is combined with Lithium citrate.
Lithium hydroxide	The risk or severity of adverse effects can be increased when Verapamil is combined with Lithium hydroxide.
Lixisenatide	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Lixisenatide.
Lofexidine	The metabolism of Lofexidine can be decreased when combined with Verapamil.
Lomefloxacin	The metabolism of Lomefloxacin can be decreased when combined with Verapamil.
Lomitapide	The metabolism of Lomitapide can be decreased when combined with Verapamil.
Lonafarnib	The metabolism of Verapamil can be decreased when combined with Lonafarnib.
Lonapegsomatropin	The metabolism of Verapamil can be increased when combined with Lonapegsomatropin.
Loncastuximab tesirine	The serum concentration of Loncastuximab tesirine can be increased when it is combined with Verapamil.
Loperamide	The excretion of Loperamide can be decreased when combined with Verapamil.
Lopinavir	The metabolism of Verapamil can be decreased when combined with Lopinavir.
Loracarbef	Loracarbef may decrease the excretion rate of Verapamil which could result in a higher serum level.
Loratadine	The metabolism of Loratadine can be decreased when combined with Verapamil.
Lorazepam	Lorazepam may decrease the excretion rate of Verapamil which could result in a higher serum level.
Lorcaserin	The metabolism of Lorcaserin can be decreased when combined with Verapamil.
Lorlatinib	The metabolism of Lorlatinib can be decreased when combined with Verapamil.
Lornoxicam	Lornoxicam may decrease the excretion rate of Verapamil which could result in a higher serum level.
Lorpiprazole	The metabolism of Lorpiprazole can be decreased when combined with Verapamil.
Losartan	Verapamil may increase the arrhythmogenic activities of Losartan.
Lovastatin	The risk or severity of myopathy and rhabdomyolysis can be increased when Verapamil is combined with Lovastatin.
Loxapine	The serum concentration of Verapamil can be increased when it is combined with Loxapine.
Loxoprofen	Loxoprofen may decrease the excretion rate of Verapamil which could result in a higher serum level.
Lubiprostone	The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Verapamil.
Lucinactant	Verapamil may increase the bradycardic activities of Lucinactant.
Lumacaftor	The serum concentration of Verapamil can be decreased when it is combined with Lumacaftor.
Lumateperone	The serum concentration of Lumateperone can be increased when it is combined with Verapamil.
Lumefantrine	The metabolism of Lumefantrine can be decreased when combined with Verapamil.
Lumiracoxib	Lumiracoxib may decrease the excretion rate of Verapamil which could result in a higher serum level.
Lurasidone	The metabolism of Lurasidone can be decreased when combined with Verapamil.
Lurbinectedin	The serum concentration of Lurbinectedin can be increased when it is combined with Verapamil.
Lusutrombopag	The serum concentration of Lusutrombopag can be increased when it is combined with Verapamil.
Lynestrenol	The metabolism of Lynestrenol can be decreased when combined with Verapamil.
Macimorelin	The metabolism of Macimorelin can be decreased when combined with Verapamil.
Macitentan	The metabolism of Macitentan can be decreased when combined with Verapamil.
Magaldrate	The risk or severity of hypotension can be increased when Magaldrate is combined with Verapamil.
Magnesium	Magnesium can cause a decrease in the absorption of Verapamil resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium acetate	The therapeutic efficacy of Magnesium acetate can be decreased when used in combination with Verapamil.
Magnesium acetate tetrahydrate	The therapeutic efficacy of Magnesium acetate tetrahydrate can be decreased when used in combination with Verapamil.
Magnesium carbonate	The risk or severity of hypotension can be increased when Magnesium carbonate is combined with Verapamil.
Magnesium cation	The therapeutic efficacy of Magnesium cation can be decreased when used in combination with Verapamil.
Magnesium chloride	The risk or severity of hypotension can be increased when Magnesium chloride is combined with Verapamil.
Magnesium citrate	The risk or severity of hypotension can be increased when Magnesium citrate is combined with Verapamil.
Magnesium gluconate	The risk or severity of hypotension can be increased when Magnesium gluconate is combined with Verapamil.
Magnesium glycinate	The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Verapamil.
Magnesium hydroxide	The risk or severity of hypotension can be increased when Magnesium hydroxide is combined with Verapamil.
Magnesium oxide	The risk or severity of hypotension can be increased when Magnesium oxide is combined with Verapamil.
Magnesium silicate	The risk or severity of hypotension can be increased when Magnesium silicate is combined with Verapamil.
Magnesium sulfate	Magnesium sulfate may increase the arrhythmogenic activities of Verapamil.
Magnesium trisilicate	The risk or severity of hypotension can be increased when Magnesium trisilicate is combined with Verapamil.
Mangafodipir	Verapamil may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
Manidipine	Verapamil may increase the arrhythmogenic activities of Manidipine.
Mannitol	The serum concentration of Mannitol can be increased when it is combined with Verapamil.
Maprotiline	The metabolism of Maprotiline can be decreased when combined with Verapamil.
Maraviroc	The metabolism of Maraviroc can be decreased when combined with Verapamil.
Maribavir	The metabolism of Maribavir can be decreased when combined with Verapamil.
Mavacamten	The serum concentration of Mavacamten can be increased when it is combined with Verapamil.
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Verapamil.
Mecasermin	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Mecasermin.
Meclizine	The metabolism of Meclizine can be decreased when combined with Verapamil.
Meclofenamic acid	Meclofenamic acid may decrease the excretion rate of Verapamil which could result in a higher serum level.
Medrogestone	The metabolism of Medrogestone can be decreased when combined with Verapamil.
Medroxyprogesterone acetate	The metabolism of Medroxyprogesterone acetate can be decreased when combined with Verapamil.
Mefenamic acid	The metabolism of Mefenamic acid can be decreased when combined with Verapamil.
Mefloquine	The metabolism of Mefloquine can be decreased when combined with Verapamil.
Megestrol acetate	The metabolism of Megestrol acetate can be decreased when combined with Verapamil.
Melatonin	The therapeutic efficacy of Verapamil can be decreased when used in combination with Melatonin.
Meloxicam	The metabolism of Meloxicam can be decreased when combined with Verapamil.
Memantine	Verapamil may decrease the excretion rate of Memantine which could result in a higher serum level.
Meperidine	The metabolism of Meperidine can be decreased when combined with Verapamil.
Mephentermine	The therapeutic efficacy of Verapamil can be decreased when used in combination with Mephentermine.
Mephenytoin	The metabolism of Verapamil can be decreased when combined with Mephenytoin.
Mepivacaine	Verapamil may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
Meprednisone	The metabolism of Meprednisone can be decreased when combined with Verapamil.
Meropenem	Verapamil may decrease the excretion rate of Meropenem which could result in a higher serum level.
Mesalazine	The risk or severity of bleeding can be increased when Verapamil is combined with Mesalazine.
Mesoridazine	The metabolism of Mesoridazine can be decreased when combined with Verapamil.
Mestranol	The metabolism of Mestranol can be decreased when combined with Verapamil.
Metamfetamine	The therapeutic efficacy of Verapamil can be decreased when used in combination with Metamfetamine.
Metamizole	Metamizole may decrease the excretion rate of Verapamil which could result in a higher serum level.
Metaraminol	The therapeutic efficacy of Metaraminol can be decreased when used in combination with Verapamil.
Metaxalone	Metaxalone may decrease the excretion rate of Verapamil which could result in a higher serum level.
Metformin	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Metformin.
Methadone	The metabolism of Methadone can be decreased when combined with Verapamil.
Methazolamide	The risk or severity of adverse effects can be increased when Verapamil is combined with Methazolamide.
Methimazole	The metabolism of Verapamil can be decreased when combined with Methimazole.
Methohexital	Methohexital may increase the hypotensive activities of Verapamil.
Methotrexate	The metabolism of Methotrexate can be decreased when combined with Verapamil.
Methotrimeprazine	The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Verapamil.
Methoxamine	The therapeutic efficacy of Methoxamine can be decreased when used in combination with Verapamil.
Methoxsalen	The metabolism of Verapamil can be decreased when combined with Methoxsalen.
Methoxyflurane	The risk or severity of myocardial depression can be increased when Verapamil is combined with Methoxyflurane.
Methoxyphenamine	The therapeutic efficacy of Verapamil can be decreased when used in combination with Methoxyphenamine.
Methsuximide	Verapamil may increase the arrhythmogenic activities of Methsuximide.
Methyl salicylate	The risk or severity of bleeding can be increased when Verapamil is combined with Methyl salicylate.
Methylcellulose	The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Verapamil.
Methyldopa	The risk or severity of adverse effects can be increased when Verapamil is combined with Methyldopa.
Methylene blue	Methylene blue may increase the orthostatic hypotensive activities of Verapamil.
Methylergometrine	The metabolism of Methylergometrine can be decreased when combined with Verapamil.
Methylnaltrexone	Verapamil may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Methylphenobarbital	Methylphenobarbital may increase the hypotensive activities of Verapamil.
Methylprednisolone	The metabolism of Methylprednisolone can be decreased when combined with Verapamil.
Methylprednisone	The metabolism of Methylprednisone can be decreased when combined with Verapamil.
Methyltestosterone	The metabolism of Methyltestosterone can be decreased when combined with Verapamil.
Methysergide	The metabolism of Methysergide can be decreased when combined with Verapamil.
Meticrane	Meticrane may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
Metipranolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Metipranolol.
Metoclopramide	The metabolism of Metoclopramide can be decreased when combined with Verapamil.
Metocurine	Verapamil may increase the neuromuscular blocking activities of Metocurine.
Metocurine iodide	Verapamil may increase the neuromuscular blocking activities of Metocurine iodide.
Metolazone	The risk or severity of adverse effects can be increased when Metolazone is combined with Verapamil.
Metoprolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Metoprolol.
Metreleptin	The metabolism of Verapamil can be increased when combined with Metreleptin.
Metronidazole	The metabolism of Metronidazole can be decreased when combined with Verapamil.
Metyrapone	Verapamil may decrease the excretion rate of Metyrapone which could result in a higher serum level.
Metyrosine	Verapamil may increase the hypotensive activities of Metyrosine.
Mexiletine	Mexiletine may increase the arrhythmogenic activities of Verapamil.
Mianserin	The metabolism of Mianserin can be decreased when combined with Verapamil.
Miconazole	The metabolism of Verapamil can be decreased when combined with Miconazole.
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Verapamil.
Midodrine	Midodrine may increase the bradycardic activities of Verapamil.
Midostaurin	The metabolism of Verapamil can be decreased when combined with Midostaurin.
Mifepristone	The metabolism of Mifepristone can be decreased when combined with Verapamil.
Migalastat	Verapamil may decrease the excretion rate of Migalastat which could result in a higher serum level.
Miglitol	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Miglitol.
Milnacipran	The metabolism of Milnacipran can be decreased when combined with Verapamil.
Milrinone	Milrinone may decrease the excretion rate of Verapamil which could result in a higher serum level.
Minaprine	Minaprine may increase the orthostatic hypotensive activities of Verapamil.
Mineral oil	The therapeutic efficacy of Mineral oil can be decreased when used in combination with Verapamil.
Minoxidil	The risk or severity of adverse effects can be increased when Minoxidil is combined with Verapamil.
Mirabegron	The metabolism of Mirabegron can be decreased when combined with Verapamil.
Mirtazapine	The metabolism of Mirtazapine can be decreased when combined with Verapamil.
Mitapivat	The metabolism of Mitapivat can be decreased when combined with Verapamil.
Mitotane	The metabolism of Verapamil can be increased when combined with Mitotane.
Mivacurium	Verapamil may increase the neuromuscular blocking activities of Mivacurium.
Mobocertinib	The metabolism of Mobocertinib can be decreased when combined with Verapamil.
Moclobemide	Moclobemide may increase the orthostatic hypotensive activities of Verapamil.
Modafinil	The metabolism of Modafinil can be decreased when combined with Verapamil.
Moexipril	The risk or severity of adverse effects can be increased when Verapamil is combined with Moexipril.
Mometasone furoate	The metabolism of Mometasone furoate can be decreased when combined with Verapamil.
Monopotassium phosphate	The therapeutic efficacy of Monopotassium phosphate can be decreased when used in combination with Verapamil.
Montelukast	The metabolism of Montelukast can be decreased when combined with Verapamil.
Moricizine	Verapamil may increase the arrhythmogenic activities of Moricizine.
Morphine	The metabolism of Morphine can be decreased when combined with Verapamil.
Moxifloxacin	The metabolism of Verapamil can be decreased when combined with Moxifloxacin.
Moxisylyte	Verapamil may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
Moxonidine	The risk or severity of adverse effects can be increased when Verapamil is combined with Moxonidine.
Muzolimine	Muzolimine may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolate mofetil	The metabolism of Mycophenolate mofetil can be decreased when combined with Verapamil.
Mycophenolic acid	Verapamil may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
N-acetyltyrosine	Verapamil may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Nabilone	The metabolism of Nabilone can be decreased when combined with Verapamil.
Nabumetone	The metabolism of Verapamil can be decreased when combined with Nabumetone.
Nadolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Nadolol.
Nafcillin	The therapeutic efficacy of Verapamil can be decreased when used in combination with Nafcillin.
Naldemedine	Verapamil may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Nalidixic acid	The metabolism of Verapamil can be decreased when combined with Nalidixic acid.
Nalmefene	Verapamil may decrease the excretion rate of Nalmefene which could result in a higher serum level.
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Verapamil.
Naloxone	Verapamil may decrease the excretion rate of Naloxone which could result in a higher serum level.
Naphazoline	The therapeutic efficacy of Naphazoline can be decreased when used in combination with Verapamil.
Naproxen	The metabolism of Naproxen can be decreased when combined with Verapamil.
Nateglinide	The metabolism of Nateglinide can be decreased when combined with Verapamil.
Nebivolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Nebivolol.
Nedaplatin	Verapamil may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Nedocromil	Verapamil may decrease the excretion rate of Nedocromil which could result in a higher serum level.
Nefazodone	The metabolism of Verapamil can be decreased when combined with Nefazodone.
Nelfinavir	The metabolism of Verapamil can be decreased when combined with Nelfinavir.
Neomycin	Verapamil may decrease the excretion rate of Neomycin which could result in a higher serum level.
Neratinib	The metabolism of Neratinib can be decreased when combined with Verapamil.
Nesiritide	The risk or severity of adverse effects can be increased when Verapamil is combined with Nesiritide.
Netilmicin	Verapamil may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Netupitant	The metabolism of Netupitant can be decreased when combined with Verapamil.
Nevirapine	The metabolism of Nevirapine can be decreased when combined with Verapamil.
Nialamide	Nialamide may increase the orthostatic hypotensive activities of Verapamil.
Nicardipine	Nicardipine may increase the arrhythmogenic activities of Verapamil.
Nicergoline	The risk or severity of hypotension can be increased when Nicergoline is combined with Verapamil.
Niclosamide	The metabolism of Verapamil can be decreased when combined with Niclosamide.
Nicorandil	Nicorandil may increase the hypotensive activities of Verapamil.
Nifedipine	Verapamil may increase the arrhythmogenic activities of Nifedipine.
Nilotinib	The metabolism of Verapamil can be decreased when combined with Nilotinib.
Nilutamide	Verapamil may decrease the excretion rate of Nilutamide which could result in a higher serum level.
Nilvadipine	Verapamil may increase the arrhythmogenic activities of Nilvadipine.
Nimesulide	Verapamil may increase the arrhythmogenic activities of Nimesulide.
Nimodipine	Nimodipine may increase the arrhythmogenic activities of Verapamil.
Nintedanib	The metabolism of Nintedanib can be decreased when combined with Verapamil.
Nirmatrelvir	The metabolism of Nirmatrelvir can be decreased when combined with Verapamil.
Nirogacestat	The serum concentration of Nirogacestat can be increased when it is combined with Verapamil.
Nisoldipine	Nisoldipine may increase the arrhythmogenic activities of Verapamil.
Nitrazepam	The metabolism of Nitrazepam can be decreased when combined with Verapamil.
Nitrendipine	Verapamil may increase the arrhythmogenic activities of Nitrendipine.
Nitric Oxide	The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Verapamil.
Nitrofurantoin	Verapamil may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Nitroglycerin	Verapamil may increase the vasodilatory activities of Nitroglycerin.
Nitroprusside	Verapamil may increase the hypotensive activities of Nitroprusside.
Nitrous acid	The risk or severity of adverse effects can be increased when Verapamil is combined with Nitrous acid.
Nitrous oxide	The risk or severity of myocardial depression can be increased when Verapamil is combined with Nitrous oxide.
Nomegestrol	The metabolism of Nomegestrol can be decreased when combined with Verapamil.
Nomegestrol acetate	The metabolism of Nomegestrol acetate can be decreased when combined with Verapamil.
Norelgestromin	The metabolism of Norelgestromin can be decreased when combined with Verapamil.
Norepinephrine	The risk or severity of adverse effects can be increased when Verapamil is combined with Norepinephrine.
Norethisterone	The metabolism of Norethisterone can be decreased when combined with Verapamil.
Norethynodrel	The metabolism of Norethynodrel can be decreased when combined with Verapamil.
Norfloxacin	The metabolism of Verapamil can be decreased when combined with Norfloxacin.
Norgestimate	The metabolism of Norgestimate can be decreased when combined with Verapamil.
Norgestrel	The metabolism of Norgestrel can be decreased when combined with Verapamil.
Nortriptyline	The serum concentration of Nortriptyline can be increased when it is combined with Verapamil.
Nylidrin	Verapamil may increase the arrhythmogenic activities of Nylidrin.
Obeticholic acid	The metabolism of Verapamil can be decreased when combined with Obeticholic acid.
Obinutuzumab	The risk or severity of adverse effects can be increased when Verapamil is combined with Obinutuzumab.
Octinoxate	Verapamil may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Octreotide	The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Verapamil.
Olanzapine	The metabolism of Verapamil can be decreased when combined with Olanzapine.
Olaparib	The metabolism of Olaparib can be decreased when combined with Verapamil.
Oliceridine	The serum concentration of Oliceridine can be increased when it is combined with Verapamil.
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Verapamil.
Olodaterol	The therapeutic efficacy of Olodaterol can be decreased when used in combination with Verapamil.
Olsalazine	The risk or severity of bleeding can be increased when Verapamil is combined with Olsalazine.
Olutasidenib	The metabolism of Olutasidenib can be decreased when combined with Verapamil.
Omadacycline	The serum concentration of Omadacycline can be increased when it is combined with Verapamil.
Omaveloxolone	The serum concentration of Omaveloxolone can be increased when it is combined with Verapamil.
Ombitasvir	The serum concentration of Ombitasvir can be increased when it is combined with Verapamil.
Ondansetron	The metabolism of Ondansetron can be decreased when combined with Verapamil.
Opicapone	The risk or severity of adverse effects can be increased when Verapamil is combined with Opicapone.
Opium	The metabolism of Opium can be decreased when combined with Verapamil.
Orciprenaline	The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Verapamil.
Orphenadrine	The metabolism of Orphenadrine can be decreased when combined with Verapamil.
Oseltamivir	Oseltamivir may decrease the excretion rate of Verapamil which could result in a higher serum level.
Osilodrostat	The metabolism of Osilodrostat can be decreased when combined with Verapamil.
Osimertinib	The serum concentration of Verapamil can be decreased when it is combined with Osimertinib.
Ospemifene	The metabolism of Ospemifene can be decreased when combined with Verapamil.
Oteseconazole	The therapeutic efficacy of Oteseconazole can be increased when used in combination with Verapamil.
Ouabain	The serum concentration of Ouabain can be increased when it is combined with Verapamil.
Oxacillin	Verapamil may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Oxaprozin	Oxaprozin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Oxazepam	Verapamil may decrease the excretion rate of Oxazepam which could result in a higher serum level.
Oxcarbazepine	The serum concentration of the active metabolites of Oxcarbazepine can be decreased when Oxcarbazepine is used in combination with Verapamil.
Oxprenolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Oxprenolol.
Oxtriphylline	The metabolism of Oxtriphylline can be decreased when combined with Verapamil.
Oxybenzone	Verapamil may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
Oxybutynin	The metabolism of Oxybutynin can be decreased when combined with Verapamil.
Oxycodone	The metabolism of Oxycodone can be decreased when combined with Verapamil.
Oxymetazoline	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Verapamil.
Oxymorphone	The metabolism of Oxymorphone can be decreased when combined with Verapamil.
Oxyphenbutazone	Oxyphenbutazone may decrease the excretion rate of Verapamil which could result in a higher serum level.
Oxyphenisatin acetate	The therapeutic efficacy of Oxyphenisatin acetate can be decreased when used in combination with Verapamil.
Oxyquinoline	Verapamil may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Paclitaxel	The metabolism of Paclitaxel can be decreased when combined with Verapamil.
Pacritinib	The serum concentration of Pacritinib can be increased when it is combined with Verapamil.
Palbociclib	The metabolism of Palbociclib can be decreased when combined with Verapamil.
Paliperidone	The metabolism of Paliperidone can be decreased when combined with Verapamil.
Palonosetron	The metabolism of Palonosetron can be decreased when combined with Verapamil.
Palovarotene	The serum concentration of Palovarotene can be increased when it is combined with Verapamil.
Pamidronic acid	Pamidronic acid may decrease the excretion rate of Verapamil which could result in a higher serum level.
Pancuronium	Verapamil may increase the neuromuscular blocking activities of Pancuronium.
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Verapamil.
Pantoprazole	The metabolism of Pantoprazole can be decreased when combined with Verapamil.
Papaverine	The risk or severity of adverse effects can be increased when Verapamil is combined with Papaverine.
Paramethadione	The metabolism of Paramethadione can be decreased when combined with Verapamil.
Parecoxib	The metabolism of Parecoxib can be decreased when combined with Verapamil.
Pargyline	Pargyline may increase the orthostatic hypotensive activities of Verapamil.
Paricalcitol	The metabolism of Paricalcitol can be decreased when combined with Verapamil.
Paritaprevir	The metabolism of Paritaprevir can be decreased when combined with Verapamil.
Paromomycin	Paromomycin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Paroxetine	The metabolism of Paroxetine can be decreased when combined with Verapamil.
Pasireotide	Verapamil may increase the bradycardic activities of Pasireotide.
Patent Blue	The therapeutic efficacy of Verapamil can be decreased when used in combination with Patent Blue.
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Verapamil.
Pefloxacin	The metabolism of Verapamil can be decreased when combined with Pefloxacin.
Pegaptanib	Verapamil may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Peginesatide	Verapamil may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Peginterferon alfa-2a	The metabolism of Verapamil can be decreased when combined with Peginterferon alfa-2a.
Peginterferon alfa-2b	The serum concentration of Verapamil can be increased when it is combined with Peginterferon alfa-2b.
Pemetrexed	Verapamil may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Pemigatinib	The metabolism of Pemigatinib can be decreased when combined with Verapamil.
Penbutolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Penbutolol.
Penciclovir	The metabolism of Verapamil can be decreased when combined with Penciclovir.
Pentaerythritol tetranitrate	Verapamil may increase the vasodilatory activities of Pentaerythritol tetranitrate.
Pentamidine	The metabolism of Pentamidine can be decreased when combined with Verapamil.
Pentastarch	Verapamil may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Pentetic acid	Verapamil may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentobarbital	The metabolism of Verapamil can be increased when combined with Pentobarbital.
Pentolinium	Verapamil may increase the hypotensive activities of Pentolinium.
Pentostatin	Verapamil may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Pentoxifylline	The metabolism of Pentoxifylline can be decreased when combined with Verapamil.
Perampanel	The metabolism of Perampanel can be decreased when combined with Verapamil.
Pergolide	The therapeutic efficacy of Pergolide can be decreased when used in combination with Verapamil.
Perhexiline	Verapamil may increase the arrhythmogenic activities of Perhexiline.
Periciazine	The risk or severity of hypotension can be increased when Periciazine is combined with Verapamil.
Perindopril	The risk or severity of adverse effects can be increased when Verapamil is combined with Perindopril.
Permethrin	Verapamil may decrease the excretion rate of Permethrin which could result in a higher serum level.
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Verapamil.
Pexidartinib	The metabolism of Pexidartinib can be decreased when combined with Verapamil.
Phenazopyridine	Phenazopyridine may decrease the excretion rate of Verapamil which could result in a higher serum level.
Phendimetrazine	The therapeutic efficacy of Verapamil can be decreased when used in combination with Phendimetrazine.
Phenelzine	Phenelzine may increase the orthostatic hypotensive activities of Verapamil.
Phenformin	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Phenformin.
Phenobarbital	The metabolism of Verapamil can be increased when combined with Phenobarbital.
Phenolphthalein	The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Verapamil.
Phenoxybenzamine	The risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Verapamil.
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Verapamil.
Phentermine	The therapeutic efficacy of Verapamil can be decreased when used in combination with Phentermine.
Phentolamine	The risk or severity of hypotension can be increased when Phentolamine is combined with Verapamil.
Phenyl aminosalicylate	The risk or severity of bleeding can be increased when Verapamil is combined with Phenyl aminosalicylate.
Phenylbutazone	Phenylbutazone may decrease the excretion rate of Verapamil which could result in a higher serum level.
Phenylephrine	The risk or severity of hypertension can be decreased when Verapamil is combined with Phenylephrine.
Phenylpropanolamine	The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Verapamil.
Phenytoin	The serum concentration of Verapamil can be decreased when it is combined with Phenytoin.
Pholcodine	Verapamil may decrease the excretion rate of Pholcodine which could result in a higher serum level.
Phosphoric acid	Verapamil may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phylloquinone	Verapamil may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Pibrentasvir	The serum concentration of Pibrentasvir can be increased when it is combined with Verapamil.
Picosulfuric acid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Verapamil.
Pimavanserin	The metabolism of Pimavanserin can be increased when combined with Verapamil.
Pimozide	The metabolism of Pimozide can be decreased when combined with Verapamil.
Pinacidil	The metabolism of Pinacidil can be decreased when combined with Verapamil.
Pinaverium	Verapamil may increase the arrhythmogenic activities of Pinaverium.
Pindolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Pindolol.
Pioglitazone	The metabolism of Pioglitazone can be decreased when combined with Verapamil.
Pipecuronium	Verapamil may increase the neuromuscular blocking activities of Pipecuronium.
Piperacillin	Piperacillin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Piperaquine	The metabolism of Piperaquine can be decreased when combined with Verapamil.
Piperazine	The metabolism of Piperazine can be decreased when combined with Verapamil.
Pipotiazine	The metabolism of Pipotiazine can be decreased when combined with Verapamil.
Piracetam	Verapamil may decrease the excretion rate of Piracetam which could result in a higher serum level.
Pirbuterol	The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Verapamil.
Piretanide	Piretanide may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
Pirfenidone	The metabolism of Pirfenidone can be decreased when combined with Verapamil.
Piroxicam	Piroxicam may decrease the excretion rate of Verapamil which could result in a higher serum level.
Pirtobrutinib	The metabolism of Pirtobrutinib can be decreased when combined with Verapamil.
Pitolisant	The serum concentration of Verapamil can be decreased when it is combined with Pitolisant.
Pizotifen	The risk or severity of hypotension can be increased when Pizotifen is combined with Verapamil.
Plantago ovata seed	The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Verapamil.
Plantago seed	The therapeutic efficacy of Plantago seed can be decreased when used in combination with Verapamil.
Plazomicin	Verapamil may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Plecanatide	The therapeutic efficacy of Plecanatide can be decreased when used in combination with Verapamil.
Plerixafor	Verapamil may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Polatuzumab vedotin	The metabolism of Polatuzumab vedotin can be decreased when combined with Verapamil.
Polyethylene glycol	The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Verapamil.
Polythiazide	Polythiazide may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Verapamil.
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Verapamil.
Ponesimod	The risk or severity of bradycardia can be increased when Ponesimod is combined with Verapamil.
Poractant alfa	Verapamil may increase the bradycardic activities of Poractant alfa.
Posaconazole	The metabolism of Verapamil can be decreased when combined with Posaconazole.
Potassium	Potassium may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
Potassium acetate	Verapamil may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium bicarbonate	Verapamil may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
Potassium cation	Verapamil may decrease the excretion rate of Potassium cation which could result in a higher serum level.
Potassium chloride	Verapamil may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
Potassium citrate	Potassium citrate may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
Potassium lactate	The therapeutic efficacy of Potassium lactate can be decreased when used in combination with Verapamil.
Potassium nitrate	Verapamil may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium perchlorate	Verapamil may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
Potassium sulfate	The therapeutic efficacy of Potassium sulfate can be decreased when used in combination with Verapamil.
Practolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Practolol.
Pralatrexate	Verapamil may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pralidoxime	Verapamil may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
Pralsetinib	The serum concentration of Pralsetinib can be increased when it is combined with Verapamil.
Pramipexole	The risk or severity of adverse effects can be increased when Verapamil is combined with Pramipexole.
Pramlintide	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Pramlintide.
Prasugrel	Verapamil may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Pravastatin	The serum concentration of Pravastatin can be increased when it is combined with Verapamil.
Prazepam	The metabolism of Prazepam can be decreased when combined with Verapamil.
Praziquantel	The metabolism of Praziquantel can be decreased when combined with Verapamil.
Prazosin	The risk or severity of adverse effects can be increased when Verapamil is combined with Prazosin.
Prednisolone	The metabolism of Prednisolone can be decreased when combined with Verapamil.
Prednisolone acetate	The metabolism of Prednisolone acetate can be decreased when combined with Verapamil.
Prednisolone phosphate	The metabolism of Prednisolone phosphate can be decreased when combined with Verapamil.
Prednisone	The metabolism of Prednisone can be decreased when combined with Verapamil.
Prednisone acetate	The metabolism of Verapamil can be increased when combined with Prednisone acetate.
Pregabalin	Pregabalin may increase the bradycardic activities of Verapamil.
Pregnenolone	The metabolism of Pregnenolone can be decreased when combined with Verapamil.
Prenylamine	Verapamil may increase the arrhythmogenic activities of Prenylamine.
Pretomanid	The serum concentration of Pretomanid can be increased when it is combined with Verapamil.
Primaquine	The metabolism of Primaquine can be decreased when combined with Verapamil.
Primidone	The metabolism of Verapamil can be increased when combined with Primidone.
Probenecid	Verapamil may decrease the excretion rate of Probenecid which could result in a higher serum level.
Procainamide	Verapamil may increase the arrhythmogenic activities of Procainamide.
Procaine	Procaine may increase the orthostatic hypotensive activities of Verapamil.
Procaine benzylpenicillin	Verapamil may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Procarbazine	Procarbazine may increase the orthostatic hypotensive activities of Verapamil.
Procaterol	The therapeutic efficacy of Procaterol can be decreased when used in combination with Verapamil.
Prochlorperazine	The metabolism of Prochlorperazine can be decreased when combined with Verapamil.
Progesterone	The metabolism of Progesterone can be decreased when combined with Verapamil.
Promazine	The metabolism of Promazine can be decreased when combined with Verapamil.
Promethazine	Verapamil may decrease the excretion rate of Promethazine which could result in a higher serum level.
Propafenone	The risk or severity of adverse effects can be increased when Verapamil is combined with Propafenone.
Propantheline	Verapamil may decrease the excretion rate of Propantheline which could result in a higher serum level.
Propiomazine	The risk or severity of hypotension can be increased when Propiomazine is combined with Verapamil.
Propiverine	The metabolism of Propiverine can be decreased when combined with Verapamil.
Propofol	The risk or severity of adverse effects can be increased when Verapamil is combined with Propofol.
Propranolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Propranolol.
Propylhexedrine	The therapeutic efficacy of Propylhexedrine can be decreased when used in combination with Verapamil.
Protokylol	Verapamil may decrease the hypertensive activities of Protokylol.
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Verapamil.
Pseudoephedrine	The therapeutic efficacy of Verapamil can be decreased when used in combination with Pseudoephedrine.
Pyrantel	Verapamil may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Pyrazinamide	Pyrazinamide may decrease the excretion rate of Verapamil which could result in a higher serum level.
Pyridoxine	Pyridoxine may decrease the excretion rate of Verapamil which could result in a higher serum level.
Quazepam	The metabolism of Quazepam can be decreased when combined with Verapamil.
Quetiapine	The metabolism of Quetiapine can be decreased when combined with Verapamil.
Quinapril	The risk or severity of adverse effects can be increased when Verapamil is combined with Quinapril.
Quinethazone	Quinethazone may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
Quinidine	Verapamil may increase the hypotensive activities of Quinidine.
Quinine	Verapamil may increase the hypotensive activities of Quinine.
Quizartinib	The metabolism of Quizartinib can be decreased when combined with Verapamil.
Rabeprazole	Verapamil may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
Racephedrine	The therapeutic efficacy of Racephedrine can be decreased when used in combination with Verapamil.
Racepinephrine	Verapamil may decrease the hypertensive activities of Racepinephrine.
Ramelteon	The metabolism of Ramelteon can be decreased when combined with Verapamil.
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Verapamil.
Ranitidine	The metabolism of Ranitidine can be decreased when combined with Verapamil.
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Verapamil.
Rapacuronium	Verapamil may increase the neuromuscular blocking activities of Rapacuronium.
Rasagiline	Rasagiline may increase the orthostatic hypotensive activities of Verapamil.
Reboxetine	The metabolism of Reboxetine can be decreased when combined with Verapamil.
Regorafenib	The serum concentration of Regorafenib can be increased when it is combined with Verapamil.
Relugolix	The serum concentration of Relugolix can be increased when it is combined with Verapamil.
Remdesivir	The metabolism of Remdesivir can be decreased when combined with Verapamil.
Remifentanil	The risk or severity of adverse effects can be increased when Verapamil is combined with Remifentanil.
Remoxipride	The metabolism of Remoxipride can be decreased when combined with Verapamil.
Repaglinide	The metabolism of Repaglinide can be decreased when combined with Verapamil.
Repotrectinib	The serum concentration of Repotrectinib can be increased when it is combined with Verapamil.
Rescinnamine	Verapamil may increase the hypotensive activities of Rescinnamine.
Reserpine	The serum concentration of Verapamil can be increased when it is combined with Reserpine.
Resorcinol	Verapamil may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Retapamulin	The metabolism of Retapamulin can be decreased when combined with Verapamil.
Revefenacin	The serum concentration of Revefenacin can be increased when it is combined with Verapamil.
Ribavirin	Verapamil may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Ribociclib	The metabolism of Verapamil can be decreased when combined with Ribociclib.
Ribostamycin	Verapamil may decrease the excretion rate of Ribostamycin which could result in a higher serum level.
Rifabutin	The metabolism of Rifabutin can be decreased when combined with Verapamil.
Rifampin	The metabolism of Verapamil can be increased when combined with Rifampicin.
Rifamycin	The metabolism of Verapamil can be increased when combined with Rifamycin.
Rifapentine	The metabolism of Verapamil can be increased when combined with Rifapentine.
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Verapamil.
Rilmenidine	The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Verapamil.
Rilonacept	The metabolism of Verapamil can be increased when combined with Rilonacept.
Rilpivirine	The serum concentration of Rilpivirine can be increased when it is combined with Verapamil.
Riluzole	The metabolism of Riluzole can be decreased when combined with Verapamil.
Rimegepant	The serum concentration of Rimegepant can be increased when it is combined with Verapamil.
Rimonabant	The metabolism of Rimonabant can be decreased when combined with Verapamil.
Riociguat	The metabolism of Riociguat can be decreased when combined with Verapamil.
Ripretinib	The metabolism of Ripretinib can be decreased when combined with Verapamil.
Risperidone	The serum concentration of Risperidone can be increased when it is combined with Verapamil.
Ritlecitinib	The serum concentration of Verapamil can be increased when it is combined with Ritlecitinib.
Ritodrine	The therapeutic efficacy of Ritodrine can be decreased when used in combination with Verapamil.
Ritonavir	The serum concentration of Verapamil can be increased when it is combined with Ritonavir.
Rivaroxaban	The metabolism of Rivaroxaban can be decreased when combined with Verapamil.
Rivastigmine	Verapamil may increase the bradycardic activities of Rivastigmine.
Rizatriptan	Verapamil may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Rocuronium	Verapamil may increase the neuromuscular blocking activities of Rocuronium.
Rofecoxib	The metabolism of Verapamil can be decreased when combined with Rofecoxib.
Roflumilast	The serum concentration of Roflumilast can be increased when it is combined with Verapamil.
Rolapitant	The metabolism of Rolapitant can be decreased when combined with Verapamil.
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Verapamil.
Ropeginterferon alfa-2b	The metabolism of Verapamil can be decreased when combined with Ropeginterferon alfa-2b.
Ropinirole	The risk or severity of adverse effects can be increased when Ropinirole is combined with Verapamil.
Ropivacaine	The metabolism of Verapamil can be decreased when combined with Ropivacaine.
Rosiglitazone	The metabolism of Rosiglitazone can be decreased when combined with Verapamil.
Rosoxacin	The metabolism of Verapamil can be decreased when combined with Rosoxacin.
Rosuvastatin	The metabolism of Rosuvastatin can be decreased when combined with Verapamil.
Rotigotine	The metabolism of Rotigotine can be decreased when combined with Verapamil.
Roxithromycin	The risk or severity of adverse effects can be increased when Roxithromycin is combined with Verapamil.
Rucaparib	The metabolism of Rucaparib can be decreased when combined with Verapamil.
Rupatadine	The metabolism of Rupatadine can be decreased when combined with Verapamil.
Ruxolitinib	Ruxolitinib may increase the bradycardic activities of Verapamil.
Sacubitril	The risk or severity of adverse effects can be increased when Verapamil is combined with Sacubitril.
Safinamide	Safinamide may increase the orthostatic hypotensive activities of Verapamil.
Salicylamide	Salicylamide may decrease the excretion rate of Verapamil which could result in a higher serum level.
Salicylic acid	The risk or severity of bleeding can be increased when Verapamil is combined with Salicylic acid.
Salmeterol	The metabolism of Salmeterol can be decreased when combined with Verapamil.
Salmon calcitonin	Salmon calcitonin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Salsalate	Salsalate may decrease the excretion rate of Verapamil which could result in a higher serum level.
Samidorphan	The metabolism of Samidorphan can be decreased when combined with Verapamil.
Sapropterin	The serum concentration of Verapamil can be increased when it is combined with Sapropterin.
Saquinavir	The metabolism of Verapamil can be decreased when combined with Saquinavir.
Sarecycline	The serum concentration of Verapamil can be increased when it is combined with Sarecycline.
Satralizumab	The serum concentration of Verapamil can be decreased when it is combined with Satralizumab.
Saxagliptin	The metabolism of Saxagliptin can be decreased when combined with Verapamil.
Scopolamine	The metabolism of Scopolamine can be decreased when combined with Verapamil.
Secobarbital	Secobarbital may increase the hypotensive activities of Verapamil.
Secukinumab	The metabolism of Verapamil can be increased when combined with Secukinumab.
Selegiline	Selegiline may increase the orthostatic hypotensive activities of Verapamil.
Selenious acid	Verapamil may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium	Verapamil may decrease the excretion rate of Selenium which could result in a higher serum level.
Selexipag	The metabolism of Selexipag can be decreased when combined with Verapamil.
Selinexor	The metabolism of Selinexor can be decreased when combined with Verapamil.
Selpercatinib	The serum concentration of Selpercatinib can be increased when it is combined with Verapamil.
Selumetinib	The serum concentration of Selumetinib can be increased when it is combined with Verapamil.
Semaglutide	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Semaglutide.
Senna leaf	The therapeutic efficacy of Senna leaf can be decreased when used in combination with Verapamil.
Sertindole	The metabolism of Sertindole can be decreased when combined with Verapamil.
Sertraline	The metabolism of Sertraline can be decreased when combined with Verapamil.
Sevoflurane	The risk or severity of myocardial depression can be increased when Verapamil is combined with Sevoflurane.
Sibutramine	The metabolism of Sibutramine can be decreased when combined with Verapamil.
Sildenafil	The metabolism of Sildenafil can be decreased when combined with Verapamil.
Silodosin	The excretion of Silodosin can be decreased when combined with Verapamil.
Siltuximab	The metabolism of Verapamil can be increased when combined with Siltuximab.
Simeprevir	The metabolism of Simeprevir can be decreased when combined with Verapamil.
Simvastatin	The risk or severity of myopathy and rhabdomyolysis can be increased when Verapamil is combined with Simvastatin.
Siponimod	The risk or severity of adverse effects can be increased when Verapamil is combined with Siponimod.
Sirolimus	The serum concentration of Sirolimus can be increased when it is combined with Verapamil.
Sitagliptin	The metabolism of Sitagliptin can be decreased when combined with Verapamil.
Sitaxentan	Verapamil may increase the hypotensive activities of Sitaxentan.
Sodium acetate	Verapamil may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Sodium ascorbate	The therapeutic efficacy of Sodium ascorbate can be decreased when used in combination with Verapamil.
Sodium aurothiomalate	Verapamil may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
Sodium ferric gluconate complex	The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Verapamil.
Sodium fluoride	Verapamil may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
Sodium fluorophosphate	The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Verapamil.
Sodium phosphate, dibasic	The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Verapamil.
Sodium phosphate, dibasic, unspecified form	The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Verapamil.
Sodium phosphate, monobasic	The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Verapamil.
Sodium phosphate, monobasic, unspecified form	The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Verapamil.
Sodium sulfate	The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Verapamil.
Sodium tartrate	The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Verapamil.
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Verapamil.
Solifenacin	The metabolism of Solifenacin can be decreased when combined with Verapamil.
Solriamfetol	Verapamil may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
Somapacitan	The metabolism of Verapamil can be increased when combined with Somapacitan.
Somatotropin	The metabolism of Verapamil can be increased when combined with Somatotropin.
Somatrem	The metabolism of Verapamil can be increased when combined with Somatrem.
Somatrogon	The metabolism of Verapamil can be increased when combined with Somatrogon.
Sonidegib	The metabolism of Sonidegib can be decreased when combined with Verapamil.
Sorafenib	The metabolism of Sorafenib can be decreased when combined with Verapamil.
Sorbitol	The therapeutic efficacy of Sorbitol can be decreased when used in combination with Verapamil.
Sotagliflozin	The serum concentration of Verapamil can be increased when it is combined with Sotagliflozin.
Sotalol	The risk or severity of adverse effects can be increased when Verapamil is combined with Sotalol.
Sotorasib	The serum concentration of Verapamil can be decreased when it is combined with Sotorasib.
Sparsentan	The metabolism of Sparsentan can be decreased when combined with Verapamil.
Spirapril	Verapamil may increase the hypotensive activities of Spirapril.
Spironolactone	The risk or severity of adverse effects can be increased when Spironolactone is combined with Verapamil.
St. John's Wort	The metabolism of Verapamil can be increased when combined with St. John's Wort.
Stiripentol	The metabolism of Verapamil can be decreased when combined with Stiripentol.
Streptokinase	The risk or severity of adverse effects can be increased when Streptokinase is combined with Verapamil.
Streptomycin	Verapamil may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Strontium chloride	Verapamil may decrease the excretion rate of Strontium chloride which could result in a higher serum level.
Sucralfate	Sucralfate may decrease the excretion rate of Verapamil which could result in a higher serum level.
Sufentanil	The metabolism of Sufentanil can be decreased when combined with Verapamil.
Sulbactam	Verapamil may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sulfadiazine	The metabolism of Sulfadiazine can be decreased when combined with Verapamil.
Sulfamethoxazole	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Sulfamethoxazole.
Sulfasalazine	The risk or severity of bleeding can be increased when Verapamil is combined with Sulfasalazine.
Sulfinpyrazone	The metabolism of Sulfinpyrazone can be decreased when combined with Verapamil.
Sulfisoxazole	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Sulfisoxazole.
Sulindac	Sulindac may decrease the excretion rate of Verapamil which could result in a higher serum level.
Sumatriptan	Verapamil may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
Sunitinib	The metabolism of Sunitinib can be decreased when combined with Verapamil.
Suvorexant	The metabolism of Suvorexant can be decreased when combined with Verapamil.
Synthetic Conjugated Estrogens, A	The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Verapamil.
Synthetic Conjugated Estrogens, B	The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Verapamil.
Tacrine	The metabolism of Verapamil can be decreased when combined with Tacrine.
Tacrolimus	The serum concentration of Tacrolimus can be increased when it is combined with Verapamil.
Tadalafil	The metabolism of Tadalafil can be decreased when combined with Verapamil.
Tafenoquine	The metabolism of Tafenoquine can be decreased when combined with Verapamil.
Talazoparib	The serum concentration of Talazoparib can be increased when it is combined with Verapamil.
Tamoxifen	The metabolism of Tamoxifen can be decreased when combined with Verapamil.
Tamsulosin	The metabolism of Tamsulosin can be decreased when combined with Verapamil.
Tasimelteon	The metabolism of Tasimelteon can be decreased when combined with Verapamil.
Tazemetostat	The metabolism of Tazemetostat can be decreased when combined with Verapamil.
Technetium Tc-99m exametazime	Verapamil may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium Tc-99m mebrofenin	Verapamil may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
Technetium Tc-99m oxidronate	Verapamil may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
Technetium Tc-99m pyrophosphate	Verapamil may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Verapamil.
Teduglutide	Verapamil may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Tegafur	The metabolism of Tegafur can be decreased when combined with Verapamil.
Tegaserod	The serum concentration of Tegaserod can be increased when it is combined with Verapamil.
Telaprevir	The metabolism of Verapamil can be decreased when combined with Telaprevir.
Telavancin	Verapamil may decrease the excretion rate of Telavancin which could result in a higher serum level.
Telithromycin	The risk or severity of adverse effects can be increased when Telithromycin is combined with Verapamil.
Telmisartan	The risk or severity of adverse effects can be increased when Verapamil is combined with Telmisartan.
Telotristat ethyl	The serum concentration of Verapamil can be decreased when it is combined with Telotristat ethyl.
Temazepam	Temazepam may decrease the excretion rate of Verapamil which could result in a higher serum level.
Temozolomide	Verapamil may decrease the excretion rate of Temozolomide which could result in a higher serum level.
Temsirolimus	The serum concentration of Temsirolimus can be increased when it is combined with Verapamil.
Teniposide	The metabolism of Teniposide can be decreased when combined with Verapamil.
Tenofovir alafenamide	The serum concentration of Tenofovir alafenamide can be increased when it is combined with Verapamil.
Tenofovir disoproxil	The serum concentration of Tenofovir disoproxil can be increased when it is combined with Verapamil.
Tenoxicam	Tenoxicam may decrease the excretion rate of Verapamil which could result in a higher serum level.
Tepotinib	The serum concentration of Tepotinib can be increased when it is combined with Verapamil.
Terazosin	The risk or severity of hypotension can be increased when Terazosin is combined with Verapamil.
Terbinafine	The metabolism of Terbinafine can be decreased when combined with Verapamil.
Terbutaline	Verapamil may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Terfenadine	The metabolism of Verapamil can be decreased when combined with Terfenadine.
Teriflunomide	The serum concentration of Verapamil can be decreased when it is combined with Teriflunomide.
Testolactone	Verapamil may decrease the excretion rate of Testolactone which could result in a higher serum level.
Testosterone	The metabolism of Testosterone can be decreased when combined with Verapamil.
Testosterone cypionate	The metabolism of Testosterone cypionate can be decreased when combined with Verapamil.
Testosterone enanthate	The metabolism of Testosterone enanthate can be decreased when combined with Verapamil.
Testosterone propionate	The metabolism of Testosterone propionate can be decreased when combined with Verapamil.
Testosterone undecanoate	Verapamil may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
Tetrabenazine	The metabolism of Tetrabenazine can be decreased when combined with Verapamil.
Tetracycline	The metabolism of Tetracycline can be decreased when combined with Verapamil.
Tetradecyl hydrogen sulfate (ester)	Verapamil may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Tetryzoline	The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Verapamil.
Tezacaftor	The metabolism of Tezacaftor can be decreased when combined with Verapamil.
Thalidomide	The metabolism of Thalidomide can be decreased when combined with Verapamil.
Theophylline	The serum concentration of Theophylline can be increased when it is combined with Verapamil.
Thiabendazole	The metabolism of Verapamil can be decreased when combined with Thiabendazole.
Thiamine	The risk or severity of adverse effects can be increased when Verapamil is combined with Thiamine.
Thiamylal	Thiamylal may increase the hypotensive activities of Verapamil.
Thiethylperazine	Thiethylperazine may decrease the excretion rate of Verapamil which could result in a higher serum level.
Thiopental	Thiopental may increase the hypotensive activities of Verapamil.
Thioridazine	The risk or severity of hypotension can be increased when Thioridazine is combined with Verapamil.
Thiotepa	The metabolism of Thiotepa can be decreased when combined with Verapamil.
Thiothixene	The metabolism of Thiothixene can be decreased when combined with Verapamil.
Tiagabine	The metabolism of Tiagabine can be decreased when combined with Verapamil.
Tiaprofenic acid	Tiaprofenic acid may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ticagrelor	The metabolism of Ticagrelor can be decreased when combined with Verapamil.
Ticlopidine	The metabolism of Verapamil can be decreased when combined with Ticlopidine.
Tiludronic acid	Verapamil may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
Timolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Timolol.
Tinidazole	The metabolism of Tinidazole can be decreased when combined with Verapamil.
Tiopronin	Verapamil may decrease the excretion rate of Tiopronin which could result in a higher serum level.
Tiotropium	The metabolism of Tiotropium can be decreased when combined with Verapamil.
Tipranavir	The metabolism of Verapamil can be decreased when combined with Tipranavir.
Tirofiban	Verapamil may decrease the excretion rate of Tirofiban which could result in a higher serum level.
Tirzepatide	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Tirzepatide.
Tisotumab vedotin	The metabolism of Tisotumab vedotin can be decreased when combined with Verapamil.
Tivozanib	The serum concentration of Tivozanib can be increased when it is combined with Verapamil.
Tixocortol	Verapamil may decrease the excretion rate of Tixocortol which could result in a higher serum level.
Tizanidine	The metabolism of Tizanidine can be decreased when combined with Verapamil.
Tobramycin	Verapamil may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tocainide	Verapamil may increase the arrhythmogenic activities of Tocainide.
Tocilizumab	The metabolism of Verapamil can be increased when combined with Tocilizumab.
Tocofersolan	The metabolism of Tocofersolan can be decreased when combined with Verapamil.
Tocopherol	The metabolism of Tocopherol can be decreased when combined with Verapamil.
Tofacitinib	The metabolism of Tofacitinib can be decreased when combined with Verapamil.
Tolazamide	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Tolazamide.
Tolazoline	The risk or severity of hypotension can be increased when Tolazoline is combined with Verapamil.
Tolbutamide	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Tolbutamide.
Tolcapone	The risk or severity of adverse effects can be increased when Tolcapone is combined with Verapamil.
Tolfenamic acid	The metabolism of Tolfenamic acid can be decreased when combined with Verapamil.
Tolmetin	Tolmetin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Tolterodine	The metabolism of Tolterodine can be decreased when combined with Verapamil.
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Verapamil.
Topiramate	Topiramate may decrease the excretion rate of Verapamil which could result in a higher serum level.
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Verapamil.
Torasemide	The risk or severity of adverse effects can be increased when Torasemide is combined with Verapamil.
Toremifene	The metabolism of Toremifene can be decreased when combined with Verapamil.
Tositumomab	Tositumomab may decrease the excretion rate of Verapamil which could result in a higher serum level.
Trabectedin	The metabolism of Trabectedin can be decreased when combined with Verapamil.
Tramadol	The metabolism of Tramadol can be decreased when combined with Verapamil.
Trametinib	Verapamil may decrease the excretion rate of Trametinib which could result in a higher serum level.
Tranylcypromine	Tranylcypromine may increase the orthostatic hypotensive activities of Verapamil.
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Verapamil.
Trazodone	The metabolism of Trazodone can be decreased when combined with Verapamil.
Treprostinil	Verapamil may increase the hypotensive activities of Treprostinil.
Tretinoin	The metabolism of Tretinoin can be decreased when combined with Verapamil.
Triamcinolone	The metabolism of Triamcinolone can be decreased when combined with Verapamil.
Triamterene	The metabolism of Verapamil can be decreased when combined with Triamterene.
Triazolam	The metabolism of Triazolam can be decreased when combined with Verapamil.
Trichlormethiazide	Trichlormethiazide may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
Trichloroethylene	The risk or severity of myocardial depression can be increased when Verapamil is combined with Trichloroethylene.
Triclabendazole	The metabolism of Triclabendazole can be decreased when combined with Verapamil.
Triethylenetetramine	Verapamil may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Trifluoperazine	The metabolism of Trifluoperazine can be decreased when combined with Verapamil.
Trifluridine	Trifluridine may decrease the excretion rate of Verapamil which could result in a higher serum level.
Trilaciclib	The serum concentration of Trilaciclib can be increased when it is combined with Verapamil.
Trimebutine	Verapamil may increase the arrhythmogenic activities of Trimebutine.
Trimethadione	Trimethadione may increase the arrhythmogenic activities of Verapamil.
Trimethaphan	Verapamil may increase the hypotensive activities of Trimethaphan.
Trimethoprim	The metabolism of Trimethoprim can be decreased when combined with Verapamil.
Trimetrexate	Verapamil may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
Trimipramine	The serum concentration of Trimipramine can be increased when it is combined with Verapamil.
Troglitazone	The metabolism of Verapamil can be decreased when combined with Troglitazone.
Troleandomycin	The metabolism of Verapamil can be decreased when combined with Troleandomycin.
Tropisetron	Verapamil may increase the arrhythmogenic activities of Tropisetron.
Trovafloxacin	The metabolism of Verapamil can be decreased when combined with Trovafloxacin.
Tubocurarine	Verapamil may increase the neuromuscular blocking activities of Tubocurarine.
Tucatinib	Tucatinib may decrease the excretion rate of Verapamil which could result in a higher serum level.
Ubrogepant	The serum concentration of Ubrogepant can be increased when it is combined with Verapamil.
Udenafil	The metabolism of Udenafil can be decreased when combined with Verapamil.
Ulipristal	The metabolism of Ulipristal can be decreased when combined with Verapamil.
Umbralisib	The serum concentration of Verapamil can be increased when it is combined with Umbralisib.
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Verapamil.
Upadacitinib	The metabolism of Upadacitinib can be decreased when combined with Verapamil.
Vaborbactam	Verapamil may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Vadadustat	The serum concentration of Verapamil can be increased when it is combined with Vadadustat.
Valaciclovir	Valaciclovir may decrease the excretion rate of Verapamil which could result in a higher serum level.
Valbenazine	The metabolism of Valbenazine can be decreased when combined with Verapamil.
Valdecoxib	The metabolism of Valdecoxib can be decreased when combined with Verapamil.
Valganciclovir	Verapamil may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Valproic acid	The metabolism of Verapamil can be decreased when combined with Valproic acid.
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Verapamil.
Vamorolone	The metabolism of Vamorolone can be decreased when combined with Verapamil.
Vancomycin	Verapamil may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Vandetanib	The metabolism of Vandetanib can be decreased when combined with Verapamil.
Vardenafil	The metabolism of Vardenafil can be decreased when combined with Verapamil.
Varenicline	Verapamil may decrease the excretion rate of Varenicline which could result in a higher serum level.
Vecuronium	Verapamil may increase the neuromuscular blocking activities of Vecuronium.
Velpatasvir	The metabolism of Velpatasvir can be decreased when combined with Verapamil.
Vemurafenib	The serum concentration of Verapamil can be increased when it is combined with Vemurafenib.
Venetoclax	The serum concentration of Venetoclax can be increased when it is combined with Verapamil.
Venlafaxine	The metabolism of Venlafaxine can be decreased when combined with Verapamil.
Vericiguat	The risk or severity of adverse effects can be increased when Verapamil is combined with Vericiguat.
Vernakalant	Verapamil may increase the arrhythmogenic activities of Vernakalant.
Vibegron	The therapeutic efficacy of Vibegron can be decreased when used in combination with Verapamil.
Vilanterol	The metabolism of Vilanterol can be decreased when combined with Verapamil.
Vilazodone	The metabolism of Vilazodone can be decreased when combined with Verapamil.
Vildagliptin	The risk or severity of hypoglycemia can be increased when Verapamil is combined with Vildagliptin.
Viloxazine	The metabolism of Verapamil can be decreased when combined with Viloxazine.
Vinblastine	The serum concentration of Vinblastine can be increased when it is combined with Verapamil.
Vincristine	The excretion of Vincristine can be decreased when combined with Verapamil.
Vindesine	The metabolism of Vindesine can be decreased when combined with Verapamil.
Vinflunine	The serum concentration of Vinflunine can be increased when it is combined with Verapamil.
Vinorelbine	The metabolism of Vinorelbine can be decreased when combined with Verapamil.
Vitamin D	The metabolism of Vitamin D can be decreased when combined with Verapamil.
Vitamin E	The metabolism of Vitamin E can be decreased when combined with Verapamil.
Voclosporin	The metabolism of Voclosporin can be decreased when combined with Verapamil.
Vonoprazan	The metabolism of Vonoprazan can be decreased when combined with Verapamil.
Vorapaxar	The metabolism of Vorapaxar can be decreased when combined with Verapamil.
Voriconazole	The metabolism of Verapamil can be decreased when combined with Voriconazole.
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Verapamil.
Voxelotor	The serum concentration of Voxelotor can be increased when it is combined with Verapamil.
Voxilaprevir	The metabolism of Voxilaprevir can be decreased when combined with Verapamil.
Warfarin	The serum concentration of Warfarin can be increased when it is combined with Verapamil.
Xamoterol	The therapeutic efficacy of Xamoterol can be decreased when used in combination with Verapamil.
Xylometazoline	Verapamil may increase the arrhythmogenic activities of Xylometazoline.
Yohimbine	The metabolism of Yohimbine can be decreased when combined with Verapamil.
Zaleplon	The metabolism of Zaleplon can be decreased when combined with Verapamil.
Zanamivir	Zanamivir may decrease the excretion rate of Verapamil which could result in a higher serum level.
Zanubrutinib	The metabolism of Zanubrutinib can be decreased when combined with Verapamil.
Ziconotide	Verapamil may increase the arrhythmogenic activities of Ziconotide.
Zidovudine	The metabolism of Zidovudine can be decreased when combined with Verapamil.
Zileuton	The metabolism of Zileuton can be decreased when combined with Verapamil.
Zimelidine	The metabolism of Verapamil can be decreased when combined with Zimelidine.
Ziprasidone	The metabolism of Verapamil can be decreased when combined with Ziprasidone.
Zofenopril	Verapamil may increase the hypotensive activities of Zofenopril.
Zolmitriptan	The metabolism of Verapamil can be decreased when combined with Zolmitriptan.
Zolpidem	The metabolism of Zolpidem can be decreased when combined with Verapamil.
Zonisamide	Verapamil may increase the arrhythmogenic activities of Zonisamide.
Zopiclone	The metabolism of Zopiclone can be decreased when combined with Verapamil.
Zotepine	The metabolism of Zotepine can be decreased when combined with Verapamil.
Zuclopenthixol	The metabolism of Zuclopenthixol can be decreased when combined with Verapamil.
Zuranolone	The metabolism of Zuranolone can be decreased when combined with Verapamil.

Food Interactions

Avoid alcohol. Verapamil significantly inhibits the elimination of alcohol, leading to elevated blood alcohol levels.
Avoid grapefruit products. Co-administration with grapefruit may significantly increase serum concentrations.
Take with or without food. Recommendations vary from product to product - consult individual product monographs for additional information.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Verapamil hydrochloride	V3888OEY5R	152-11-4	DOQPXTMNIUCOSY-UHFFFAOYSA-N

Product Images

International/Other Brands

Bosoptin (Bosnalijek) / Isoptin (Abbott) / Verisop (Gerard) / Vermin (Ratiopharm) / Vermine (Pharmasant) / Verogalid (Ivax) / Verogalid ER (Ivax) / Verpamil (Mylan) / Vertab (Trinity-Chiesi) / Vetrimil (CCPC) / Zolvera (Rosemont)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Calan	Tablet, film coated	120 mg/1	Oral	G.D. Searle LLC Division of Pfizer Inc	1984-09-10	Not applicable
Calan	Tablet, film coated	120 mg/1	Oral	Physicians Total Care, Inc.	1994-07-05	2012-06-30
Calan	Tablet, film coated	40 mg/1	Oral	G.D. Searle LLC	2006-06-01	2006-06-01
Calan	Tablet, film coated	80 mg/1	Oral	G.D. Searle LLC Division of Pfizer Inc	1984-09-10	2018-06-30
Calan SR	Tablet, film coated, extended release	240 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc	1986-12-16	2022-01-31
Calan SR	Tablet, film coated, extended release	120 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc	2021-10-25	2023-07-31
Calan SR	Tablet, film coated, extended release	180 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc	1989-12-15	2021-03-31
Calan SR	Tablet, film coated, extended release	240 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc	2021-06-01	2023-05-31
Calan SR	Tablet, film coated, extended release	180 mg/1	Oral	Physicians Total Care, Inc.	1992-11-17	2012-06-30
Calan SR	Tablet, film coated, extended release	120 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc	1991-03-06	2022-02-28
Calan SR	Tablet, film coated, extended release	180 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc	2020-12-16	Not applicable
Calan SR	Tablet, film coated, extended release	120 mg/1	Oral	Physicians Total Care, Inc.	1994-07-25	2012-06-30
Covera-HS	Tablet, extended release	240 mg/1	Oral	G.D. Searle LLC Division of Pfizer Inc	1996-02-26	2012-02-29
Covera-HS	Tablet, extended release	180 mg/1	Oral	G.D. Searle LLC Division of Pfizer Inc	1996-02-26	2011-07-31
Covera-HS	Tablet, extended release	240 mg	Oral	Pfizer Canada Ulc	1997-11-13	2013-02-15
Covera-HS	Tablet, extended release	180 mg	Oral	Pfizer Canada Ulc	1997-11-13	2013-02-15
Isoptin Inj 2.5mg/ml	Liquid	2.5 mg / mL	Intravenous	Abbott	1984-12-31	2007-07-31
Isoptin SR	Tablet, coated	120 mg/1	Oral	Ranbaxy Inc.	2008-03-11	Not applicable
Isoptin SR	Tablet, extended release	180 mg	Oral	Bgp Pharma Ulc	1994-04-21	Not applicable
Isoptin SR	Tablet, coated	240 mg/1	Oral	Ranbaxy Inc.	2008-03-11	Not applicable
Isoptin SR	Tablet, extended release	120 mg	Oral	Bgp Pharma Ulc	1991-12-31	Not applicable
Isoptin SR	Tablet, coated	240 mg/1	Oral	Physicians Total Care, Inc.	2008-03-01	2012-06-30
Isoptin SR	Tablet, coated	180 mg/1	Oral	Ranbaxy Inc.	2008-03-11	Not applicable
Isoptin SR	Tablet, extended release	240 mg	Oral	Bgp Pharma Ulc	1988-12-31	Not applicable
Isoptin Tab 120mg	Tablet	120 mg	Oral	Abbott	1982-12-31	2007-07-31
Isoptin Tab 80mg	Tablet	80 mg	Oral	Abbott	1982-12-31	2007-07-31
Verapamil Hci	Injection	2.5 mg/1mL	Intravenous	HF Acquisition Co LLC, DBA HealthFirst	2019-12-22	Not applicable
Verapamil HCl	Injection	5 mg/1mL	Intravenous	American Regent	2006-01-23	2006-07-25
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable
Verapamil Hydrochloride	Capsule, extended release	100 mg/1	Oral	Chartwell Rx, Llc	1998-11-25	Not applicable
Verapamil Hydrochloride	Capsule, delayed release pellets	360 mg/1	Oral	bryant ranch prepack	1990-05-29	Not applicable
Verapamil Hydrochloride	Capsule, extended release	100 mg/1	Oral	Lannett Company, Inc.	1998-11-25	Not applicable
Verapamil Hydrochloride	Capsule, delayed release pellets	180 mg/1	Oral	Carilion Materials Management	1990-05-29	Not applicable
Verapamil Hydrochloride	Tablet, film coated	40 mg/1	Oral	Watson Labs	2007-02-06	2007-07-12
Verapamil Hydrochloride	Capsule, extended release	300 mg/1	Oral	bryant ranch prepack	1998-11-25	Not applicable
Verapamil Hydrochloride	Capsule, delayed release pellets	180 mg/1	Oral	Teva Pharmaceuticals Inc	1990-05-29	Not applicable
Verapamil Hydrochloride	Capsule, delayed release pellets	360 mg/1	Oral	Physicians Total Care, Inc.	2009-02-12	Not applicable
Verapamil Hydrochloride	Capsule, extended release	300 mg/1	Oral	Lannett Company, Inc.	1998-11-25	Not applicable
Verapamil Hydrochloride	Capsule, delayed release pellets	360 mg/1	Oral	Teva Pharmaceuticals Inc	1990-05-29	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Watson Labs	2007-02-06	2007-07-12
Verapamil Hydrochloride	Injection	2.5 mg/1mL	Intravenous	Exela Pharma Sciences, LLC	2018-06-11	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable
Verapamil Hydrochloride	Injection	2.5 mg/1mL	Intravenous	Exela Pharma Sciences, Llc.	2017-02-01	Not applicable
Verapamil Hydrochloride	Capsule, extended release	200 mg/1	Oral	Lannett Company, Inc.	1998-11-25	Not applicable
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Watson Labs	2007-02-06	2007-07-12
Verapamil Hydrochloride	Injection	2.5 mg/1mL	Intravenous	Medical Purchasing Solutions, Llc	2016-04-22	Not applicable
Verapamil Hydrochloride	Capsule, delayed release pellets	240 mg/1	Oral	Teva Pharmaceuticals Inc	1990-05-29	Not applicable
Verapamil Hydrochloride	Capsule, delayed release pellets	120 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2012-07-24	2016-05-04
Verapamil Hydrochloride	Capsule, extended release	100 mg/1	Oral	bryant ranch prepack	1998-11-25	Not applicable
Verapamil Hydrochloride	Capsule, delayed release pellets	360 mg/1	Oral	bryant ranch prepack	1990-05-29	Not applicable
Verapamil Hydrochloride	Injection	2.5 mg/1mL	Intravenous	Exela Pharma Sciences, LLC	2016-04-22	Not applicable
Verapamil Hydrochloride	Capsule, delayed release pellets	120 mg/1	Oral	Teva Pharmaceuticals Inc	1990-05-29	Not applicable
Verapamil Hydrochloride Injection USP	Solution	2.5 mg / mL	Intravenous	Pfizer Canada Ulc	1994-12-31	2024-03-18
Verapamil Hydrochloride Injection USP	Liquid	2.5 mg / mL	Intravenous	Sandoz Canada Incorporated	1995-12-31	Not applicable
Verapamil Injection 2.5mg/ml	Liquid	2.5 mg / mL	Intravenous	Novopharm Limited	1994-12-31	2005-08-10
Verapamil SR	Tablet, extended release	240 mg	Oral	Sorres Pharma Inc	2009-06-22	2014-06-20
Verapamil Tab 80mg	Tablet	80 mg	Oral	Pro Doc Limitee	1990-12-31	2012-07-23
Verapamil-120 Tab	Tablet	120 mg	Oral	Pro Doc Limitee	1990-12-31	2009-07-23
Verelan	Capsule, delayed release pellets	240 mg/1	Oral	Physicians Total Care, Inc.	2004-08-12	Not applicable
Verelan	Capsule, delayed release pellets	120 mg/1	Oral	Lannett Company, Inc.	1990-05-29	Not applicable
Verelan	Capsule, delayed release pellets	180 mg/1	Oral	Ucb Inc	1990-05-29	2016-06-30
Verelan	Capsule, extended release	180 mg	Oral	Recro Gainesville Llc	1994-12-31	Not applicable
Verelan	Capsule, delayed release pellets	240 mg/1	Oral	Lannett Company, Inc.	1990-05-29	Not applicable
Verelan	Capsule, delayed release pellets	360 mg/1	Oral	Ucb Inc	1990-05-29	2016-06-30
Verelan	Capsule, delayed release pellets	120 mg/1	Oral	Ucb Inc	1990-05-29	2016-06-30
Verelan	Capsule, extended release	240 mg	Oral	Recro Gainesville Llc	1994-12-31	Not applicable
Verelan	Capsule, delayed release pellets	360 mg/1	Oral	Physicians Total Care, Inc.	2003-06-12	Not applicable
Verelan	Capsule, delayed release pellets	180 mg/1	Oral	Lannett Company, Inc.	1990-05-29	Not applicable
Verelan	Capsule, extended release	120 mg	Oral	Recro Gainesville Llc	1994-12-31	Not applicable
Verelan	Capsule, delayed release pellets	240 mg/1	Oral	Ucb Inc	1990-05-29	2016-06-30
Verelan	Capsule, delayed release pellets	360 mg/1	Oral	Lannett Company, Inc.	1990-05-29	Not applicable
Verelan PM	Capsule, extended release	200 mg/1	Oral	Ucb Inc	1998-11-25	2016-06-30
Verelan PM	Capsule, extended release	100 mg/1	Oral	Lannett Company, Inc.	1998-11-25	Not applicable
Verelan PM	Capsule, extended release	300 mg/1	Oral	Lannett Company, Inc.	1998-11-25	Not applicable
Verelan PM	Capsule, extended release	300 mg/1	Oral	bryant ranch prepack	1998-11-25	2017-12-31
Verelan PM	Capsule, extended release	300 mg/1	Oral	Ucb Inc	1998-11-25	2016-06-30
Verelan PM	Capsule, extended release	200 mg/1	Oral	Lannett Company, Inc.	1998-11-25	Not applicable
Verelan PM	Capsule, extended release	100 mg/1	Oral	Ucb Inc	1998-11-25	2016-06-30

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Alti-verapamil - 120mg	Tablet	120 mg	Oral	Altimed Pharma Inc.	1990-12-31	2004-08-03
Alti-verapamil - 80mg	Tablet	80 mg	Oral	Altimed Pharma Inc.	1990-12-31	2004-08-03
Apo-verap SR	Tablet, extended release	180 mg	Oral	Apotex Corporation	2003-04-24	Not applicable
Apo-verap SR	Tablet, extended release	120 mg	Oral	Apotex Corporation	2003-04-24	Not applicable
Apo-verap SR	Tablet, extended release	240 mg	Oral	Apotex Corporation	2003-04-24	Not applicable
Apo-verap Tab 80mg	Tablet	80 mg	Oral	Apotex Corporation	1989-12-31	Not applicable
Apo-verap Tablet 120mg	Tablet	120 mg	Oral	Apotex Corporation	1989-12-31	Not applicable
Dom-verapamil SR 240mg Tablets	Tablet, extended release	240 mg	Oral	Dominion Pharmacal	1999-12-16	Not applicable
Med Verapamil Tablets	Tablet	120 mg	Oral	Medican Pharma Incorporated	1999-03-08	2011-03-29
Med Verapamil Tablets	Tablet	80 mg	Oral	Medican Pharma Incorporated	1999-03-08	2011-03-29
Mylan-verapamil	Tablet	80 mg	Oral	Mylan Pharmaceuticals	1998-05-25	Not applicable
Mylan-verapamil	Tablet	120 mg	Oral	Mylan Pharmaceuticals	1998-05-11	Not applicable
Mylan-verapamil SR	Tablet, extended release	240 mg	Oral	Mylan Pharmaceuticals	1996-12-31	2022-06-13
Mylan-verapamil SR	Tablet, extended release	180 mg	Oral	Mylan Pharmaceuticals	2016-06-29	Not applicable
Mylan-verapamil SR	Tablet, extended release	240 mg	Oral	Mylan Pharmaceuticals	2016-09-01	Not applicable
Mylan-verapamil SR	Tablet, extended release	120 mg	Oral	Mylan Pharmaceuticals	Not applicable	Not applicable
Mylan-verapamil SR	Tablet, extended release	120 mg	Oral	Mylan Pharmaceuticals	1996-12-31	Not applicable
Mylan-verapamil SR	Tablet, extended release	180 mg	Oral	Mylan Pharmaceuticals	1996-12-31	2022-06-13
Novo-veramil	Tablet	120 mg	Oral	TEVA Canada Limited	1989-12-31	2018-05-15
Novo-veramil	Tablet	80 mg	Oral	TEVA Canada Limited	1989-12-31	2018-05-15
Novo-veramil SR	Tablet, extended release	240 mg	Oral	TEVA Canada Limited	1996-12-31	2018-05-15
Nu-verap SR	Tablet, extended release	120 mg	Oral	Nu Pharm Inc	Not applicable	Not applicable
Nu-verap SR	Tablet, extended release	240 mg	Oral	Nu Pharm Inc	2004-07-19	2012-09-04
Nu-verap SR	Tablet, extended release	180 mg	Oral	Nu Pharm Inc	Not applicable	Not applicable
Nu-verap Tab 120mg	Tablet	120 mg	Oral	Nu Pharm Inc	1990-12-31	2012-09-04
Nu-verap Tab 80mg	Tablet	80 mg	Oral	Nu Pharm Inc	1990-12-31	2012-09-04
Penta-verapamil - 120mg	Tablet	120 mg	Oral	Pentapharm Ltd.	1997-06-25	2004-07-30
Penta-verapamil - 80mg	Tablet	80 mg	Oral	Pentapharm Ltd.	1997-06-25	2004-07-30
PHL-verapamil SR	Tablet, extended release	240 mg	Oral	Pharmel Inc	2002-05-31	2013-07-17
PMS-verapamil SR	Tablet, extended release	240 mg	Oral	Pharmascience Inc	1999-09-01	Not applicable
Pro-verapamil SR	Tablet, extended release	180 mg	Oral	Pro Doc Limitee	2009-06-15	2015-05-31
Pro-verapamil SR	Tablet, extended release	240 mg	Oral	Pro Doc Limitee	2008-07-09	2018-07-26
Pro-verapamil SR	Tablet, extended release	120 mg	Oral	Pro Doc Limitee	2009-06-15	2015-10-31
Riva-verapamil SR	Tablet, extended release	240 mg	Oral	Laboratoire Riva Inc	2005-09-14	2019-03-05
Taro-verapamil Tab 120mg	Tablet	120 mg	Oral	Taro Pharmaceuticals, Inc.	1993-12-31	2000-08-31
Taro-verapamil Tab 80mg	Tablet	80 mg	Oral	Taro Pharmaceuticals, Inc.	1993-12-31	2000-08-31
Verapamil	Tablet, film coated, extended release	180 mg/1	Oral	Amerincan Health Packaging	2014-01-14	2015-12-31
Verapamil	Tablet, film coated, extended release	120 mg/1	Oral	Apotex Corporation	2012-11-19	2016-12-31
Verapamil	Tablet, film coated, extended release	120 mg/1	Oral	Amerincan Health Packaging	2014-01-14	2016-03-31
Verapamil	Tablet, film coated, extended release	240 mg/1	Oral	Apotex Corporation	2012-11-19	2016-12-31
Verapamil	Tablet, film coated, extended release	240 mg/1	Oral	Amerincan Health Packaging	2014-01-14	2016-04-30
Verapamil	Tablet, film coated, extended release	180 mg/1	Oral	St. Marys Medical Park Pharmacy	2013-02-05	2017-03-31
Verapamil	Tablet, film coated, extended release	120 mg/1	Oral	St. Marys Medical Park Pharmacy	2014-04-21	2017-03-31
Verapamil	Tablet, film coated, extended release	180 mg/1	Oral	Apotex Corporation	2012-11-19	2016-12-31
Verapamil	Tablet, film coated, extended release	180 mg/1	Oral	Unit Dose Services	2012-11-19	2016-12-31
Verapamil Hci	Injection, solution	2.5 mg/1mL	Intravenous	HF Acquisition Co LLC, DBA HealthFirst	2022-05-20	Not applicable
Verapamil Hci	Injection, solution	2.5 mg/1mL	Intravenous	HF Acquisition Co LLC, DBA HealthFirst	2018-09-17	Not applicable
Verapamil HCl	Tablet	120 mg/1	Oral	Direct_Rx	2019-06-03	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Nucare Pharmaceuticals,inc.	2011-08-05	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	REMEDYREPACK INC.	2018-05-14	2020-05-19
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	REMEDYREPACK INC.	2019-08-29	Not applicable
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	PD-Rx Pharmaceuticals, Inc.	2012-01-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Denton Pharma, Inc. Dba Northwind Pharmaceuticals	2019-05-22	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Glenmark Pharmaceuticals Inc., USA	2011-08-05	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Mylan Pharmaceuticals	2011-01-30	2011-01-31
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Denton Pharma, Inc. Dba Northwind Pharmaceuticals	2020-05-22	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Cardinal Health	2011-03-25	2016-01-31
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Carilion Materials Management	2014-01-29	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Denton Pharma, Inc. Dba Northwind Pharmaceuticals	2019-06-25	2023-08-31
Verapamil Hydrochloride	Injection	5 mg/2mL	Intravenous	Armas Pharmaceuticals Inc.	2020-01-01	Not applicable
Verapamil hydrochloride	Tablet, extended release	240 mg/301	Oral	Northwind Pharmaceuticals	2014-05-27	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2012-02-23	Not applicable
Verapamil Hydrochloride	Tablet, film coated	40 mg/1	Oral	bryant ranch prepack	1993-06-29	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Eugia US LLC	2020-07-06	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	REMEDYREPACK INC.	2017-07-03	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Med Health Pharma LLC	2011-02-18	2012-05-10
Verapamil Hydrochloride	Tablet	180 mg/1	Oral	Nucare Pharmaceuticals,inc.	2019-05-15	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Blenheim Pharmacal, Inc.	2010-08-20	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Clinical Solutions Wholesale	1986-10-01	2018-10-30
Verapamil Hydrochloride	Tablet	240 mg/1	Oral	Nivagen Pharmaceuticals, Inc.	2019-05-15	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	REMEDYREPACK INC.	2018-07-26	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	bryant ranch prepack	2011-08-05	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Mylan Pharmaceuticals Inc.	1997-02-25	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Physicians Total Care, Inc.	1996-02-05	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Zydus Lifesciences Limited	2020-10-22	Not applicable
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Cardinal Health	1986-10-01	2014-01-31
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Amneal Pharmaceuticals LLC	2018-07-17	Not applicable
Verapamil Hydrochloride	Capsule, extended release	120 mg/1	Oral	Mylan Institutional Inc.	1999-10-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	IVAX Pharmaceuticals, Inc.	1992-08-01	2015-04-30
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Henry Schein, Inc.	2022-01-10	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2014-01-29	2020-03-31
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Caplin Steriles Limited	2020-05-01	Not applicable
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	Remedy Repack	2010-11-09	2012-02-15
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Physicians Total Care, Inc.	1996-01-15	Not applicable
Verapamil Hydrochloride	Tablet	180 mg/1	Oral	Northwind Pharmaceuticals	2021-06-17	Not applicable
Verapamil Hydrochloride	Tablet	80 mg/1	Oral	Rebel Distributors	1995-04-24	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Cardinal Health	2012-07-12	2015-11-30
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	RedPharm Drug, Inc.	2019-01-01	Not applicable
Verapamil Hydrochloride	Tablet	80 mg/1	Oral	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	2011-01-07	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	General Injectables and Vaccines, Inc.	2019-07-09	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Major Pharmaceuticals	1986-10-01	2022-07-31
Verapamil hydrochloride	Injection	2.5 mg/1mL	Intravenous	Gland Pharma Limited	2020-10-15	Not applicable
Verapamil Hydrochloride	Injection	2.5 mg/1mL	Intravenous	Micro Labs Limited	2019-03-04	Not applicable
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	Remedy Repack	2010-06-16	2011-06-17
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	HF Acquisition Co. LLC, DBA HealthFirst	2018-09-01	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Hospira, Inc.	2005-02-28	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	A S Medication Solutions	1986-10-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2011-08-05	2014-12-31
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	AvKARE	2020-04-13	Not applicable
Verapamil Hydrochloride	Tablet	80 mg/1	Oral	Remedy Repack	2010-07-23	2011-07-24
Verapamil Hydrochloride	Capsule, extended release	200 mg/1	Oral	Physicians Total Care, Inc.	2010-05-17	Not applicable
Verapamil Hydrochloride	Tablet, extended release	120 mg/1	Oral	Cadila Pharmaceuticals Limited	2017-05-27	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Mylan Institutional Inc.	1998-04-17	2019-09-30
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	Sun Pharmaceutical Industries, Inc.	2012-01-01	2020-11-30
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Cardinal Health	2009-09-17	2015-09-30
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	A-S Medication Solutions	1986-10-01	Not applicable
Verapamil Hydrochloride	Capsule, extended release	240 mg/1	Oral	Mylan Pharmaceuticals Inc.	1999-05-20	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Northwind Pharmaceuticals	2020-06-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Teva Pharmaceuticals USA Inc	2014-01-29	2020-01-31
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	A-S Medication Solutions	2011-08-05	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	American Health Packaging	2022-07-19	2024-04-30
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Glenmark Pharmaceuticals Inc., USA	2009-09-17	Not applicable
Verapamil Hydrochloride	Capsule, extended release	120 mg/1	Oral	Med Health Pharma LLC.	2011-02-22	2012-04-15
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Avera McKennan Hospital	2015-04-06	2017-05-24
Verapamil Hydrochloride	Injection	5 mg/2mL	Intravenous	Medical Purchasing Solutions, Llc	2020-01-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	bryant ranch prepack	1992-08-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	1986-10-01	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Medical Purchasing Solutions, Llc	2018-06-18	Not applicable
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2018-07-06	2019-10-11
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Mylan Pharmaceuticals Inc.	1989-02-15	2020-11-30
Verapamil Hydrochloride	Tablet, film coated	40 mg/1	Oral	Actavis Pharma, Inc.	1993-06-29	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	bryant ranch prepack	2014-01-29	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2009-09-17	2016-10-20
Verapamil Hydrochloride	Tablet	80 mg/1	Oral	bryant ranch prepack	2011-01-07	Not applicable
Verapamil Hydrochloride	Injection	2.5 mg/1mL	Intravenous	Medical Purchasing Solutions, Llc	2019-03-04	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Mylan Pharmaceuticals Inc.	1996-03-25	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Mylan Pharmaceuticals	2011-01-30	2011-01-31
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Zydus Pharmaceuticals USA Inc.	2023-10-17	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	REMEDYREPACK INC.	2016-07-14	2018-04-16
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	Cadila Pharmaceuticals Limited	2017-05-27	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Proficient Rx LP	1986-10-01	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Somerset Therapeutics, Llc	2018-06-18	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Medical Purchasing Solutions, Llc	2018-06-18	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Rpk Pharmaceuticals, Inc.	2011-08-05	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Clinical Solutions Wholsesale	2009-09-17	2017-06-21
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	bryant ranch prepack	2018-07-20	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Lifestar Pharma Llc	2022-06-16	Not applicable
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	Preferred Pharmaceuticals, Inc.	2013-09-26	2019-04-23
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	REMEDYREPACK INC.	2019-02-06	Not applicable
Verapamil Hydrochloride	Capsule, extended release	120 mg/1	Oral	Remedy Repack	2010-11-22	2011-11-23
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Golden State Medical Supply, Inc.	1997-02-21	2019-11-01
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2011-08-05	Not applicable
Verapamil Hydrochloride	Tablet	40 mg/1	Oral	Chartwell Rx, Llc	2015-10-15	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Preferred Pharmaceuticals, Inc.	2012-06-04	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	bryant ranch prepack	1997-10-10	2017-12-31
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Amneal Pharmaceuticals LLC	2018-07-17	Not applicable
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	REMEDYREPACK INC.	2018-10-04	Not applicable
Verapamil Hydrochloride	Capsule, extended release	120 mg/1	Oral	bryant ranch prepack	1999-05-20	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Med Health Pharma LLC	2011-02-18	2012-05-10
Verapamil Hydrochloride	Tablet	180 mg/1	Oral	A-S Medication Solutions	2019-05-15	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	A-S Medication Solutions	2011-08-05	Not applicable
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	A-S Medication Solutions	2012-01-01	2017-04-30
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	A-S Medication Solutions	2011-01-07	Not applicable
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	State of Florida DOH Central Pharmacy	2014-11-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	PD-Rx Pharmaceuticals, Inc.	2011-08-05	2019-09-09
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	PD-Rx Pharmaceuticals, Inc.	2012-01-01	Not applicable
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2012-01-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	RedPharm Drug, Inc.	1986-10-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Major Pharmaceuticals	1986-10-01	2022-08-31
Verapamil Hydrochloride	Tablet	80 mg/1	Oral	Nucare Pharmaceuticals,inc.	2011-01-07	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Preferred Pharmaceuticals Inc.	2016-10-17	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Unit Dose Services	2009-09-17	2017-12-31
Verapamil Hydrochloride	Injection	5 mg/2mL	Intravenous	Medical Purchasing Solutions, Llc	2020-01-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2009-09-17	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Baxter Healthcare Corporation	2020-03-25	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Physicians Total Care, Inc.	2004-02-18	2011-06-30
Verapamil Hydrochloride	Tablet	240 mg/1	Oral	Denton Pharma, Inc. Dba Northwind Pharmaceuticals	2020-02-25	Not applicable
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	A-S Medication Solutions	2012-01-01	2016-07-01
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Remedy Repack	2013-01-21	2014-07-10
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Aphena Pharma Solutions - Tennessee, LLC	1996-03-25	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	State of Florida DOH Central Pharmacy	2014-01-01	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Henry Schein, Inc.	2022-01-11	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	PD-Rx Pharmaceuticals, Inc.	1989-02-15	2019-08-15
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Heritage Pharmaceuticals Inc.	2011-01-07	2020-04-30
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	bryant ranch prepack	2009-09-17	Not applicable
Verapamil Hydrochloride	Capsule, extended release	180 mg/1	Oral	Mylan Pharmaceuticals Inc.	1999-05-20	Not applicable
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Northwind Pharmaceuticals, LLC	2022-11-23	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Teva Pharmaceuticals USA Inc	2014-03-10	2019-12-31
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Caremark L.L.C.	2009-11-10	2011-07-31
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Clinical Solutions Wholesale	1986-10-01	2017-06-22
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	American Health Packaging	2020-07-16	2024-05-31
Verapamil Hydrochloride	Tablet	180 mg/1	Oral	Nivagen Pharmaceuticals, Inc.	2019-05-15	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Caplin Steriles Limited	2020-05-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Physicians Total Care, Inc.	2000-11-28	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Zydus Pharmaceuticals USA Inc.	2020-10-22	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Remedy Repack	2013-01-04	2014-12-23
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	General Injectables & Vaccines, Inc	2010-09-01	2020-11-01
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	IVAX Pharmaceuticals, Inc.	1997-10-10	2015-03-31
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Denton Pharma, Inc. Dba Northwind Pharmaceuticals	2021-09-28	2023-04-30
Verapamil Hydrochloride	Tablet	40 mg/1	Oral	Avera McKennan Hospital	2016-07-01	2017-05-24
Verapamil Hydrochloride	Tablet	40 mg/1	Oral	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	2015-10-15	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	bryant ranch prepack	1996-03-25	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	A-S Medication Solutions	2009-09-17	Not applicable
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Preferred Pharmaceuticals Inc.	2023-02-02	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2011-08-05	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Caremark L.L.C.	2006-12-11	2011-04-30
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Mylan Institutional Inc.	1996-04-15	2019-08-31
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Golden State Medical Supply, Inc.	1996-03-23	2020-03-01
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Chartwell Rx, Llc	2018-07-20	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Aphena Pharma Solutions - Tennessee, LLC	2009-09-17	Not applicable
Verapamil Hydrochloride	Tablet	80 mg/1	Oral	AvKARE	2020-04-13	Not applicable
Verapamil Hydrochloride	Capsule, extended release	100 mg/1	Oral	Physicians Total Care, Inc.	2008-08-07	Not applicable
Verapamil hydrochloride	Injection	2.5 mg/1mL	Intravenous	Gland Pharma Limited	2020-10-15	Not applicable
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Remedy Repack	2007-05-25	2014-05-22
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	General Injectables & Vaccines, Inc.	2019-12-03	2023-03-31
Verapamil Hydrochloride	Capsule, extended release	240 mg/1	Oral	Med Health Pharma LLC.	2011-02-22	2012-04-15
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	Sun Pharmaceutical Industries, Inc.	2012-01-01	2020-11-30
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Direct Rx	2017-03-15	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Cardinal Health	2011-03-25	2019-11-30
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Methapharm Inc.	2021-02-03	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	A-S Medication Solutions	2011-08-05	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	bryant ranch prepack	1986-10-01	Not applicable
Verapamil Hydrochloride	Tablet	240 mg/1	Oral	Aphena Pharma Solutions - Tennessee, LLC	2019-05-15	Not applicable
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Nucare Pharmaceuticals,inc.	2023-01-02	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Rebel Distributors	2010-04-20	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	PD-Rx Pharmaceuticals, Inc.	2009-09-17	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2012-02-23	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Eugia US LLC	2020-07-06	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Glenmark Pharmaceuticals Inc., USA	2011-08-05	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Mylan Pharmaceuticals	2011-04-29	2011-04-30
Verapamil Hydrochloride	Tablet, film coated	40 mg/1	Oral	Clinical Solutions Wholesale	1993-06-29	2017-06-22
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Actavis Pharma, Inc.	1986-10-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	bryant ranch prepack	2014-04-07	2018-05-30
Verapamil Hydrochloride	Tablet	80 mg/1	Oral	REMEDYREPACK INC.	2019-07-09	Not applicable
Verapamil Hydrochloride	Tablet	240 mg/1	Oral	REMEDYREPACK INC.	2022-09-23	Not applicable
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	A-S Medication Solutions	2018-07-20	Not applicable
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	REMEDYREPACK INC.	2017-10-12	2020-05-04
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2011-01-07	Not applicable
Verapamil Hydrochloride	Tablet	240 mg/1	Oral	Nucare Pharmaceuticals,inc.	2019-05-15	Not applicable
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Mylan Pharmaceuticals Inc.	2009-12-28	2020-10-31
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable
Verapamil Hydrochloride	Tablet	180 mg/1	Oral	Proficient Rx LP	2019-05-15	Not applicable
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	Cadila Pharmaceuticals Limited	2017-05-27	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Preferred Pharmaceuticals Inc.	2016-11-21	2019-04-23
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	A-S Medication Solutions	2009-09-17	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Mylan Pharmaceuticals Inc.	1997-09-22	Not applicable
Verapamil Hydrochloride	Tablet, film coated	40 mg/1	Oral	Physicians Total Care, Inc.	2000-10-06	2011-06-30
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Clinical Solutions Wholsesale	2011-08-05	2017-06-21
Verapamil Hydrochloride	Tablet	240 mg/1	Oral	bryant ranch prepack	2019-05-15	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Lifestar Pharma Llc	2022-06-16	Not applicable
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	2018-07-20	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Somerset Therapeutics, Llc	2018-06-18	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	bryant ranch prepack	2011-08-05	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Northwind Pharmaceuticals, LLC	2023-01-31	Not applicable
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Rebel Distributors	1996-02-05	Not applicable
Verapamil Hydrochloride	Tablet	240 mg/1	Oral	Denton Pharma, Inc. Dba Northwind Pharmaceuticals	2021-03-24	2023-03-31
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	1986-10-01	2019-10-11
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Rpk Pharmaceuticals, Inc.	2009-09-17	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	HF Acquisition Co LLC, DBA HealthFirst	2019-10-17	Not applicable
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	REMEDYREPACK INC.	2014-07-03	2018-09-20
Verapamil Hydrochloride	Tablet	80 mg/1	Oral	Remedy Repack	2011-11-14	2013-02-03
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Proficient Rx LP	2011-08-05	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Denton Pharma, Inc. Dba Northwind Pharmaceuticals	2018-12-27	Not applicable
Verapamil Hydrochloride	Injection	10 mg/4mL	Intravenous	Armas Pharmaceuticals Inc.	2020-01-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1992-08-01	2015-04-30
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	HF Acquisition Co LLC, DBA HealthFirst	2022-05-20	Not applicable
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	Nucare Pharmaceuticals,inc.	2012-01-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated	40 mg/1	Oral	Carilion Materials Management	1993-06-29	Not applicable
Verapamil Hydrochloride	Tablet	180 mg/1	Oral	Nucare Pharmaceuticals,inc.	2019-05-15	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	bryant ranch prepack	1997-02-25	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Med Health Pharma LLC	2011-02-18	2012-05-10
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Nivagen Pharmaceuticals, Inc.	2023-01-02	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Rpk Pharmaceuticals, Inc.	2011-08-05	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Mylan Institutional Inc.	1998-11-15	2019-08-31
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Unit Dose Services	2011-08-05	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Preferred Pharmaceuticals Inc.	2016-05-04	2019-04-23
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Blenheim Pharmacal, Inc.	2011-02-15	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Proficient Rx LP	2009-09-17	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Teva Pharmaceuticals USA Inc	2014-04-07	2020-01-31
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Aphena Pharma Solutions - Tennessee, LLC	1997-09-22	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	IVAX Pharmaceuticals, Inc.	1992-08-01	2015-04-30
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Aphena Pharma Solutions - Tennessee, LLC	2011-08-05	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1 mL	Intravenous	Henry Schein, Inc.	2022-01-10	Not applicable
Verapamil Hydrochloride	Tablet, extended release	120 mg/1	Oral	Sun Pharmaceutical Industries, Inc.	2012-01-01	2020-11-30
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Baxter Healthcare Corporation	2020-03-25	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	bryant ranch prepack	2014-03-10	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Physicians Total Care, Inc.	2000-05-09	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Methapharm Inc.	2021-02-03	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Zydus Lifesciences Limited	2020-10-22	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Cardinal Health	2011-03-25	2019-01-31
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2014-12-04	Not applicable
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	Remedy Repack	2011-07-21	2016-11-09
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	American Health Packaging	2020-06-25	2024-11-30
Verapamil Hydrochloride	Tablet	80 mg/1	Oral	bryant ranch prepack	2011-01-07	Not applicable
Verapamil Hydrochloride	Tablet, film coated	40 mg/1	Oral	Avera McKennan Hospital	2015-03-06	2017-05-24
Verapamil Hydrochloride	Capsule, extended release	120 mg/1	Oral	Mylan Pharmaceuticals Inc.	1999-05-20	Not applicable
Verapamil Hydrochloride	Tablet	40 mg/1	Oral	bryant ranch prepack	2015-10-15	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Hospira, Inc.	2005-12-02	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1992-08-01	2015-04-30
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Nucare Pharmaceuticals,inc.	2018-07-20	Not applicable
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Actavis Pharma, Inc.	1986-10-01	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	St. Marys Medical Park Pharmacy	2013-05-22	2017-02-28
Verapamil Hydrochloride	Tablet	180 mg/1	Oral	Aphena Pharma Solutions - Tennessee, LLC	2019-05-15	Not applicable
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	bryant ranch prepack	2012-01-01	Not applicable
Verapamil Hydrochloride	Capsule, extended release	300 mg/1	Oral	Physicians Total Care, Inc.	2007-12-20	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Nucare Pharmaceuticals,inc.	1986-10-01	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Zydus Pharmaceuticals USA Inc.	2020-10-22	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1 mL	Intravenous	General Injectables & Vaccines, Inc	2010-03-01	2023-06-01
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Remedy Repack	2012-07-23	2013-10-31
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Golden State Medical Supply, Inc.	1997-09-09	2020-02-01
Verapamil Hydrochloride	Tablet	80 mg/1	Oral	Chartwell Rx, Llc	2011-01-07	Not applicable
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	bryant ranch prepack	2010-04-20	2017-12-31
Verapamil Hydrochloride	Tablet	240 mg/1	Oral	A-S Medication Solutions	2019-05-15	Not applicable
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Nucare Pharmaceuticals,inc.	2018-07-20	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Hospira, Inc.	2005-03-31	Not applicable
Verapamil Hydrochloride	Capsule, extended release	180 mg/1	Oral	Med Health Pharma LLC.	2011-02-22	2012-04-15
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Sagent Pharmaceuticals	2021-03-15	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Rpk Pharmaceuticals, Inc.	1986-10-01	Not applicable
Verapamil Hydrochloride	Tablet	40 mg/1	Oral	AvKARE	2020-04-13	Not applicable
Verapamil Hydrochloride	Tablet	180 mg/1	Oral	bryant ranch prepack	2019-05-15	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Blenheim Pharmacal, Inc.	2013-12-17	Not applicable
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	1986-10-01	Not applicable
Verapamil Hydrochloride	Tablet	240 mg/1	Oral	Northwind Pharmaceuticals, LLC	2022-05-19	Not applicable
Verapamil Hydrochloride	Tablet	180 mg/1	Oral	Denton Pharma, Inc. Dba Northwind Pharmaceuticals	2019-12-04	Not applicable
Verapamil Hydrochloride	Injection, solution	2.5 mg/1mL	Intravenous	Somerset Therapeutics, Llc	2018-06-18	Not applicable
Verapamil Hydrochloride	Tablet	240 mg/1	Oral	Remedy Repack	2012-10-02	2012-10-03
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Physicians Total Care, Inc.	1995-04-24	Not applicable
Verapamil Hydrochloride PM	Capsule, extended release	200 mg/1	Oral	Mylan Pharmaceuticals Inc.	2007-08-09	2019-11-30
Verapamil Hydrochloride PM	Capsule, extended release	100 mg/1	Oral	Avera McKennan Hospital	2015-06-25	2017-05-24
Verapamil Hydrochloride PM	Capsule, extended release	100 mg/1	Oral	Mylan Pharmaceuticals Inc.	2007-08-09	2019-11-30
Verapamil Hydrochloride PM	Capsule, extended release	300 mg/1	Oral	Mylan Pharmaceuticals Inc.	2007-08-09	2019-02-28

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Tarka	Verapamil hydrochloride (180 mg/1) + Trandolapril (2 mg/1)	Tablet, film coated, extended release	Oral	AbbVie Inc.	1996-10-22	2021-08-14
Tarka	Verapamil hydrochloride (240 mg/1) + Trandolapril (2 mg/1)	Tablet, film coated, extended release	Oral	AbbVie Inc.	1996-10-22	2021-09-13
Tarka	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Tablet, extended release	Oral	Abbott	2002-07-15	2010-11-12
Tarka	Verapamil hydrochloride (240 mg/1) + Trandolapril (2 mg/1)	Tablet, film coated, extended release	Oral	Physicians Total Care, Inc.	2005-05-27	Not applicable
Tarka	Verapamil hydrochloride (240 mg) + Trandolapril (2 mg)	Tablet, extended release	Oral	Bgp Pharma Ulc	2002-07-15	2019-11-19
Tarka	Verapamil hydrochloride (240 mg) + Trandolapril (4 mg)	Tablet, extended release	Oral	Bgp Pharma Ulc	2002-07-15	2019-11-19
Tarka	Verapamil hydrochloride (180 mg/1) + Trandolapril (2 mg/1)	Tablet, film coated, extended release	Oral	Physicians Total Care, Inc.	2009-01-01	Not applicable
Tarka	Verapamil hydrochloride (240 mg/1) + Trandolapril (1 mg/1)	Tablet, film coated, extended release	Oral	AbbVie Inc.	1996-10-22	2018-02-28
Tarka	Verapamil hydrochloride (240 mg/1) + Trandolapril (4 mg/1)	Tablet, film coated, extended release	Oral	AbbVie Inc.	1996-10-22	2021-08-18
Tarka	Verapamil hydrochloride (240 mg/1) + Trandolapril (4 mg/1)	Tablet, film coated, extended release	Oral	Physicians Total Care, Inc.	2009-06-25	Not applicable
Tarka	Verapamil hydrochloride (240 mg) + Trandolapril (1 mg)	Tablet, extended release	Oral	Abbott	2002-07-15	2010-11-12
TARKA 180/2 FILM TABLET, 28 ADET	Verapamil (180 mg) + Trandolapril (2 mg)	Tablet, film coated	Oral	ABBOTT LABORATUARLARI İTHALAT İHRACAT VE TİC. LTD. ŞTİ.	2013-01-29	Not applicable
TARKA 180MG/2MG	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Tablet, delayed release	Oral		2016-07-01	Not applicable
TARKA 180MG/2MG	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Tablet, delayed release	Oral		2016-07-01	Not applicable
TARKA 180MG/2MG	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Tablet, delayed release	Oral		2016-07-01	Not applicable
TARKA 180MG/2MG	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Tablet, delayed release	Oral		2016-07-01	Not applicable
TARKA 180MG/2MG	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Tablet, delayed release	Oral		2016-07-01	Not applicable
TARKA 180MG/2MG	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Tablet, delayed release	Oral		2016-07-01	Not applicable
TARKA 180MG/2MG	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Tablet, delayed release	Oral		2016-07-01	Not applicable
TARKA 180MG/2MG	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Tablet, delayed release	Oral		2016-07-01	Not applicable
TARKA 180MG/2MG	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Tablet, delayed release	Oral		2016-07-01	Not applicable
TARKA 180MG/2MG	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Tablet, delayed release	Oral		2016-07-01	Not applicable
TARKA 180MG/2MG	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Tablet, delayed release	Oral		2016-07-01	Not applicable
TARKA 240MG/2MG	Verapamil hydrochloride (240 mg) + Trandolapril (2 mg)	Tablet, delayed release	Oral		2016-07-01	Not applicable
TARKA 240MG/4MG	Verapamil hydrochloride (240 mg) + Trandolapril (4 mg)	Tablet, delayed release	Oral		2016-07-01	Not applicable
TARKA FORTE 240/4 FILM TABLET, 28 ADET	Verapamil (240 mg) + Trandolapril (4 mg)	Tablet, film coated	Oral	ABBOTT LABORATUARLARI İTHALAT İHRACAT VE TİC. LTD. ŞTİ.	2013-01-29	Not applicable
TARKA® SR TABLETAS	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Tablet, extended release	Oral	ABBOTT LABORATORIES DE COLOMBIA S.A.S.	2008-12-01	Not applicable
TARKA® SR240/4 TABLETAS.	Verapamil hydrochloride (240 mg) + Trandolapril (4 mg)	Tablet, extended release	Oral	ABBOTT LABORATORIES DE COLOMBIA S.A.	2007-07-18	Not applicable
Trandolapril and Verapamil Hydrochloride	Verapamil hydrochloride (180 mg/1) + Trandolapril (2 mg/1)	Tablet, film coated, extended release	Oral	Med Pharma Co., Ltd.	2011-07-15	2012-08-01
Trandolapril and Verapamil Hydrochloride	Verapamil hydrochloride (240 mg/1) + Trandolapril (1 mg/1)	Tablet, film coated, extended release	Oral	Glenmark Pharmaceuticals Inc., USA	2015-02-25	Not applicable
Trandolapril and Verapamil Hydrochloride	Verapamil hydrochloride (240 mg/1) + Trandolapril (4 mg/1)	Tablet, film coated, extended release	Oral	Glenmark Pharmaceuticals Inc., USA	2015-02-25	Not applicable
Trandolapril and Verapamil Hydrochloride	Verapamil hydrochloride (240 mg/1) + Trandolapril (4 mg/1)	Tablet, film coated, extended release	Oral	Med Pharma Co., Ltd.	2011-07-15	2012-08-01
Trandolapril and Verapamil Hydrochloride	Verapamil hydrochloride (240 mg/1) + Trandolapril (1 mg/1)	Tablet, film coated, extended release	Oral	Med Pharma Co., Ltd.	2011-07-15	2012-08-01
Trandolapril and Verapamil Hydrochloride	Verapamil hydrochloride (240 mg/1) + Trandolapril (2 mg/1)	Tablet, film coated, extended release	Oral	Glenmark Pharmaceuticals Inc., USA	2015-02-25	Not applicable
Trandolapril and Verapamil Hydrochloride	Verapamil hydrochloride (240 mg/1) + Trandolapril (2 mg/1)	Tablet, film coated, extended release	Oral	Med Pharma Co., Ltd.	2011-07-15	2012-08-01
Trandolapril and Verapamil Hydrochloride	Verapamil hydrochloride (180 mg/1) + Trandolapril (2 mg/1)	Tablet, film coated, extended release	Oral	Glenmark Pharmaceuticals Inc., USA	2015-02-25	Not applicable
Trandolapril and Verapamil Hydrochloride ER	Verapamil hydrochloride (240 mg/1) + Trandolapril (2 mg/1)	Tablet, film coated, extended release	Oral	Greenstone LLC	2015-02-25	2021-05-28
Trandolapril and Verapamil Hydrochloride ER	Verapamil hydrochloride (240 mg/1) + Trandolapril (1 mg/1)	Tablet, film coated, extended release	Oral	Greenstone LLC	2015-02-25	2018-02-28
Trandolapril and Verapamil Hydrochloride ER	Verapamil hydrochloride (240 mg/1) + Trandolapril (4 mg/1)	Tablet, film coated, extended release	Oral	Greenstone LLC	2015-02-25	2021-08-18
Trandolapril and Verapamil Hydrochloride ER	Verapamil hydrochloride (180 mg/1) + Trandolapril (2 mg/1)	Tablet, film coated, extended release	Oral	Greenstone LLC	2015-02-25	2021-08-14
VERACOMB MR 180/2 MG KAPSÜL, 28 ADET	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Capsule	Oral	NEUTEC İLAÇ SAN. TİC. A.Ş.	2012-10-17	Not applicable
VERACOMB MR 240/4 MG KAPSÜL, 28 ADET	Verapamil hydrochloride (240 mg) + Trandolapril (4 mg)	Capsule	Oral	NEUTEC İLAÇ SAN. TİC. A.Ş.	2012-10-17	Not applicable
VERAPIN 180 MG/2 MG FILM TABLET, 28 ADET	Verapamil hydrochloride (180 mg) + Trandolapril (2 mg)	Tablet, film coated	Oral	İLKO İLAÇ SAN.VE TİC. A.Ş.	2017-01-25	Not applicable
VERAPIN FORTE 240MG/4MG FILM TABLET,28 ADET	Verapamil hydrochloride (240 mg) + Trandolapril (4 mg)	Tablet, film coated	Oral	İLKO İLAÇ SAN.VE TİC. A.Ş.	2016-06-15	Not applicable

Chemical Identifiers

UNII: CJ0O37KU29
CAS number: 52-53-9
InChI Key: SGTNSNPWRIOYBX-UHFFFAOYSA-N
InChI: InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
IUPAC Name: 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
SMILES: COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1

References

Synthesis Reference

Philippe Baudier, Arthur De Boeck, Jacques Fossion, "Novel galenic forms of verapamil, their preparation and medicines containing said novel galenic forms." U.S. Patent US4859469, issued April, 1987.

US4859469

General References

Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-83. [Article]
Ahmed JH, Meredith PA, Elliott HL: The influence of age on the pharmacokinetics of verapamil. Pharmacol Res. 1991 Oct;24(3):227-33. doi: 10.1016/1043-6618(91)90085-c. [Article]
Dadashzadeh S, Javadian B, Sadeghian S: The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm Drug Dispos. 2006 Oct;27(7):329-34. doi: 10.1002/bdd.512. [Article]
Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [Article]
Busse D, Fromm MF, Morike K, Drescher S, Kuhlkamp V, Eichelbaum M: Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. Clin Pharmacol Ther. 2001 May;69(5):324-32. doi: 10.1067/mcp.2001.115125. [Article]
Ninomiya T, Takano M, Haruna T, Kono Y, Horie M: Verapamil, a Ca2+ entry blocker, targets the pore-forming subunit of cardiac type KATP channel (Kir6.2). J Cardiovasc Pharmacol. 2003 Aug;42(2):161-8. doi: 10.1097/00005344-200308000-00002. [Article]
Bergson P, Lipkind G, Lee SP, Duban ME, Hanck DA: Verapamil block of T-type calcium channels. Mol Pharmacol. 2011 Mar;79(3):411-9. doi: 10.1124/mol.110.069492. Epub 2010 Dec 13. [Article]
Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [Article]
Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [Article]
Striessnig J, Ortner NJ, Pinggera A: Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets? Curr Mol Pharmacol. 2015;8(2):110-22. [Article]
Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G: Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. [Article]
Motulsky HJ, Snavely MD, Hughes RJ, Insel PA: Interaction of verapamil and other calcium channel blockers with alpha 1- and alpha 2-adrenergic receptors. Circ Res. 1983 Feb;52(2):226-31. [Article]
Echizen H, Eichelbaum M: Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet. 1986 Nov-Dec;11(6):425-49. doi: 10.2165/00003088-198611060-00002. [Article]
Dobrev D, Milde AS, Andreas K, Ravens U: The effects of verapamil and diltiazem on N-, P- and Q-type calcium channels mediating dopamine release in rat striatum. Br J Pharmacol. 1999 May;127(2):576-82. doi: 10.1038/sj.bjp.0702574. [Article]
Freeze BS, McNulty MM, Hanck DA: State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel. Mol Pharmacol. 2006 Aug;70(2):718-26. Epub 2006 May 12. [Article]
Duan JJ, Ma JH, Zhang PH, Wang XP, Zou AR, Tu DN: Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. Acta Pharmacol Sin. 2007 Jul;28(7):959-67. [Article]
FDA Approved Drug Products: Verelan® PM extended-release capsules [Link]
FDA Approved Drug Products: Verapamil HCl for intravenous injection [Link]
Verapamil FDA Label [Link]
FDA Approved Drugs: Tarka® extended-release tablets [Link]
CaymanChem: Verapamil MSDS [Link]
FDA Approved Drug Products: Calan SR tablets [Link]

External Links

Human Metabolome Database: HMDB0001850
KEGG Drug: D02356
KEGG Compound: C07188
PubChem Compound: 2520
PubChem Substance: 46508158
ChemSpider: 2425
BindingDB: 81939
RxNav: 11170
ChEBI: 77733
ChEMBL: CHEMBL6966
Therapeutic Targets Database: DAP000040
PharmGKB: PA451868
Guide to Pharmacology: GtP Drug Page
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
Wikipedia: Verapamil

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Prevention	Kidney Stones	1
4	Completed	Treatment	Acute Myocardial Infarction (AMI) / Percutaneous Coronary Intervention (PCI)	1
4	Completed	Treatment	Coronary Artery Disease (CAD) / Hypertension	1
4	Completed	Treatment	Diabetes / Hypertension	1
4	Completed	Treatment	Diabetes / Hypertension / Proteinuria	1
4	Completed	Treatment	Hypertension	2
4	Completed	Treatment	Hypertension / Syndrome, Metabolic	1
4	Completed	Treatment	Hypoglycemia / Obesity / Surgery	1
4	Completed	Treatment	Ischemic Heart Disease	1
4	Completed	Treatment	Marfan Syndrome	1
4	Completed	Treatment	Paroxysmal Supraventricular Tachycardia (PSVT)	1
4	Completed	Treatment	Rapid Ventricular Response Atrial Fibrillation	1
4	Recruiting	Diagnostic	Premature Ventricular Contraction (PVC)	1
4	Recruiting	Health Services Research	Cerebral Vasospasm	1
4	Recruiting	Other	Cluster Headache	1
4	Recruiting	Treatment	Nonobstructive Hypertrophic Cardiomyopathy	1
4	Recruiting	Treatment	Tinnitus / Tinnitus, Subjective	1
4	Suspended	Prevention	Coronavirus Disease 2019 (COVID‑19) / Hypertension	1
4	Terminated	Prevention	Keloids Scars	1
4	Unknown Status	Treatment	Atrial Fibrillation / Heart Failure	1
4	Unknown Status	Treatment	Cardiomyopathy / Hearth Failure With Reduced Ejection Fraction (HFrEF) / Myocardial Diseases	1
4	Unknown Status	Treatment	Dilated Cardiomyopathy (DCM)	1
4	Withdrawn	Other	Atrial Fibrillation	1
4	Withdrawn	Treatment	Reversible cerebral vasoconstriction syndrome	1
3	Completed	Treatment	Arrhythmia / Atrial Fibrillation / Cardiovascular Disease (CVD)	1
3	Completed	Treatment	Atrial Fibrillation	1
3	Completed	Treatment	Hypertension / Obesity	1
3	Completed	Treatment	Mania	1
3	Completed	Treatment	Type 1 Diabetes Mellitus	1
3	Terminated	Treatment	Atrial Fibrillation / Heart Failure	1
2	Completed	Treatment	Brain Cancer / Cancer / Meningiomas	1
2	Completed	Treatment	Dravet Syndrome (DS)	1
2	Completed	Treatment	Type 1 Diabetes Mellitus	1
2	Enrolling by Invitation	Treatment	Short-coupled Idiopathic Ventricular Fibrillation	1
2	Recruiting	Prevention	Coronary Artery Disease (CAD)	1
2	Recruiting	Treatment	Type 1 Diabetes Mellitus	1
2	Terminated	Prevention	Episodic Cluster Headache	1
2	Unknown Status	Diagnostic	Epilepsy	1
2, 3	Completed	Treatment	Cluster Headache	1
2, 3	Completed	Treatment	Coronavirus Disease 2019 (COVID‑19)	1
2, 3	Unknown Status	Treatment	Ventricular Arrhythmia	1
1	Completed	Not Available	Crohn's Disease (CD)	1
1	Completed	Not Available	Healthy Volunteers (HV)	1
1	Completed	Not Available	Substance Dependence	1
1	Completed	Basic Science	Drug Drug Interaction (DDI)	1
1	Completed	Basic Science	Drug Drug Interaction (DDI) / Healthy Volunteers (HV)	2
1	Completed	Basic Science	Healthy Volunteers (HV)	2
1	Completed	Basic Science	Healthy Volunteers (HV) / Pharmacokinetics of ASP015K	1
1	Completed	Basic Science	Opioid Dependence	1
1	Completed	Basic Science	Pharmacokinetics	1
1	Completed	Basic Science	Substance Dependence	1
1	Completed	Diagnostic	Chronic Subjective Dizziness / Vestibular Migraine	1
1	Completed	Other	Drug-induced QT Interval Prolongation / Pharmacodynamics / Pharmacokinetics	1
1	Completed	Other	Healthy Volunteers (HV)	5
1	Completed	Treatment	Chronic Obstructive Pulmonary Disease (COPD) / Chronic Obstructive Pulmonary Disease Exacerbation	1
1	Completed	Treatment	Drug-induced Surface ECG Changes	1
1	Completed	Treatment	Healthy Adult Subjects	1
1	Completed	Treatment	Healthy Volunteers (HV)	5
1	Completed	Treatment	Immune Thrombocytopenia (ITP)	1
1	Completed	Treatment	Ischemic Stroke	2
1	Completed	Treatment	Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma	1
1	Completed	Treatment	Respiratory Syncytial Virus (RSV) Infection	1
1	Completed	Treatment	Type 2 Diabetes Mellitus	1
1	Recruiting	Treatment	Atrial Fibrillation / Diastolic Dysfunction / Heart Failure With Preserved Ejection Fraction (HFpEF)	1
1	Recruiting	Treatment	Ischemic Stroke	1
1	Recruiting	Treatment	Obstructive Hypertrophic Cardiomyopathy	1
1	Terminated	Basic Science	Adverse Drug Reaction (ADR) / Cardiovascular System Disease	1
1	Terminated	Treatment	Nasal Polyps / Sinusitis	1
1	Withdrawn	Treatment	Ischemic Stroke	1
1, 2	Completed	Health Services Research	Healthy Volunteers (HV)	1
1, 2	Terminated	Treatment	Osteoarthritis of the Knee	1
0	Active Not Recruiting	Prevention	Bloodloss / Heart Rates / Sinus Endoscopic Surgery	1
0	Completed	Basic Science	Endothelial Dysfunction / Obesity / Vasodilation / Venous Occlusion Plethysmography	1
0	Completed	Basic Science	Type 1 Diabetes Mellitus	1
0	Not Yet Recruiting	Prevention	Diltiazim / FESS / Verapamil	1
0	Recruiting	Prevention	Pain / Pain, Burning / Vasospasm;Peripheral	1
Not Available	Completed	Not Available	Coronary Heart Disease (CHD) / Verapamil Toxicity	1
Not Available	Completed	Not Available	Coronavirus Disease 2019 (COVID‑19) / COVID / Hypertension	1
Not Available	Completed	Not Available	Erectile Dysfunction	1
Not Available	Completed	Treatment	Arrhythmia / Atrial Fibrillation	1
Not Available	Completed	Treatment	Atrial Fibrillation	1
Not Available	Completed	Treatment	No Reflow Phenomenon / Percutaneous Coronary Intervention (PCI) / ST Segment Elevation Myocardial Infarction (STEMI)	1
Not Available	Completed	Treatment	Premature Ventricular Contraction (PVC)	1
Not Available	Completed	Treatment	Supraventricular Tachycardia (SVT)	1
Not Available	Completed	Treatment	Type 2 Diabetes Mellitus	1
Not Available	Not Yet Recruiting	Other	Regional Anesthesia Morbidity	1
Not Available	Not Yet Recruiting	Treatment	Hyaluronic Acid / Peyronie's Disease / Verapamil	1
Not Available	Recruiting	Not Available	Breastfed Infants of Mothers on Select DOI / Lactating Women on Select DOI	1
Not Available	Terminated	Treatment	Nasal Polyps / Sinusitis	1
Not Available	Unknown Status	Treatment	Atrial Fibrillation / Cardiopulmonary Exercise Test / Rate Control	1
Not Available	Unknown Status	Treatment	Epilepsy / Seizures	1
Not Available	Withdrawn	Treatment	Catamenial Epilepsy	1

Pharmacoeconomics

Manufacturers

Mylan pharmaceuticals inc
Elan drug delivery inc
Gd searle llc
Fsc laboratories inc
Abraxis pharmaceutical products
Bedford laboratories div ben venue laboratories inc
Hospira inc
International medication system
Luitpold pharmaceuticals inc
Marsam pharmaceuticals llc
Smith and nephew solopak div smith and nephew
Solopak medical products inc
Ranbaxy laboratories inc
Glenmark generics ltd
Ivax pharmaceuticals inc sub teva pharmaceuticals usa
Par pharmaceutical inc
Pliva inc
Actavis elizabeth llc
Heritage pharmaceuticals inc
Mutual pharmaceutical co inc
Sandoz inc
Warner chilcott div warner lambert co
Watson laboratories inc

Packagers

Abbott Laboratories Ltd.
Advanced Pharmaceutical Services Inc.
Alza Corp.
Amerisource Health Services Corp.
Apotheca Inc.
A-S Medication Solutions LLC
Atlantic Biologicals Corporation
BASF Corp.
Cardinal Health
Caremark LLC
Comprehensive Consultant Services Inc.
Copley Chemical Co.
Dee Stevens and Son Feeder
Dept Health Central Pharmacy
Direct Dispensing Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Duramed
Elan Pharmaceuticals Inc.
FSC Laboratories
GD Searle LLC
General Injectables and Vaccines Inc.
Glenmark Generics Ltd.
Golden State Medical Supply Inc.
Group Health Cooperative
H.J. Harkins Co. Inc.
Heartland Repack Services LLC
Hospira Inc.
Ivax Pharmaceuticals
Kaiser Foundation Hospital
Lake Erie Medical and Surgical Supply
Liberty Pharmaceuticals
Major Pharmaceuticals
Medisca Inc.
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Nucare Pharmaceuticals Inc.
Palmetto Pharmaceuticals Inc.
PD-Rx Pharmaceuticals Inc.
Pfizer Inc.
Pharmaceutical Utilization Management Program VA Inc.
Pharmacia Inc.
Pharmedix
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepackage Specialists
Prepak Systems Inc.
Prescript Pharmaceuticals
Ranbaxy Laboratories
Remedy Repack
Resource Optimization and Innovation LLC
Sandhills Packaging Inc.
Schwarz Pharma Inc.
Southwood Pharmaceuticals
Talbert Medical Management Corp.
Tya Pharmaceuticals
UDL Laboratories
United Research Laboratories Inc.
Vangard Labs Inc.
Watson Pharmaceuticals

Dosage Forms

Form	Route	Strength
Tablet, film coated	Oral	80 mg
Tablet	Oral
Tablet, extended release	Oral	180 mg
Tablet	Oral	240.000 mg
Capsule		180 mg
Capsule		240 mg
Capsule, coated	Oral	240 mg
Tablet, coated	Oral	120 mg
Injection, solution	Intravenous	125 MG/50ML
Pill		80 MG
Solution	Intravenous	5 mg/2ml
Solution		5 mg/2ml
Tablet, film coated	Oral	120 MG
Tablet, sugar coated	Oral	40 mg
Injection, solution	Intravenous	5 mg/2ml
Tablet, sugar coated	Oral
Tablet, film coated	Oral	40 MG
Tablet, film coated	Oral	240 mg
Tablet, coated	Oral	120 mg/1
Tablet, coated	Oral	180 mg/1
Tablet, coated	Oral	240 mg/1
Tablet, extended release	Oral
Tablet, extended release	Oral	240 mg
Tablet, film coated	Oral	240.0 mg
Injection	Parenteral	5 mg
Tablet	Oral	120 mg
Tablet, extended release	Oral	120 mg
Solution	Parenteral	5 mg
Tablet	Oral	40 mg
Tablet	Oral	80 mg
Tablet, extended release	Oral
Tablet, film coated, extended release	Oral
Tablet, film coated	Oral
Tablet, delayed release	Oral
Capsule, coated	Oral
Capsule
Tablet	Oral	80.00 mg
Capsule	Oral
Solution	Intravenous	5.000 mg
Tablet, film coated	Oral
Capsule, delayed release
Tablet, coated	Oral
Pill
Tablet	Oral	240 MG
Injection	Intravenous	5 mg/1mL
Capsule, delayed release pellets	Oral	120 mg/1
Capsule, delayed release pellets	Oral	180 mg/1
Capsule, extended release	Oral	100 mg/1
Capsule, extended release	Oral	120 mg/1
Capsule, extended release	Oral	180 mg/1
Capsule, extended release	Oral	200 mg/1
Capsule, extended release	Oral	240 mg/1
Capsule, extended release	Oral	300 mg/1
Injection	Intravenous	10 mg/4mL
Injection	Intravenous	2.5 mg/1mL
Injection	Intravenous	5 mg/2mL
Injection, solution	Intravenous	2.5 mg/1mL
Injection, solution	Intravenous	2.5 mg/1 mL
Powder	Not applicable	1 kg/1kg
Tablet	Oral	120 mg/1
Tablet	Oral	180 mg/1
Tablet	Oral	240 mg/1
Tablet	Oral	40 mg/1
Tablet	Oral	80 mg/1
Tablet, extended release	Oral	120 mg/1
Tablet, extended release	Oral	180 mg/1
Tablet, extended release	Oral	240 mg/1
Tablet, extended release	Oral	240 mg/301
Tablet, film coated	Oral	120 mg/1
Tablet, film coated	Oral	40 mg/1
Tablet, film coated	Oral	80 mg/1
Tablet, film coated, extended release	Oral	120 mg/1
Tablet, film coated, extended release	Oral	180 mg/1
Tablet, film coated, extended release	Oral	240 mg/1
Liquid	Intravenous	2.5 mg / mL
Solution	Intravenous	2.5 mg / mL
Capsule, extended release	Oral
Solution	Intravenous	2.50 mg
Tablet, coated	Oral	12000000 mg
Tablet, coated	Oral	84 mg
Tablet, film coated	Oral	81.6 mg
Tablet, coated	Oral	80 mg
Solution	Intravenous	5 mg
Tablet, delayed release	Oral	80 mg
Capsule, delayed release pellets	Oral	240 mg/1
Capsule, delayed release pellets	Oral	360 mg/1
Capsule, extended release	Oral	120 mg
Capsule, extended release	Oral	180 mg
Capsule, extended release	Oral	240 mg
Injection, solution	Intravenous	2.5 mg/mL
Injection	Intravenous	2.5 mg/ml
Tablet	Oral	80.000 mg
Solution	Parenteral	250.000 mg
Tablet, coated	Oral	40 mg

Prices

Unit description	Cost	Unit
Verelan 360 mg 24 Hour Capsule	6.82USD	capsule
Verelan 360 mg cap pellet	6.73USD	pellet
Verelan pm 300 mg cap pellet	5.87USD	pellet
Verelan 240 mg 24 Hour Capsule	4.76USD	capsule
Verelan 240 mg cap pellet	4.58USD	pellet
Verelan 180 mg 24 Hour Capsule	4.22USD	capsule
Verelan 180 mg cap pellet	4.06USD	pellet
Verelan pm 200 mg cap pellet	4.04USD	pellet
Verelan 120 mg cap pellet	3.87USD	pellet
Verapamil HCl CR 300 mg 24 Hour Capsule	3.82USD	capsule
Isoptin sr 240 mg tablet	3.32USD	tablet
Verapamil hcl powder	3.24USD	g
Calan SR 240 mg Controlled Release Tabs	3.15USD	tab
Isoptin SR 240 mg Controlled Release Tabs	3.14USD	tab
Verelan pm 100 mg cap pellet	3.13USD	pellet
Calan sr 240 mg caplet	3.09USD	caplet
Covera-HS 240 mg 24 Hour tablet	3.09USD	tablet
Covera-hs 240 mg tablet sa	2.97USD	tablet
Isoptin sr 180 mg tablet	2.9USD	tablet
Calan SR 180 mg Controlled Release Tabs	2.8USD	tab
Isoptin SR 180 mg Controlled Release Tabs	2.74USD	tab
Calan sr 180 mg caplet	2.7USD	caplet
Verapamil HCl CR 200 mg 24 Hour Capsule	2.62USD	capsule
Isoptin sr 120 mg tablet	2.29USD	tablet
Calan SR 120 mg Controlled Release Tabs	2.27USD	tab
Covera-HS 180 mg 24 Hour tablet	2.2USD	tablet
Isoptin SR 120 mg Controlled Release Tabs	2.16USD	tab
Calan sr 120 mg caplet	2.13USD	caplet
Covera-hs 180 mg tablet sa	2.11USD	tablet
Verapamil HCl CR 360 mg 24 Hour Capsule	2.1USD	capsule
Verapamil HCl CR 100 mg 24 Hour Capsule	2.04USD	capsule
Isoptin Sr 240 mg Sustained-Release Tablet	2.03USD	tablet
Calan sr 240 mg caplet sa	1.77USD	caplet
Verapamil HCl CR 240 mg 24 Hour Capsule	1.69USD	capsule
Verapamil HCl CR 240 mg Controlled Release Tabs	1.6USD	tab
Calan 120 mg tablet	1.56USD	tablet
Isoptin Sr 180 mg Sustained-Release Tablet	1.52USD	tablet
Verapamil HCl CR 180 mg 24 Hour Capsule	1.5USD	capsule
Calan sr 180 mg caplet sa	1.46USD	caplet
Verapamil HCl CR 120 mg 24 Hour Capsule	1.43USD	capsule
Verapamil HCl CR 180 mg Controlled Release Tabs	1.41USD	tab
Isoptin Sr 120 mg Sustained-Release Tablet	1.34USD	tablet
Calan 80 mg tablet	1.25USD	tablet
Verapamil 2.5 mg/ml vial	1.18USD	ml
Verapamil HCl CR 120 mg Controlled Release Tabs	1.12USD	tab
Apo-Verap Sr 240 mg Sustained-Release Tablet	0.91USD	tablet
Mylan-Verapamil Sr 240 mg Sustained-Release Tablet	0.91USD	tablet
Novo-Veramil Sr 240 mg Sustained-Release Tablet	0.91USD	tablet
Pms-Verapamil Sr 240 mg Sustained-Release Tablet	0.91USD	tablet
Calan 40 mg tablet	0.76USD	tablet
Apo-Verap Sr 120 mg Sustained-Release Tablet	0.72USD	tablet
Mylan-Verapamil Sr 120 mg Sustained-Release Tablet	0.72USD	tablet
Verapamil HCl 120 mg tablet	0.71USD	tablet
Apo-Verap Sr 180 mg Sustained-Release Tablet	0.69USD	tablet
Mylan-Verapamil Sr 180 mg Sustained-Release Tablet	0.69USD	tablet
Verapamil HCl 80 mg tablet	0.56USD	tablet
Apo-Verap 120 mg Tablet	0.45USD	tablet
Mylan-Verapamil 120 mg Tablet	0.45USD	tablet
Nu-Verap 120 mg Tablet	0.45USD	tablet
Verapamil 120 mg tablet	0.39USD	tablet
Verapamil 80 mg tablet	0.31USD	tablet
Verapamil HCl 40 mg tablet	0.29USD	tablet
Apo-Verap 80 mg Tablet	0.29USD	tablet
Mylan-Verapamil 80 mg Tablet	0.29USD	tablet
Nu-Verap 80 mg Tablet	0.29USD	tablet
Verapamil 40 mg tablet	0.28USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
US5785994	No	1998-07-28	2009-10-22
US6096339	No	2000-08-01	2017-04-04

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00394 mg/mL	ALOGPS
logP	5.23	ALOGPS
logP	5.04	Chemaxon
logS	-5.1	ALOGPS
pKa (Strongest Basic)	9.68	Chemaxon
Physiological Charge	1	Chemaxon
Hydrogen Acceptor Count	6	Chemaxon
Hydrogen Donor Count	0	Chemaxon
Polar Surface Area	63.95 Å²	Chemaxon
Rotatable Bond Count	13	Chemaxon
Refractivity	132.65 m³·mol^-1	Chemaxon
Polarizability	51.7 Å³	Chemaxon
Number of Rings	2	Chemaxon
Bioavailability	0	Chemaxon
Rule of Five	No	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9371
Blood Brain Barrier	+	0.6323
Caco-2 permeable	+	0.738
P-glycoprotein substrate	Substrate	0.7874
P-glycoprotein inhibitor I	Inhibitor	0.9056
P-glycoprotein inhibitor II	Inhibitor	0.855
Renal organic cation transporter	Inhibitor	0.6259
CYP450 2C9 substrate	Non-substrate	0.8029
CYP450 2D6 substrate	Non-substrate	0.8706
CYP450 3A4 substrate	Substrate	0.7657
CYP450 1A2 substrate	Non-inhibitor	0.9553
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Non-inhibitor	0.9026
CYP450 3A4 inhibitor	Inhibitor	0.796
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9181
Ames test	Non AMES toxic	0.8393
Carcinogenicity	Non-carcinogens	0.6463
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	3.4137 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.7687
hERG inhibition (predictor II)	Inhibitor	0.8188

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	splash10-0cdu-4391500000-cd36ebd65bc8c7765961
Mass Spectrum (Electron Ionization)	MS	splash10-0udi-3519000000-b5e0b9e0caac5cb57222
MS/MS Spectrum - Quattro_QQQ 10V, Positive	LC-MS/MS	splash10-004l-0702900000-6a46ea2d5eed6d8b01eb
MS/MS Spectrum - Quattro_QQQ 25V, Positive	LC-MS/MS	splash10-0006-4109800000-80d342090a0be3344e82
MS/MS Spectrum - Quattro_QQQ 40V, Positive	LC-MS/MS	splash10-054w-0954400000-2def387c7c93ab211423
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positive	LC-MS/MS	splash10-0a4i-0000900000-4cde9a4b3a4f83d16afc
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positive	LC-MS/MS	splash10-0a4i-0000900000-980b47834e505d54a0e6
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positive	LC-MS/MS	splash10-066r-0902800000-ae024239c46b33917426
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positive	LC-MS/MS	splash10-014i-0901000000-81d1159b3102cff76218
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positive	LC-MS/MS	splash10-014i-0900000000-d9c344fee7b45b4030e6
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive	LC-MS/MS	splash10-0gb9-0914000000-070bdb975910e9aae99c
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive	LC-MS/MS	splash10-03di-0390000000-f41d80462c5d06c4f001
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive	LC-MS/MS	splash10-0097-2980000000-9a2ab0bcab33f7eaac6b
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive	LC-MS/MS	splash10-0uxr-0900000000-252a9989a8511cb2db80
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive	LC-MS/MS	splash10-0f79-0900000000-4fd6ca2c6c19c3bbf8f0
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0a4i-0000900000-4365a47b2dc2f86bb272
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0a4i-0000900000-e6a2b357160bf5b92c22
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-066r-0902400000-d8eac2ccd0a767c7e432
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-014i-0901000000-688f3c2345c5d9ccb8a5
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-014i-0900000000-cd09f8a2be876936f662
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0uxr-0918000000-76641dd6dbc5cb05e79a
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0000900000-05ea95eb1f39b6515212
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-066r-0902600000-a675e624692c25472ce8
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-014i-0901000000-70d820628d2613557239
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0gb9-0900000000-e3ca24cf75d574df08a8
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0uyi-0900000000-f3a9fa002c56d3e5689a
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0zg0-2900000000-101e077b890671063633
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0000900000-84b4516ac84e6912cc15
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-066r-0902600000-bc1701c307e45ee4dcd7
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-014i-0901000000-6fbdab598bcb6147a4bf
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0gb9-0900000000-ce61116806eaa908681c
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0uxr-0900000000-ad3f25e02a7c8e66fb6a
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0zgr-2900000000-792b9009086561f6c398
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0uxr-0918000000-e7a5a3f8c88dc40683fd
LC-MS/MS Spectrum - LC-ESI-QQ , positive	LC-MS/MS	splash10-0a4i-0000900000-4cde9a4b3a4f83d16afc
LC-MS/MS Spectrum - LC-ESI-QQ , positive	LC-MS/MS	splash10-0a4i-0000900000-9a5c5240148f82cc6add
LC-MS/MS Spectrum - LC-ESI-QQ , positive	LC-MS/MS	splash10-066r-0902800000-ae024239c46b33917426
LC-MS/MS Spectrum - LC-ESI-QQ , positive	LC-MS/MS	splash10-014i-0901000000-81d1159b3102cff76218
LC-MS/MS Spectrum - LC-ESI-QQ , positive	LC-MS/MS	splash10-014i-0900000000-2411d65dfe09741dde81
LC-MS/MS Spectrum - LC-ESI-IT , positive	LC-MS/MS	splash10-0gb9-0914000000-0463345a8ab0de7aa99e
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-014i-0900000000-42074ab645b7af0ef79f
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0zgi-0900000000-20360f78435d5f482709
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0uxr-0819000000-7f68ebd6e344adf12101
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0uxr-0918000000-d3727bbe601b80eabfb3
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0a4i-0100900000-0a928f78000f291f031d
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-066r-0902600000-40f800e4a364d9ca214c
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0gb9-0900000000-4dea228d69d59705fc18
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0a4i-0500900000-c0bc440571b30d4b5b27
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-066r-0900300000-47a59c15bdbcbc62d6c6
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0ab9-1011900000-1069b9a1ca6cd213f235
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0006-9461300000-a946e3883af52b0d7378
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0udi-0021900000-b2bedd2dcc3f0133959c
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-014i-1941300000-ef1ad82262f513c09d33
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0umi-0034900000-91a579384abf3d7d9470
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-014i-0119300000-c075679051e5a631201a
1H NMR Spectrum	1D NMR	Not Applicable
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable
[1H,13C] 2D NMR Spectrum	2D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å²)	Source type	Source
[M-H]-	227.5669678	predicted	DarkChem Lite v0.1.0
[M-H]-	212.53043	predicted	DeepCCS 1.0 (2019)
[M+H]+	227.2429678	predicted	DarkChem Lite v0.1.0
[M+H]+	214.88843	predicted	DeepCCS 1.0 (2019)
[M+Na]+	227.7249678	predicted	DarkChem Lite v0.1.0
[M+Na]+	221.00804	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Voltage-dependent L-type calcium channel subunit alpha-1C

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Inhibitor

General Function: Voltage-gated calcium channel activity
Specific Function: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name: CACNA1C
Uniprot ID: Q13936
Uniprot Name: Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight: 248974.1 Da

References

Dilmac N, Hilliard N, Hockerman GH: Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2. Mol Pharmacol. 2004 Nov;66(5):1236-47. Epub 2004 Jul 30. [Article]
Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [Article]
Patel MK, Clunn GF, Lymn JS, Austin O, Hughes AD: Effect of serum withdrawal on the contribution of L-type calcium channels (CaV1.2) to intracellular Ca2+ responses and chemotaxis in cultured human vascular smooth muscle cells. Br J Pharmacol. 2005 Jul;145(6):811-7. [Article]
Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [Article]

Details2. Voltage-dependent N-type calcium channel subunit alpha-1B

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Voltage-gated calcium channel activity
Specific Function: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name: CACNA1B
Uniprot ID: Q00975
Uniprot Name: Voltage-dependent N-type calcium channel subunit alpha-1B
Molecular Weight: 262493.84 Da

References

Dobrev D, Milde AS, Andreas K, Ravens U: The effects of verapamil and diltiazem on N-, P- and Q-type calcium channels mediating dopamine release in rat striatum. Br J Pharmacol. 1999 May;127(2):576-82. doi: 10.1038/sj.bjp.0702574. [Article]

Details3. Voltage-dependent P/Q-type calcium channel subunit alpha-1A

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Voltage-gated calcium channel activity
Specific Function: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name: CACNA1A
Uniprot ID: O00555
Uniprot Name: Voltage-dependent P/Q-type calcium channel subunit alpha-1A
Molecular Weight: 282362.39 Da

References

Dobrev D, Milde AS, Andreas K, Ravens U: The effects of verapamil and diltiazem on N-, P- and Q-type calcium channels mediating dopamine release in rat striatum. Br J Pharmacol. 1999 May;127(2):576-82. doi: 10.1038/sj.bjp.0702574. [Article]

Details4. ATP-sensitive inward rectifier potassium channel 11

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Voltage-gated potassium channel activity
Specific Function: This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage ...
Gene Name: KCNJ11
Uniprot ID: Q14654
Uniprot Name: ATP-sensitive inward rectifier potassium channel 11
Molecular Weight: 43540.375 Da

References

Ninomiya T, Takano M, Haruna T, Kono Y, Horie M: Verapamil, a Ca2+ entry blocker, targets the pore-forming subunit of cardiac type KATP channel (Kir6.2). J Cardiovasc Pharmacol. 2003 Aug;42(2):161-8. doi: 10.1097/00005344-200308000-00002. [Article]

Details5. Voltage-dependent T-type calcium channel subunit alpha-1G

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Scaffold protein binding
Specific Function: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name: CACNA1G
Uniprot ID: O43497
Uniprot Name: Voltage-dependent T-type calcium channel subunit alpha-1G
Molecular Weight: 262468.62 Da

References

Freeze BS, McNulty MM, Hanck DA: State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel. Mol Pharmacol. 2006 Aug;70(2):718-26. Epub 2006 May 12. [Article]
Bergson P, Lipkind G, Lee SP, Duban ME, Hanck DA: Verapamil block of T-type calcium channels. Mol Pharmacol. 2011 Mar;79(3):411-9. doi: 10.1124/mol.110.069492. Epub 2010 Dec 13. [Article]

Details6. Voltage-dependent T-type calcium channel subunit alpha-1H

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Scaffold protein binding
Specific Function: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name: CACNA1H
Uniprot ID: O95180
Uniprot Name: Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight: 259160.2 Da

References

Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [Article]

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	145	N/A	N/A	A27847
IC 50 (nM)	141.25	N/A	N/A	A27558

Details7. Potassium voltage-gated channel subfamily H member 2

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function: Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name: KCNH2
Uniprot ID: Q12809
Uniprot Name: Potassium voltage-gated channel subfamily H member 2
Molecular Weight: 126653.52 Da

References

Duan JJ, Ma JH, Zhang PH, Wang XP, Zou AR, Tu DN: Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. Acta Pharmacol Sin. 2007 Jul;28(7):959-67. [Article]
Schneider J, Hauser R, Andreas JO, Linz K, Jahnel U: Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. Eur J Pharmacol. 2005 Apr 4;512(1):53-60. [Article]
Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [Article]

Details8. Sodium-dependent serotonin transporter

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Unknown

General Function: Serotonin:sodium symporter activity
Specific Function: Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name: SLC6A4
Uniprot ID: P31645
Uniprot Name: Sodium-dependent serotonin transporter
Molecular Weight: 70324.165 Da

References

Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [Article]
Brown NL, Sirugue O, Worcel M: The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes. Eur J Pharmacol. 1986 Apr 9;123(1):161-5. [Article]

Details9. Alpha-1A adrenergic receptor

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Antagonist
Curator comments: Inhibits receptor activity but shows little competition for binding. Likely an allosteric modulator.

General Function: Protein heterodimerization activity
Specific Function: This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name: ADRA1A
Uniprot ID: P35348
Uniprot Name: Alpha-1A adrenergic receptor
Molecular Weight: 51486.005 Da

References

Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G: Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. [Article]

Details10. Alpha-1B adrenergic receptor

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Antagonist
Curator comments: Inhibits receptor activity but shows little competition for binding. Likely an allosteric modulator.

General Function: Protein heterodimerization activity
Specific Function: This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name: ADRA1B
Uniprot ID: P35368
Uniprot Name: Alpha-1B adrenergic receptor
Molecular Weight: 56835.375 Da

References

Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G: Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. [Article]

Details11. Alpha-1D adrenergic receptor

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Antagonist
Curator comments: Inhibits receptor activity but shows little competition for binding. Likely an allosteric modulator.

General Function: Alpha1-adrenergic receptor activity
Specific Function: This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name: ADRA1D
Uniprot ID: P25100
Uniprot Name: Alpha-1D adrenergic receptor
Molecular Weight: 60462.205 Da

References

Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G: Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. [Article]

Details12. Voltage-dependent calcium channel (Protein Group)

Kind: Protein group
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Voltage-gated calcium channel activity
Specific Function: This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only...

Components:

Name	UniProt ID
Voltage-dependent calcium channel gamma-1 subunit	Q06432
Voltage-dependent calcium channel gamma-2 subunit	Q9Y698
Voltage-dependent calcium channel gamma-3 subunit	O60359
Voltage-dependent calcium channel gamma-4 subunit	Q9UBN1
Voltage-dependent calcium channel gamma-5 subunit	Q9UF02
Voltage-dependent calcium channel gamma-6 subunit	Q9BXT2
Voltage-dependent calcium channel gamma-7 subunit	P62955
Voltage-dependent calcium channel gamma-8 subunit	Q8WXS5
Voltage-dependent calcium channel subunit alpha-2/delta-1	P54289
Voltage-dependent calcium channel subunit alpha-2/delta-2	Q9NY47
Voltage-dependent calcium channel subunit alpha-2/delta-3	Q8IZS8
Voltage-dependent calcium channel subunit alpha-2/delta-4	Q7Z3S7
Voltage-dependent L-type calcium channel subunit alpha-1C	Q13936
Voltage-dependent L-type calcium channel subunit alpha-1D	Q01668
Voltage-dependent L-type calcium channel subunit alpha-1F	O60840
Voltage-dependent L-type calcium channel subunit alpha-1S	Q13698
Voltage-dependent L-type calcium channel subunit beta-1	Q02641
Voltage-dependent L-type calcium channel subunit beta-2	Q08289
Voltage-dependent L-type calcium channel subunit beta-3	P54284
Voltage-dependent L-type calcium channel subunit beta-4	O00305
Voltage-dependent N-type calcium channel subunit alpha-1B	Q00975
Voltage-dependent P/Q-type calcium channel subunit alpha-1A	O00555
Voltage-dependent R-type calcium channel subunit alpha-1E	Q15878
Voltage-dependent T-type calcium channel subunit alpha-1G	O43497
Voltage-dependent T-type calcium channel subunit alpha-1H	O95180
Voltage-dependent T-type calcium channel subunit alpha-1I	Q9P0X4

References

Shima E, Katsube M, Kato T, Kitagawa M, Hato F, Hino M, Takahashi T, Fujita H, Kitagawa S: Calcium channel blockers suppress cytokine-induced activation of human neutrophils. Am J Hypertens. 2008 Jan;21(1):78-84. doi: 10.1038/ajh.2007.13. [Article]

Details13. P-glycoprotein 1

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor
Blocker

General Function: Xenobiotic-transporting atpase activity
Specific Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name: ABCB1
Uniprot ID: P08183
Uniprot Name: Multidrug resistance protein 1
Molecular Weight: 141477.255 Da

References

Asakura T, Imai A, Ohkubo-Uraoka N, Kuroda M, Iidaka Y, Uchida K, Shibasaki T, Ohkawa K: Relationship between expression of drug-resistance factors and drug sensitivity in normal human renal proximal tubular epithelial cells in comparison with renal cell carcinoma. Oncol Rep. 2005 Sep;14(3):601-7. [Article]

Enzymes

Property	Measurement	pH	Temperature (°C)	References
Ki (nM)	5100	N/A	N/A	A18342
Ki (nM)	1390	N/A	N/A	A18342
Ki (nM)	6460	N/A	N/A	A18342
Ki (nM)	2970	N/A	N/A	A18342

Details1. Cytochrome P450 3A4

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [Article]
Wang YH, Jones DR, Hall SD: Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71. doi: 10.1124/dmd.104.001834. Epub 2005 Feb 2. [Article]
Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL: Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279-304. doi: 10.2165/00003088-200544030-00005. [Article]
Flockhart Table of Drug Interactions [Link]
FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
Verapamil FDA Label [Link]

Details2. Cytochrome P450 1A2

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP1A2
Uniprot ID: P05177
Uniprot Name: Cytochrome P450 1A2
Molecular Weight: 58293.76 Da

References

Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M: Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7. [Article]
Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E: Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009 Sep;11(3):481-94. doi: 10.1208/s12248-009-9127-y. Epub 2009 Jul 10. [Article]
Flockhart Table of Drug Interactions [Link]
Verapamil FDA Label [Link]

Details3. Cytochrome P450 2C8

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Steroid hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP2C8
Uniprot ID: P10632
Uniprot Name: Cytochrome P450 2C8
Molecular Weight: 55824.275 Da

References

Totah RA, Rettie AE: Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther. 2005 May;77(5):341-52. doi: 10.1016/j.clpt.2004.12.267. [Article]
Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M: Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21. doi: 10.1007/bf00168924. [Article]
Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [Article]
Verapamil FDA Label [Link]

Details4. Cytochrome P450 2C9

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Steroid hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP2C9
Uniprot ID: P11712
Uniprot Name: Cytochrome P450 2C9
Molecular Weight: 55627.365 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [Article]
Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [Article]
Verapamil FDA Label [Link]

Details5. Cytochrome P450 2C18

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Steroid hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP2C18
Uniprot ID: P33260
Uniprot Name: Cytochrome P450 2C18
Molecular Weight: 55710.075 Da

References

Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [Article]
Verapamil FDA Label [Link]

Details6. Cytochrome P450 3A5

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Oxygen binding
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP3A5
Uniprot ID: P20815
Uniprot Name: Cytochrome P450 3A5
Molecular Weight: 57108.065 Da

References

Wang YH, Jones DR, Hall SD: Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71. doi: 10.1124/dmd.104.001834. Epub 2005 Feb 2. [Article]
Langaee TY, Gong Y, Yarandi HN, Katz DA, Cooper-DeHoff RM, Pepine CJ, Johnson JA: Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther. 2007 Mar;81(3):386-91. doi: 10.1038/sj.clpt.6100090. [Article]
Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [Article]
Flockhart Table of Drug Interactions [Link]

Details7. Cytochrome P450 2B6

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate
Activator

General Function: Steroid hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP2B6
Uniprot ID: P20813
Uniprot Name: Cytochrome P450 2B6
Molecular Weight: 56277.81 Da

References

Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [Article]

Details8. Cytochrome P450 2C19

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Steroid hydroxylase activity
Specific Function: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name: CYP2C19
Uniprot ID: P33261
Uniprot Name: Cytochrome P450 2C19
Molecular Weight: 55930.545 Da

References

Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M: Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21. doi: 10.1007/bf00168924. [Article]
Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [Article]

Details9. Cytochrome P450 2D6

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Steroid hydroxylase activity
Specific Function: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name: CYP2D6
Uniprot ID: P10635
Uniprot Name: Cytochrome P450 2D6
Molecular Weight: 55768.94 Da

References

Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [Article]

Details10. Cytochrome P450 2E1

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Steroid hydroxylase activity
Specific Function: Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name: CYP2E1
Uniprot ID: P05181
Uniprot Name: Cytochrome P450 2E1
Molecular Weight: 56848.42 Da

References

Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [Article]

Carriers

Details1. Serum albumin

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Toxic substance binding
Specific Function: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name: ALB
Uniprot ID: P02768
Uniprot Name: Serum albumin
Molecular Weight: 69365.94 Da

References

FDA Approved Drug Products: Verelan® PM extended-release capsules [Link]

Details2. Alpha-1-acid glycoprotein 1

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Not Available
Specific Function: Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name: ORM1
Uniprot ID: P02763
Uniprot Name: Alpha-1-acid glycoprotein 1
Molecular Weight: 23511.38 Da

References

FDA Approved Drug Products: Verelan® PM extended-release capsules [Link]

Transporters

Property	Measurement	pH	Temperature (°C)	References
EC 50 (nM)	120	N/A	N/A	A28728
EC 50 (nM)	3100	N/A	N/A	A15814
EC 50 (nM)	20000	N/A	N/A	A28730 / A2804 / A27307 / A27308
EC 50 (nM)	1041	N/A	N/A	A28731
IC 50 (nM)	3100	N/A	N/A	A28729
IC 50 (nM)	53000	N/A	N/A	A28729
IC 50 (nM)	2100	N/A	N/A	A15809
IC 50 (nM)	4200	N/A	N/A	A15821 / A15813
IC 50 (nM)	4700	N/A	N/A	A15813
IC 50 (nM)	28900	N/A	N/A	A15813
IC 50 (nM)	446500	N/A	N/A	A15813
IC 50 (nM)	6500	N/A	N/A	A15813
IC 50 (nM)	42000	N/A	N/A	A15813
IC 50 (nM)	38200	N/A	N/A	A15813
IC 50 (nM)	2090	N/A	N/A	A27451
IC 50 (nM)	1480	N/A	N/A	A27451
IC 50 (nM)	2110	N/A	N/A	A27451
IC 50 (nM)	2370	N/A	N/A	A27451
IC 50 (nM)	4780	N/A	N/A	A15835
IC 50 (nM)	5330	N/A	N/A	A15835
IC 50 (nM)	5520	N/A	N/A	A15835
IC 50 (nM)	2210	N/A	N/A	A15835
IC 50 (nM)	2440	N/A	N/A	A15835
IC 50 (nM)	2580	N/A	N/A	A15835
IC 50 (nM)	6300	N/A	N/A	A15818
IC 50 (nM)	400	N/A	N/A	A15818 / A15832
IC 50 (nM)	8440	N/A	N/A	A15837
IC 50 (nM)	4571	N/A	N/A	A27306 / A4107
IC 50 (nM)	6607	N/A	N/A	A27306 / A4107
IC 50 (nM)	134896288	N/A	N/A	A27306
IC 50 (nM)	5800	N/A	N/A	A4107
IC 50 (nM)	5754	N/A	N/A	A4107
IC 50 (nM)	14000	N/A	N/A	A28732
IC 50 (nM)	9800	N/A	N/A	A28733
IC 50 (nM)	500	N/A	N/A	A28727
Ki (nM)	15100	N/A	N/A	A15815
Ki (nM)	1600	N/A	N/A	A27451
Ki (nM)	300	N/A	N/A	A27451
Ki (nM)	2500	N/A	N/A	A27451

Details1. P-glycoprotein 1

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Xenobiotic-transporting atpase activity
Specific Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name: ABCB1
Uniprot ID: P08183
Uniprot Name: Multidrug resistance protein 1
Molecular Weight: 141477.255 Da

References

Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [Article]
FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
Verapamil FDA Label [Link]

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	6800	N/A	N/A	A16058

Details2. Solute carrier family 22 member 1

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Secondary active organic cation transmembrane transporter activity
Specific Function: Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name: SLC22A1
Uniprot ID: O15245
Uniprot Name: Solute carrier family 22 member 1
Molecular Weight: 61153.345 Da

References

Cho SK, Kim CO, Park ES, Chung JY: Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers. Br J Clin Pharmacol. 2014 Dec;78(6):1426-32. doi: 10.1111/bcp.12476. [Article]
Boxberger KH, Hagenbuch B, Lampe JN: Common drugs inhibit human organic cation transporter 1 (OCT1)-mediated neurotransmitter uptake. Drug Metab Dispos. 2014 Jun;42(6):990-5. doi: 10.1124/dmd.113.055095. Epub 2014 Mar 31. [Article]

Details3. Solute carrier family 22 member 4

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Symporter activity
Specific Function: Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name: SLC22A4
Uniprot ID: Q9H015
Uniprot Name: Solute carrier family 22 member 4
Molecular Weight: 62154.48 Da

References

Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [Article]

Details4. Solute carrier family 22 member 5

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Symporter activity
Specific Function: Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name: SLC22A5
Uniprot ID: O76082
Uniprot Name: Solute carrier family 22 member 5
Molecular Weight: 62751.08 Da

References

Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [Article]
Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001 Feb;59(2):358-66. [Article]

Details5. Canalicular multispecific organic anion transporter 2

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Organic anion transmembrane transporter activity
Specific Function: May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name: ABCC3
Uniprot ID: O15438
Uniprot Name: Canalicular multispecific organic anion transporter 2
Molecular Weight: 169341.14 Da

References

Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [Article]

Details6. Solute carrier organic anion transporter family member 1B1

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name: SLCO1B1
Uniprot ID: Q9Y6L6
Uniprot Name: Solute carrier organic anion transporter family member 1B1
Molecular Weight: 76447.99 Da

References

Oostendorp RL, van de Steeg E, van der Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, Schellens JH: Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos. 2009 Apr;37(4):917-23. doi: 10.1124/dmd.108.024901. Epub 2009 Jan 12. [Article]

Details7. Solute carrier organic anion transporter family member 1A2

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name: SLCO1A2
Uniprot ID: P46721
Uniprot Name: Solute carrier organic anion transporter family member 1A2
Molecular Weight: 74144.105 Da

References

Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [Article]

Details8. Multidrug resistance-associated protein 1

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Transporter activity
Specific Function: Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name: ABCC1
Uniprot ID: P33527
Uniprot Name: Multidrug resistance-associated protein 1
Molecular Weight: 171589.5 Da

References

Perrotton T, Trompier D, Chang XB, Di Pietro A, Baubichon-Cortay H: (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. J Biol Chem. 2007 Oct 26;282(43):31542-8. doi: 10.1074/jbc.M703964200. Epub 2007 Jul 22. [Article]

Details9. Multidrug resistance-associated protein 4

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Atpase activity, coupled to transmembrane movement of substances
Specific Function: May be an organic anion pump relevant to cellular detoxification.
Gene Name: ABCC4
Uniprot ID: O15439
Uniprot Name: Multidrug resistance-associated protein 4
Molecular Weight: 149525.33 Da

References

Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50. [Article]
Bai J, Lai L, Yeo HC, Goh BC, Tan TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57. [Article]

Details10. Multidrug resistance-associated protein 7

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Atpase activity, coupled to transmembrane movement of substances
Specific Function: ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name: ABCC10
Uniprot ID: Q5T3U5
Uniprot Name: Multidrug resistance-associated protein 7
Molecular Weight: 161627.375 Da

References

Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [Article]

Details11. Multidrug and toxin extrusion protein 1

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Monovalent cation:proton antiporter activity
Specific Function: Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfat...
Gene Name: SLC47A1
Uniprot ID: Q96FL8
Uniprot Name: Multidrug and toxin extrusion protein 1
Molecular Weight: 61921.585 Da

References

Radchenko M, Symersky J, Nie R, Lu M: Structural basis for the blockade of MATE multidrug efflux pumps. Nat Commun. 2015 Aug 6;6:7995. doi: 10.1038/ncomms8995. [Article]

Details12. Multidrug and toxin extrusion protein 2

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Drug transmembrane transporter activity
Specific Function: Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide, metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acy...
Gene Name: SLC47A2
Uniprot ID: Q86VL8
Uniprot Name: Multidrug and toxin extrusion protein 2
Molecular Weight: 65083.915 Da

References

Radchenko M, Symersky J, Nie R, Lu M: Structural basis for the blockade of MATE multidrug efflux pumps. Nat Commun. 2015 Aug 6;6:7995. doi: 10.1038/ncomms8995. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 07, 2024 08:21

Verapamil

Identification

Structure for Verapamil (DB00661)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)

Targets

References

References

References

References

References

References

References

References

References

References

References

Components:

References

References

Enzymes

References

References

References

References

References

References

References

References

References

References

Carriers

References

References

Transporters

References

References

References

References

References

References

References

References

References

References

References

References